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Abstract 
 
The preparations of SEC/IEC supports from commercially available, underivatised base 
matrices by AGE activation-partial bromination technique via two different approaches; (i) 
viscosity enhanced-reaction diffusion (VE-RD) and (ii) microwave-assisted reaction 
diffusion, were studied and optimised. Selected supports produced by both approaches were 
further evaluated by applying to packed bed chromatography system in order to purify target 
pDNA from neutralized E.coli cleared lysates.For VE-RD approach, viscosity enhancement 
by sucrose (< 0.032 Pa.s) was found to greatly aid the creation of thin inert outer layer. The 
optimum condition for SEC/IEC Sepharose CL-6B production observed was 10% single 
bromination at room temperature in 64% (w/v) aqueous sucrose without sodium acetate 
addition. The effects of different base matrices, conductivities, linear flow rate, target pDNA 
sizes and support preparations on chromatography performance were investigated. 
Microwave irradiation heated up the reaction in a rapid controlled manner compared to 
conventional heating. SEC/IEC Sepharose CL-6B produced via microwave-assisted reaction 
diffusion approach at 80oC with 10% partial bromination showed almost complete surface 
charge elimination with the highest SI value of 57.4. This support showed the high core 
binding capacity. However, a delayed pDNA breakthrough was also observed. It was noted 
that the plasmid forms remain unchanged after SEC/IEC column purification. 
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Chapter 1 
Introduction 
 
1.1 Nanoplex 
Nanoplexes are biotechnological products which are nanoparticulate in nature and generally 
composed of sophisticated biological structures with the large particle size of 10 - >300 nm 
(Zhang et al., 2001b, Jahanshahi, 2004). Examples of nanoplexes includes non-viral vectors 
i.e. plasmid DNA, polyplex and lipoplex; viral vectors, mega molecular vaccines and virus-
like particles (VLPs) (Arpanaei et al., 2010, Zhang et al., 2001b). Main applications of 
nanoplexes are drug and gene delivery vehicles, especially for gene therapy (Azari et al., 
2011, Bonoiu et al., 2009, Thomas et al., 2010) which dictate the requirements of high 
product purity in order to be administered safely in human clinical treatments. Purification of 
nanoplexes have several challenges due to the similarity of target molecules and impurities 
for example, in plasmid DNA purification where impurities such as RNA, genomic DNA, 
proteins, and endotoxins possess the same charge properties as plasmid, worsen by similarity 
in size between pDNA, RNA and genomic DNA resulting in co-purification of impurities 
alongside the plasmid of interest (Prazeres and Ferreira, 2004, Wicks et al., 1995). Other 
challenges in nanoplex purification are caused by the large size of the molecules, fragility and 
complex chemical properties on the surface (Arpanaei et al., 2010). The large size of 
nanoplexes results in a compromised mass transfer especially for chromatography 
purification where commercially available matrices are designed to accommodate much 
smaller molecules such as proteins. For example, a study on direct visualization of plasmid 
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DNA adsorption on individual Q Sepharose XL particles revealed that plasmid adsorption is 
restricted on the surface of the support (Ljunglöf et al., 1999). The fragility of nanoplex 
molecules is another factor to consider in purification process. Shear-induced structural 
damage can occur in some nanoplexes i.e. budding viruses such as lentiviral vectors 
(Sheridan, 2011) and plasmid DNA (Levy et al., 1999). This shear sensitivity property led to 
difficulties in process design since some unit operations i.e. homogenization or freeze-thaw 
are not applicable (Carlson et al., 1995, Kong et al., 2008), making chromatography more 
preferable due to its considerably mild process. 
In this chapter, the main applications of nanoplexes, i.e. gene therapy and DNA vaccination, 
are further discussed, as well as gene delivery vectors. Since plasmid DNA was used as the 
test system representing nanoplexes in the entire study, the detailed information and 
discussions will be mainly focused on plasmid DNA purification and especially on 
chromatography techniques. Lastly, the idea of bilayered SEC/IEC supports is also explained 
and discussed. 
 
1.2 Gene therapy and DNA vaccination 
  1.2.1 Overview 
 
Since the success of the first approved clinical trial on a four year-old girl, Ashanti 
DeSilva, suffering from severe combined immunodeficiency (SCID) in 1990 (Blaese et al., 
1995, Sheridan, 2011, Bess, 2008), gene therapy and DNA vaccination have raised huge 
interests as the new choices for preventing or treating a disease via gene transfer, with great 
promises to fulfill current requirements worldwide for therapeutic usages. The prospect of 
genetic medicine that could treat diseases by compensating the errors in an individual’s DNA 
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sequence emerged from the combination of the successful development of virus-based 
method transformation in mammalian cells in the1960s and the advent of recombinant DNA 
technology in the 1970s (Friedmann, 1992, Sheridan, 2011). In 1990, the first approved gene 
therapy was performed by Blaese and coworkers in order to treat SCID using ex-vivo 
retroviral mediated gene transfer into T-cells. One of the two children undergone the 
treatment, DeSilva, exhibited a temporary response. Although this procedure did not correct 
the defective genes or enable the withdrawal of enzyme-replacement therapy, this very first 
attempt showed that the procedure was feasible and safe, led to the persistence of transduced 
T-cells as much as 15-20 years later (Fischer et al., 2010). On October 16, 2003, another 
milestone in gene therapy was established when a recombinant human adenovirus-p53 
encoding the p53 tumor suppressor gene (Gendicine™) developed by Shenzhen SiBiono 
GeneTech (Shenzhen, China) was approved by the State Food and Drug Administration of 
China (SFDA) for the treatment of head and neck squamous cell carcinoma (Peng, 2005). 
Gendicine™ was formally launched in April 2004 and became the world’s first gene therapy 
product approved by a governmental agency (Peng, 2005, Thanou et al., 2007). Up to date, 
Gene therapy trials have been carried out worldwide in hopes for the approved clinical 
applications. Examples of clinical trial status of gene therapy products up to 2011 are 
presented in Table 1.1. 
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Table 1.1 Examples of clinical trial status of gene therapy products up to 2011 (Sheridan, 
2011) 
Company Therapy Indication Phase of 
development 
Retrovirus 
San Raffaele ADA-SCID GT: CD34+ cells transduced with 
Moloney murine leukemia virus carrying ADA gene 
Primary 
immunodeficiencies 
Phase 1/2 
Neurologix NLX-P101: GAD in virus injected into subthalmic 
nucleus of the brain 
Parkinson’s disease Phase 2 
Ribozyme 
CO, USA 
CD34+ cells transduced with retrovirus vector with 
multiple ribozymes 
Non-Hodgkin’s 
lymphoma 
HIV/AIDS 
Phase 2 
Tocagen 
San Diego 
Toca-511: replication competent retrovirus with 
prodrug activator cytosine 
deamidase gene injected into tumor 
Glioma  Phase 1/2 
Lentivirus 
Bluebird Bio Bluebird Bio LentiGlobin: introduces globin gene 
into patient hematopoietic stem cells 
β-thalassemia and sickle 
cell anemia 
Phase 1/2 
Lentigen LG-740: T cells treated ex vivo with lentivirus with 
chimeric T-cell receptor gene 
B-cell leukemia and 
lymphoma 
Phase 1 
Oxford 
BioMedica 
ProSavin: lentivirus with three genes required for 
dopamine biosynthesis injected 
into striatum of brain 
Parkinson’s disease Phase 1/2 
Adenovirus 
Advantagene 
MA, USA 
ADV-tk: replication-deficient adenovirus with HSV 
thymidine kinase gene injected into tumor during 
biopsy 
Glioma 
Pancreatic cancer 
Phase 1 
Phase 1 
Applied Genetic 
Technologies 
FL, USA 
rAAV1-CB-hAAT: AAV with alpha-1-antitrypsin 
gene 
Alpha1-antitrypsin 
deficiency 
Phase 2 
rAAV2-CB-human retinal pigment epithelium 
specific 65 dalton protein (RPE65) 
Congenital amaurosis 
(blindness with 
mutation in RPE gene) 
Phase 1/2 
Amsterdam 
Molecular 
AMT-101: adeno-associated virus with human 
lipoprotein lipase gene 
LPL deficiency Filed 
Aventis 
Paris 
Ad5CMV-p53 Head and neck cancer Phase 2 
Biogen Adenoviral mediated interferon-β Pleural mesothelioma 
Colon cancer, glioma 
Phase 1 
Phase 1/2 
Ceregene 
San Diego 
CERE-120: adeno-associated virus with neurotrophic 
factor, neurturin 
Parkinson’s disease Phase 1/2 
CERE-110: adeno-associated virus with gene for 
nerve growth factor 
Alzheimer’s disease Phase 1/2 
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Table 1.1 (continued)  Examples of clinical trial status of gene therapy products up to 2011 
(Sheridan, 2011) 
 
Company Therapy Indication Phase of 
development 
Adenovirus (continued) 
Celladon 
CA, USA 
SERCA-2a: sarcoplasmic reticulum Ca2+ATPase 
gene with AAV vector 
Congestive heart failure Phase 1/2 
Genzyme AAV2-sFLT01: adeno-associated virus with anti-
VEGF 
Wet macular 
degeneration 
Phase 1 
 
GenVec TNFerade: replication deficient adenovirus with 
TNF-a controlled by 
radiation-induced promoter 
Esophageal cancer Phase 2 
Shenzhen 
SiBiono 
GeneTech 
rAd-p53: replication deficient adenovirus encoding hu 
recombinant p53 
Advanced thyroid 
tumors, oral, 
maxillofacial tumors 
Phase 4 
Targeted Genetics 
Seattle 
tgAAG76: AAV with human RPE65 Congenital amaurosis 
(blindness with 
mutation in RPE gene) 
Phase 1/2 
tgAAC94: AAV2 with TNF-a –IgG1 fusion gene Arthritis Phase 2 
completed 
Plasmid 
AnGes, Tokyo Hepatocyte growth factor-plasmid Arterial disease Phase 2 
Genexine 
Seoul, Korea 
GX-12: plasmid plus IL-12 mutant, given with 
HAART 
HIV-AIDS Phase 1 
ScanCell 
Nottingham, UK 
SCIB1: plasmid with tyrosine-related protein Melanoma Phase 1/2 
Vical 
San Diego 
Allovectin-7: plasmid with gene for HLA-B7 and 
b2microglobulin genes, injected into tumors 
Melanoma Phase 3 
ViroMed 
 MN, USA 
VM202: plasmid with two isoforms of hepatocyte 
growth factor, HGF728 and HGF 723 
Limb ischemia 
Myocardial ischemia 
Phase 2 
Phase 1/2 
Other 
Diamyd Medical 
Stockholm, 
Sweden 
Nerve Targeting Drug Delivery System: HSV vector 
with enkaphalin administered  intradermally 
Pain Phase 1 
Epeius 
Biotechnologies 
CA, USA 
Rexin-G: nanoparticle delivering cyclin-G1 gene Advanced pancreatic, 
metastatic breast, 
osteosarcoma, and soft 
tissue sarcoma 
Phase 1/2 
MultiGene 
Vascular Systems 
Nesher, Israel 
Patient cells modified with four angiogenic genes Peripheral artery disease Phase 1/2 
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Gene therapy targets to treat genetic defects by making functional genes available to 
assist or replace defective or mutant genes (Tente, 2011). Example of genetic defects that 
have been studies for a cure by gene therapy varies from innate genetic defects such as severe 
combined immunodeficiency (SCID) (FISCHER et al., 2011, Blaese et al., 1995, Fischer et 
al., 2010), to acquired diseases i.e. cancer (Frederiksen et al., 1999, Horn et al., 1995, Jia et 
al., 2012, Wysocki et al., 2002), AIDS (Lisziewicz, 1997, Sorg and Methali, 1997, Zaia, 
2003, Delgado and Regueiro, 2005, Kitchen et al., 2011), parkinson’s disease (Dass and 
Kordower, 2007, Fiandaca et al., 2008, Lewis and Standaert, 2008, Lim et al., 2010, 
Rodnitzky, 2012) even heart failure (Kawase et al., 2011, Rapti et al., 2011, Hajjar, 2012, 
Delgado and Regueiro, 2005, Kitchen et al., 2011) etc. Gene therapy treats diseases via three 
different mechanisms; (i) by introducing therapeutic genes into a host to replace defective 
genes (replacement therapy); (ii) by suppressing expression of certain undesirable genes 
(antisense therapy); or (iii) provide additional biological activities (supplement therapy) 
(Yang et al., 1996).  
For inserting genetic material into human chromosomes, two different methods have 
been employed. The first is ‘ex vivo’ technique in which genetic alterations of target cells 
occur outside of the body (Fig 1.1a). Cells from the affected tissue area are surgically 
removed, injected with therapeutic DNA to correct the disease and grown in cultures. The 
corrected tissues are then transferred back into patient’s affected organ. This method is time 
consuming and causes pain in patients therefore, raises more interest on another technique. 
The second method, namely ‘in vivo’ technique (Fig 1.1b), does not require surgery. 
Therapeutic DNA is directly introduced into the body by cell-specific carrier, usually via 
gene transfer vectors, i.e. viruses or plasmids. 
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Fig. 1.1 In gene therapy, genetic materials can be inserted into human chromosomes 
by; a) ex vivo or, b) in vivo technique. The figure was retrieved and modified from                                
http://gene-therapy.yolasite.com/process.php, last accessed on Sept, 3rd, 2012. 
 
DNA vaccines bases on plasmid DNA containing specific genes encoding target 
proteins and can activate both cell-mediated immunity and humoral responses (Prather et al., 
2003). DNA vaccinations have yielded highly attractive results against parasitic infections 
(Da'dara and Harn 2005); (Ivory and Chadee, 2004, Carvalho et al., 2010) such as malaria 
(Doolan and Hoffman, 2001, Doolan et al., 2003) and viral infection such as AIDS (Mascola 
and Nabel, 2001, Smith et al., 2004). Recent developments of DNA vaccine for cancer 
treatment have been also reported (Anderson and Schneider, 2007, Cohen, 2001, Ma and 
Yang, 2010). The main advantages of DNA vaccination compared to other types of 
vaccination (i.e. weakened bacteria or virus, modified exotoxins or modified attenuated viral 
vaccines) are the more cost effective process for large scale production, moderate storage 
conditions (stable at ambient temperature) as well as being generally regarded as safer for 
administration (Ferreira et al., 2000). The main disadvantage with DNA vaccine is the less 
efficiency compared to its viral counterparts therefore, high dose is required. It is estimated 
a)                                                                        b)                                   
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that milligram amounts may be needed for full treatment (Ferreira et al., 2000). Fig. 1.2 
demonstrates the principle and overall process of DNA vaccination. Antigen coding genes 
from pathogen are isolated and cloned into a vaccine plasmid. The resulting pDNA is grown 
in bacteria, purified and dissolved before being injected into the host, usually by a direct 
intramuscular (i.m.) injection. After injection the pDNA will, in theory, be taken up by a cell 
(e.g. myocytes) and the pDNA encoded gene(s) will be transcribed and translated into 
protein(s), resulting in immune responses (Gillund et al., 2008). 
 
 
Fig. 1.2 The principle of DNA vaccination, from isolation of the gene encoding the 
antigenic protein to final immune responses. The figure is modified from publication of 
Gillund et al. (2008). 
 
1.2.2     Vectors used in gene therapy  
Vectors used for gene therapy can be categorized as viral and non-viral vectors. 
According to The Journal of Gene Medicine clinical trial site, vectors utilized in gene therapy 
clinical trials by June 2012 is presented in Fig. 1.3. 
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Fig.1.3  Vectors used in gene therapy clinical trials up to 2012. (Data source: The 
journal of gene medicine clinical trial site; http://www.abedia.com/wiley/vectors.php; last 
accessed on June, 17th, 2012)  
 
 1.2.2.1 Viral vectors 
  Viral vectors have been designed based on the advantage of the efficiency of 
viruses to enter and insert genetic material into target cells, with the assuring ability to 
transport its genomic DNA to the nucleus of the host cell without being degraded by 
lysosomes (Wivel and Wilson, 1998). Viral genome insertion can potentially remove the 
pathological functions by delivering a normal copy of defective genes and in some cases, 
involving the inactivation of deleterious functions (Cearley and Wolfe, 2009). Delivering the 
gene of interest into the target cells by viral vector is one of the basic methods of gene 
transfer. Many successful in gene delivery and therapy has been achieved with viral vectors 
due to their high transduction efficiency in cells in vivo (Selvam et al., 2006). However, viral 
vectors also possess several disadvantages, such as immunogenicity towards host, restricted 
23.27%
20.03%
18.50%
8.01%
6.04%
5.21%
4.72%
3.18%
2.63%
4.99%3.40%
Adenovirus (n=424)
Retrovirus (n=365)
Naked/ Plasmid DNA 
(n=337)
Vaccinia virus (n=146)
Lipofection (n=110)
Poxvirus (n=95)
Adeno-associated virus 
(n=86)
Herpes simplex virus 
(n=58)
Lentivirus (n=48)
Other catagories (n=91)
Unknown (n=62)
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target cell types, production problems, and limited DNA carrying capacity (Wolf et al., 
2009). 
  The major criteria in the design of viral vectors are safety, target cell 
specificity and availability of efficient permissive cell lines (Wu and Ataai, 2000). For viral 
vectors development, the usual approach is to remove the unneeded or pathogenic features of 
the virus while retaining the efficiency of gene delivery, expression, and persistence wherever 
appropriate. Designing viral vectors addresses many common considerations for both safety 
and biological activity including removal of virulent genes, elimination of the replication 
component of the parental virus, and responses to components of the vector by host (Patel 
and Misra, 2011). Viral-encoded functions can be separated into cis and trans elements. 
The cis elements, such as the origin of replication or the packaging signal, must be carried by 
the virus itself. Whereas the trans elements can be complemented from DNA sequences 
inserted into the host genome or carried on transfected plasmid. In viruses with small viral 
genomes, usually all trans genes are removed to create space for insertion of the therapeutic 
gene and to render the vector replication defective. The deleted genes are either stably 
transfected into packaging cell lines or transiently expressed by transfection of helper 
plasmids or helper virus. Packaging cell lines must be carefully selected and modified to 
avoid the presence of overlapping regions between the vector and the cell genome, thus 
eliminating the possibility of rescuing the replication competent virus from integrated 
complementary genes or provirus (Wu and Ataai, 2000). Some of the different types of 
viruses used as gene therapy vectors are briefly discussed as followed: 
 
   1.2.2.1.1 Retrovirus 
   Retroviruses are small RNA viruses that can perform reverse 
transcription to produce proviral double stranded DNA from its RNA genome by the activity 
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of the enzyme reverse transcriptase (Geiger et al., 2010, Robbins and Ghivizzani, 1998). The 
infection of retrovirus to target cells occurs through a specific interaction between the viral 
envelope protein and a receptor on the surface of the target cell (Robbins and Ghivizzani, 
1998). The virus is then internalized by fusion or via endosome formation, depending on the 
envelope protein (Baum et al., 2006). After entering the cell, retroviruses can deliver three 
forms of genetic information (i) if reverse transcription does not occur, the mRNA may be 
subject to immediate translation; (ii) if integration of viral DNA to the host chromosome is 
blocked, episomal circles can be generated and may persist in non-dividing cells; (iii) if all 
steps of the retroviral transduction process are completed, a double-stranded DNA integrates 
in cellular chromosomes by an virally coded integrase enzyme and expresses therapeutic 
product as part of the host cell’s DNA (Baum et al., 2006, Robbins and Ghivizzani, 1998). 
The ability of retroviruses to integrate their genome into the host chromosome enables a 
stable genetic modification to remain in host cell for life, unlike some other viral vectors, i.e. 
adenovirus, herpes simplex virus (HSV) or papilloma virus (Robbins and Ghivizzani, 1998). 
Delivery of nucleic acids by retroviral particles is demonstrated in Fig. 1.4.  
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Fig. 1.4 Delivery of nucleic acids by Retrovirus.  Retroviruses can deliver three forms 
of genetic information after receptor-mediated uptake,: (1) if reverse transcription does not 
occur, the mRNA may be subject to immediate translation; (2) if integration is blocked, 
episomal circles can be generated that may persist in non-dividing cells; (3) if all steps of the 
retroviral transduction process are completed, a double-stranded DNA integrates in cellular 
chromosomes. Diagram was modified from (Baum et al., 2006).  Abbreviation; Ψ : Retroviral 
packaging sequence, LTR : Long terminal repeat. 
 
   1.2.2.1.2 Adenovirus (AV) 
   Adenovirus is a nonenveloped virus with a moderate size of 60-90 nm 
(Rapti et al., 2011), consists of a linear double strand DNA at the size of ~30-35 kbp with 
capacity for 4.5–30 kb of foreign DNA, which accommodates most of the known cDNA 
sequences (Lim et al., 2010). Adenovirus has been intensively used as a non-integrating 
vector for gene therapy due to its episomal nature which eliminates the risk of insertional 
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mutagenesis or oncogenesis that might occur in integrating vectors (Robbins and Ghivizzani, 
1998, Geiger et al., 2010, Rapti et al., 2011). Adenovirus has a broad tissue tropism, which 
means it can infect a wide range of cell types, including non-dividing cells such as neurons 
(Wu and Ataai, 2000, Robbins and Ghivizzani, 1998, Lim et al., 2010). The cell entry 
pathway of adenoviral vectors is shown in Fig. 1.5. 
 
 
Fig. 1.5 Cell-entry pathway of the adenoviral vector. The adenovirus vector initially 
binds to the cell via the specific cellular receptor, coxsackievirus and adenovirus receptor 
(CAR). After binding, the virion achieves internalization via receptor-mediated endocytosis 
pathway. After internalization, the virus is localized within the endosomes. Acidification of 
the endosomes allows the virions to be released within the cytosol and consequently the 
virion will be translocated into the nucleus to begin gene expression (Contreras et al., 2004). 
Abbreviation; CAR: Coxsackievirus and adenovirus receptor. 
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Although adenoviral vectors demonstrate prolonged gene expression, its 
major problem is the ability to rapidly trigger strong host immune responses which 
potentially cause a harmful side effects (Wu and Ataai, 2000). Therefore, the use of 
recombinant adenoviral vectors has gained more interest.  
The genome of wild type adenovirus contains five early genes 
responsible for the activation of viral DNA replication and the expression of viral structural 
proteins. These genes consist of E1A, E1B, E2, E3, and E4. In recombinant Ad vectors, 
portions of the early genes are replaced with the transgenic DNA of interest. The first 
generation adenoviral vectors was lacking only one or two early genes; E1 and/or E3 
resulting in the impaired replication ability. Despite the absence of E1 gene, the first 
generation adenoviral vector still replicated and expressed other adenoviral gene at decreased 
level and was found to induce strong cellular immune response (Byrnes et al., 1996a, Byrnes 
et al., 1996b). The second and third generations of adenoviral vectors were created by the 
additional deletions of genes E2 and/or E4 and were reported to exhibit decreased 
immunogenicity and increased transgene capacity compared to the first generation vectors 
(Lusky et al., 1998, Moorhead et al., 1999).   
Another development of adenoviral vectors is ‘gutless adenovirus’ which 
only contains a packaging signal and can carry up to 37 kb of foreign DNA (Hardy et al., 
1997, Lim et al., 2010, Mandel et al., 2008). In these vectors, the expression of viral proteins 
was eliminated, led to an improved stability of transgene expression and reduced potential 
immune response. However, these vectors were reported to still induce capsid-mediated 
inflammatory response (Lim et al., 2010).    
 
15 
 
 
1.2.2.1.3 Adeno-associated viruses (AAV) 
Adeno-associated virus is a small virus at a size of ~20 nm carrying a 
4.7 kb single stranded DNA genome (Wu and Ataai, 2000, Geiger et al., 2010, Mandel et al., 
2008). AAV vector is non-pathogenic and non-immunogenic which means that the 
inflammatory response toward these vectors is minimal compared to adenoviral vectors. 
These features, combined with the capability to infect both dividing and non-dividing cells 
including muscle cells and neurons with prolonged gene expression make AAV an attractive 
vector for gene therapy (Rapti et al., 2011, Lim et al., 2010).  
The wild-type AAV genome comprises of two open reading frames 
encoding the four replication and packaging function genes (rep) to control viral replication, 
structural gene expression and integration into the host genome and three capsid (cap) genes 
encoding capsid structural proteins, rep and cap genes are flanked by two inverted terminal 
repeats (ITRs).The rep and cap genes alone are insufficient to cause a productive infection. 
Once infects a cell, wild type AAV normally integrates into the host cell genome and goes 
into latency at a specific site on human chromosome 19q13.4. In order to enter a lytic cycle in 
which progeny are produced, wild type AAV requires superinfection of a helper virus, i.e. 
adenovirus or herpes virus (Lim et al., 2010, Mandel et al., 2008, Geiger et al., 2010, Robbins 
and Ghivizzani, 1998, Daya and Berns, 2008) or cotransfection of helper plasmid containing 
DNA regions mediating AAV vector replication from adenovirus (Matsushita et al., 1998). 
Recombinant AAV (rAAV) vectors are created by replacing the 4.7 kb 
viral genome with the expression cassette of choice, flanked by the viral ITRs (Rapti et al., 
2011). Since rep and cap genes were removed, rAAV genome losses the ability to integrate 
to host genome and remain episomal. This non-integrating property eliminates the risk of 
insertional mutagenesis. Another advantage of rAAV is the long term expression even in 
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episomal form. It has been observed in several clinical trials that rAAV showed sustainable 
transgene expression for 6 months to 3.7 years in patients (Rapti et al., 2011). Moreover, 
AAVs are very resistant to extreme conditions of pH, detergent and temperature, making 
them easy to manipulate (Galibert and Merten, 2011). Despite of these advantages, the small 
size of AAV, however, limits the size of the therapeutic DNA that it can carry. Other major 
problems of AAV include low production yield and contamination associated with the helper 
virus (Wu and Ataai, 2000, Kawase et al., 2011). The transduction of AAV into host cell is 
demonstrated in Fig 1.6. 
 
Fig. 1.6 AAV transduction into host cell: (1) binding to a membrane 
receptor/coreceptor; (2) endocytosis by host cell; (3) endosome formation; (4) escape from 
the endosome; (5) uncoating to release the viral genome; (6) entering host nucleus; (7) 
conversion of viral genome from single to double stranded; and (8) integration to host 
genome or remaining in episomal form  (Coura and Nardi, 2008). 
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1.2.2.1.4  Herpes-simplex virus (HSV) 
Herpes simplex virus is an enveloped double-strand linear DNA virus. 
HSV is rather complicated virus with a ∼150 kb viral genome encoding at least 84 almost 
entirely contiguous (unspliced) genes. Approximately half of these genes are nonessential for 
viral replication in cell culture. These nonessential genes can be removed to provide multiple 
sites of foreign gene insertion capable to carry at least 30 kb of foreign genes either a large 
single gene or multiple transgenes for coordinately or simultaneously expression (Wu and 
Ataai, 2000, Kay et al., 2001, Robbins and Ghivizzani, 1998, Mata et al., 2002, Aravindaram 
and Yang, 2009). Wild type HSV is pathogenic, associating with cold sores, corneal 
blindness, and encephalitis (Mandel et al., 2008). HSV can infect a wide range of cells, both 
dividing and non-dividing, since its cellular receptors; heparan sulfate (HS), herpesvirus entry 
mediator (HVEM), and nectin-1 and -2, are widely expressed on the cell surface of numerous 
cell types (Patel and Misra, 2011). After endocytosis, the wild type HSV is retrogradely 
transported to the cell body and eventually to the nucleus where it replicates. Upon infection, 
wild type HSV can either undergo lytic cycle or establish latency, especially in neurons 
(Millhouse and Wigdahl, 2000). Due to its attractive features such as neural tropism, 
retrograde transport, and large transgene capacity properties, HSV has gained a large interest 
for gene therapy application towards the nervous system (Lim et al., 2010, Mandel et al., 
2008).  
HSV-1 is currently the most extensively engineered herpesvirus for gene 
transfer purposes. HSV-1 is neurotrophic and can establish lifelong presence in sensory 
neurons (Lim et al., 2010). Two types of HSV-1 vector systems; recombinant virus and 
amplicons, have been developed. The recombinant HSV (rHSV) vectors are created by 
replacing nonessential viral genes with a transgene(s) of interest at different sites in the viral 
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genome. These vectors can usually accommodate up to 40 kb of transgenic DNA (Lim et al., 
2010). rHSV can be divided to two catagories; replication-competent attenuated vector and 
replication-incompetent attenuated vector. Replication-competent attenuated vectors still 
contain essential genes for in vivo replication whereas the genes that are required for 
replication in replication-incompetent vectors are deleted (Lim et al., 2010). The properties of 
rHSV vectors are highly dependent on the presence of immediate early (IE) genes. The 
absence of multiple IE genes led to a diminished toxicity but the transgene expression was 
also found to be severely decreased (Krisky et al., 1998) while the presence of IE gene 
products results in cytopathic effects (Johnson et al., 1992). 
The HSV-1 amplicon is similar to the gutless adenoviral vector system. 
The viral genome only contains a viral origin of replication and a packaging signal. The 
genes necessary for viral production and replication are provided in trans, by a helper 
virus/transfection system (Mandel et al., 2008, Lim et al., 2010, Robbins and Ghivizzani, 
1998). Advantages of using amplicon are simple vector construction, reduced cellular toxicity 
and immunogenicity compared to the rHSV-1 vectors and the capacity to carry large 
fragments of foreign DNA. The latter feature not only allows for the insertion of entire 
genomic loci but also the addition of various elements, i.e. promoters, inducible systems for 
regulated gene expression or several separate expression cassettes (Lim et al., 2010, Wu and 
Ataai, 2000). 
  1.2.2.1.5  Lentivirus (LV) 
 Lentivirus (LV) is subclass of retrovirus. In contrast to more 
commonly studied oncoretroviruses, LVs are capable of integrating their genome into both 
mitotic cells and post-mitotic cells (Naldini and Verma, 2000). LV genome is a single-
stranded RNA (∼9.7 kb) encoding cis-acting sequences for packaging, reverse transcription, 
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nuclear localization and integration. LV genome also includes gag, pol and env encoding the 
core proteins, the virion-associated enzymes, and the envelope glycoprotein, flanked by the 
long terminal repeats (LTR). The LTRs are important for integration, transcription and 
polyadenylation. LV genome also contains regulatory genes (rev and tat) and accessory genes 
(vpu, vpr, vif, and nef) (Lim et al., 2010, Mandel et al., 2008, Naldini and Verma, 2000). 
Human Immunodeficiency Virus type I (HIV-I) is classified as a 
lentivirus and has been engineered for gene therapy applications since it has been widely and 
thoroughly studied (Naldini et al., 1996). The first generation of LV vectors based on the 
human immunodeficiency virus 1 (HIV-1) was generated using a three-plasmid system 
consisting of a packaging plasmid, vector plasmid and envelope plasmid. The packaging 
plasmid contains the viral genes under the Cytomegaloviral (CMV) promoter except for the 
env and vpu open reading frames (ORFs), which have been deleted and provided by the 
envelope plasmid that encodes vesicular stomatitis virus G protein (VSV-G) instead of the 
HIV-1 env proteins. The vector plasmid contains HIV-1 cis-acting elements that enable the 
transgene and its promoter to be packaged (Lim et al., 2010). In second and third generation, 
the additional viral sequences were removed from the vector plasmid in order to decrease the 
possibility of replication-competent recombinant virus. One of the third generation LV called 
self-inactivating lentivirus was produced by inactivating the 5′ LTR. The absence of the 
promoter and enhancer sequences in the LTR prevents possible replication of the virus during 
vector production, resulting in a vast reduction of recombination probability after the vector 
genome has integrated into the host (Miyoshi et al., 1998). Lentiviral vectors can 
accommodate a transgenic DNA at the size up to 18 kb proviral length (Lim et al., 2010). 
The oncogenic mutation caused by the random integration of a lentiviral 
vector genome into the host cell genome is the primary safety concern for its application in 
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gene therapy. The non-integrating lentiviral (NIL) vectors were developed by removal of 
integrase activity which is required to catalyze the integration of viral genome into the host 
genome. As a result, NIL genome remains in the nuclease of target cell as a linear or circular 
double stranded DNA (Philpott and Thrasher, 2007, Sarkis et al., 2008). However, integration 
properties of lentiviral genome into the host genomes holds great promise for ex vivo gene 
delivery allowing a stable transduction in cell lines, primary cells or stem cells (Lim et al., 
2010). Lentiviral vector transduction is illustrated in Fig. 1.7. 
 
Fig. 1.7 The mechanism of Lentiviral (LV) vector transduction. First, LVs bind to 
target cells using an envelope protein which allows for release of the LV RNA containing the 
transgenes into the cell. The LV RNA is then converted into DNA using reverse transcriptase 
by a process called reverse transcription. The DNA then enters the nucleus and integrates into 
the target cell's chromosomal DNA.  (Illustration was modified from: Lentigen; 
http://www.lentigen.com/technology/vectors; last accessed on September, 21st, 2012)  
 
1.2.2.2 Non-viral vectors 
Despite the high gene transfer efficiency, the potential dangers of using of 
viral vectors in gene therapy have been highlighted in clinical trials history (Glover et al., 
2005, Park et al., 2006, Fang et al., 1996, Madsen and Mooney, 2000, Sheridan, 2011, Wolf 
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et al., 2009). In 1999, the death of an 18 year-old volunteer, Jesse Gelsinger, caused by 
vector-associated toxicity in a gene therapy trial using adenoviral vector has triggered the 
interest on the safer, non-viral vectors (Glover et al., 2005, Sheridan, 2011). Advantages of 
non-viral vectors over viral vectors are their low immunogenecity, absence of endogenous 
virus recombination, low production cost and reproducibility (Wolf et al., 2009, Lee and 
Kim, 2005). Moreover,  non-viral vectors have no limitation in DNA size for packaging and 
the possibility of modification with ligands for tissue- or cell-specific targeting (Lee and Kim, 
2005). Non-viral gene delivery vectors are briefly discussed as followed; 
 
  1.2.2.2.1 Plasmid DNA 
Plasmid-based gene expression system for use in gene therapy and 
DNA vaccination minimally consists of three major components, (i) a prokaryotic plasmid 
vector, essentially containing origin of replication (ori) which enables plasmid to replicate in 
production host (normally E. coli); (ii) eukaryotic regulatory elements to control the 
expression of therapeutic gene inserted to target cells; and (iii) a gene or genes encoding 
therapeutic or antigenic protein (s) (Durland and Eastman, 1998). 
 Plasmid DNA can be injected directly into a tissue without additional 
help from either a chemical agent or a physical force. Gene transfer with naked DNA is 
attractive to many researchers because of its simplicity and lack of toxicity. However, local 
injection of plasmid DNA leads to low-level gene expression since naked DNA is susceptible 
to degradation by serum enzymes such as endonucleases, thereby reducing the amount of 
intact functional pDNA that is available in hosts to express antigen. The transportation of 
pDNA across cell membranes while entering into a host cell is limited by its net negative 
surface charge and large hydrodynamic diameter (Han et al., 2009, Ledley, 1996). In 
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addition, DNA may be degraded during being uptaken by endocytosis. These mechanisms 
reduce the chance that DNA entering nuclei will be intact and functional. The strategy to 
improve gene transfer of naked plasmid DNA is to include substances, capable of enhancing 
the efficiency of DNA internalization by target cells, in DNA solution (Gao et al., 2007). For 
example, transferrin was observed to enhance transfection in vitro (Sato et al., 2000), the 
addition of water-immiscible solvents (Schughart and Rasmussen, 2001, Schughart et al., 
1999, Desigaux et al., 2005) non-ionic polymers (Desigaux et al., 2005), surfactants 
(Freeman and Niven, 1996), hypotonic solution (Lemoine et al., 2005) has also been reported 
to increase gene transfer across cell membranes. Furthermore, several nuclease inhibitors 
have been shown to enhance naked DNA–mediated gene transfer in cultured cells, muscle, 
and lungs (Gao et al., 2007). Plasmid DNA can also be introduced into target cells by 
physical methods such as gene gun (Aravindaram and Yang, 2009, Dileo et al., 2003), 
electroporation (Li et al., 2012, Peng et al., 2012), ultrasound-facilitated gene transfer (Saliba 
et al., 2012, Song et al., 2012) and hydrodynamic gene delivery (Crespo et al., 2005, 
Herweijer and Wolff, 2006). 
 
  1.2.2.2.2 DNA lipoplex 
   Low gene transfer efficiency in naked pDNA is mainly caused by its 
susceptibility to degradation by serum and cellular enzymes such as endonucleases and 
difficulty to travel across cell membrane due to its size and charge. Lipoplexes solve these 
disadvantages by facilitating the transportation of DNA into target cells and at the same time, 
protecting DNA from being attacked by nuclease (Gregoriadis et al., 2000). However, some 
types of liposomes are subject to nonspecific binding by a large range of different cell types 
(Wivel and Wilson, 1998). 
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Due to similarity between liposomes and lipid bilayer structure of cell 
membrane, lipoplexes can fuse with the cell membrane and directly release contained DNA 
or be internalized by endocytosis –mediated mechanism. The result of endocytosis –mediated 
mechanism is the formation of a double-layer inverted micellar vesicle called endosome. 
During the maturation of the endosome into a lysosome, the rupture of endosome’s wall 
might occur resulting in a release of the contained DNA into cytoplasm and potentially 
towards the nucleus. DNA imported into the nucleus might result in gene expression. 
Alternatively, DNA might be degraded within the lysosome (Parker et al., 2003, Ferrari et al., 
2001, Tros de Ilarduya et al., 2010). Transfection of lipoplexes can be promoted by adjusting 
vesicle surface charge, size and lipid composition, or by the co-entrapment of plasmids 
expressing appropriate cytokines (e.g., interleukin 2), or immunostimulatory sequences 
(Gregoriadis et al., 2000). Transfection mechanism of lipoplex is shown in Fig. 1.8. 
 
 
Fig. 1.8 Lipoplex-mediated transfection and endocytosis (Parker et al., 2003).  
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 1.2.2.2.3 DNA polyplex 
 Polyplexes (polyelectrolyte complexes) are formed by self-assembling of 
cationic polymers, i.e. polyethylenimine (PEI), with DNA by involving ionic interactions 
(Howard et al., 2004, Duarte et al., 2007). Polyplex enables gene delivery by condensing and 
shielding DNA into small particles and facilitating cellular uptake via endocytosis through 
charge-charge interaction with anionic sites on cell surfaces (Gao et al., 2007, Tros de 
Ilarduya et al., 2010). Main difference on delivery mechanism between polyplexes and 
lipoplexes is that the release of DNA from polyplexes into cytoplasm cannot occur unassisted 
(Gao et al., 2007). Therefore, co-transfection with endosome-lytic agents such as inactivated 
adenovirus, is required. However, some cationic polymers, i.e. PEI, exhibit endosomolytic 
properties and consequently are powerful transfection agents (Boussif et al., 1995). Example 
of cationic polymers widely used in polyplex formation includes PEI, polyallylamine, 
polyamidoamine, and polypropylamine dendrimers, cationic dextran, chitosan, cationic 
proteins (polylysine, protamine, and histones) and cationic peptides (Gao et al., 2007). The 
principle of gene delivery using polyplexes is demonstrated in Fig. 1.9. 
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Fig. 1.9 Principle of gene therapy using polyplexes as carriers. Therapeutic nucleic 
acid (DNA or RNA) is mixed with a cationic polymer to form polyplex particles which can 
enter target cells by endocytosis. The polymer promotes the release of polynucleotide from 
the endosomes and the entrance of DNA to the nucleus while protecting the target nucleic 
acid from lysosomes degradation. (Reprinted with permission from Biomedical Chemistry 
group, University of Twente; http://www.utwente.nl/tnw/bmc/; last accessed on September, 
6th, 2012)  
 
1.3 Chromatography of plasmid DNA 
Although nanoplexes include wide range of nanoparticulate bioproducts such as protein 
nanoparticles, plasmid DNA, viruses, virus-like particles and macromolecular assemblies 
(Zhang et al., 2001a, Jahanshahi and Ebrahimpour, 2009, Liu and Zhang, 2011), plasmid 
DNA had been used as the test system in this thesis. Therefore, in this section, the detailed 
discussion will be solely focused on plasmid DNA. 
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1.3.1 Characteristics of plasmid DNA 
Plasmid DNA (pDNA) is double stranded extrachromosomal circular DNA molecule 
containing at least one origin of replication (ori) which results in an ability to undergo DNA 
replication independently from chromosomal DNA (Lara and Ramirez, 2012). Each strand of 
DNA is a polymer of deoxyribonucleotide monomers linked to each other by 
3’5’phosphodiester bonds to create a so-called ‘backbone’. Deoxyribonucleotide molecule 
consists of a deoxyribose and a nitrogenous base. Two single-strand DNA connect to each 
other by hydrogen bond between two complementary nitrogenous bases (Peter et al., 1998, 
Urthaler et al., 2005a), exposing sugar-phosphate backbone to the outside.  These two strands 
wind around each other and around a common axis in antiparallel fashion to form right 
handed double helix structure (Hames, 2000, Alberts, 2002) stabilised by hydrogen bonds 
between A-T and G-C base pairs and by stacking forces (Sinden, 1994). The interior of the 
double helix is highly hydrophobic due to the close packing of the aromatic bases while the 
exterior is rich in phosphate groups which are negatively charged at pH > 4 (Diogo et al., 
2005). The structure of DNA is demonstrated in Fig. 1.10. 
In order to modulate the potential energy of the molecule, pDNA helix can be coiled 
in space to form a supercoiled (SC) pDNA (see Fig 1.11). DNA supercoiling is important for 
DNA packaging within all cells since the length of DNA can be thousands of times longer 
than a cell. Moreover, supercoiling also plays an important biological function of facilitating 
local- and global-strand separation of DNA molecules during transcription and replication, 
respectively (Witz and Stasiak, 2010, Marians et al., 1977, Nollmann et al., 2007). On the 
othe hand, another portion of pDNA population can be in a non-supercoiled or open circular 
(OC) form where breakages of one of double strand (single strand nick) occur. In case of the 
cell lysate, linear or denatured pDNA can also be found. Linear pDNA results from cleavage 
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of the phosphodiester bonds in opposite site of double strand DNA (double strand nick) while 
denatured forms are caused by disruption of hydrogen bonds of complementary base pair on 
each strand (Diogo et al., 2005, Urthaler et al., 2005a). Diagram showing three different 
forms of pDNA is shown in Fig 1.12 . 
 
 
Fig. 1.10 DNA structure. (Alberts, 2002) 
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Fig. 1.11 Electron micrographs of relaxed and supercoiled plasmid DNAs. The 
molecule at the left is relaxed, and the degree of supercoiling increases from left to 
right. (Kornberg and Baker, 2005) 
 
 
Fig 1.12 Three different forms of plasmid DNA; covalently closed circular (CCC) or 
supercoiled (SC), open circular (OC) and linear. (Uji-i et al., 2006) 
 
 1.3.2 Large scale purification of plasmid DNA 
 The demands for manufacture of large amounts of high-purity therapeutic or 
pharmaceutical grade supercoiled-form pDNA have been raised due to the increasing use of 
pDNA vectors in pre-clinical and clinical trials of gene therapy and DNA vaccination 
(Przybylowski et al., 2007). Since transfection efficiency of pDNA is considerably low (only 
one in every 1000 plasmid DNA molecules presented to the cells reaches the nucleus and is 
expressed) (Varley et al., 1999),  full treatments therefore require milligram quantities of 
plasmid DNA (Ferreira et al., 2000, Deshmukh and Lali, 2005). Thus, the development of 
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cost effective large-scale processes for the production of plasmid DNA has become one of the 
challenges associated with therapeutic pDNA technology. 
For the industrial scale production of pharmaceutical-grade plasmid DNA, three main 
requirements have to be met. First, the therapeutic DNA produced must be of highest purity, 
free from contamination of host cell components. Second, the process has to produce a cost-
effective yield. Last, for safety, the whole process must be compliant to regulatory guidelines 
(Urthaler et al., 2005a, Epstein, 1996). The overall process should be designed specifically to 
deliver a pDNA product that meets quality specifications set or recommended by regulatory 
organizations, such as the World Health Organization (WHO), Food and Drug 
Administration (FDA) and the European Agency for the Evaluation of Medical Products 
(EMEA) (Prazeres et al., 2001, Stadler et al., 2004). Summary of these specifications for final 
pDNA product is shown in Table 1.2. 
 
Table 1.2 Specifications of accepted levels of impurities for the final pDNA product, 
adapted from FDA and WHO guidance. (Diogo et al., 2005, Stadler et al., 2004, Urthaler et 
al., 2005a, Sousa et al., 2008) 
Issue in focus Range of acceptance Determined by 
Endotoxin < 0.1 E.U./mg pDNA LAL test 
Host genomic DNA < 0.05 µg/ mg pDNA TaqMan-PCR 
RNA undetectable Analytical HPLC 
Host protein undetectable BCA test 
SC over total pDNA > 97%  CGE 
       FDA guidance for cellular and gene therapy can be accessed via the U.S. Food and Drug Administration 
officaial website; 
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Cellulara
ndGeneTherapy/default.htm 
       WHO regulatory policy for gene therapy can be accessed via WHO official website; http://www.who.int/en/ 
       Abbreviations; LAL : Limulus amebocyte lysate, PCR : Polymerase chain reaction, HPLC : High     
               performance liquid chromatography, BCA : Bicinchoninic acid, CGE : capillary gel  
   electrophoresis. 
 
30 
 
 
The supercoiled (SC) form is considered as most stable and most appropriate for 
therapeutic applications due to the highest transfection efficiency compared to the other 
plasmid isoforms and is therefore the most desirable form (Urthaler et al., 2005a, Urthaler et 
al., 2005b, Han et al., 2009, Latulippe and Zydney, 2009). According to regulatory 
organizations guidelines, percentage of supercoiled form compare to the total pDNA is one of 
the main parameter to consider the quality of a pDNA preparation for therapeutic use (Table. 
1.2).  
Generally, a process for production of therapeutic pDNA mainly consists of 3 steps 
(see Fig. 1.13); (i) fermentation, (ii) cell lysis and (iii) purification (Urthaler et al., 2005a). 
This chapter will only focus on the downstream processes; cell lysis and chromatographic 
purification. 
 
Fig. 1.13 Overall process for therapeutic plasmid DNA production. Modified from 
Prather et al. (Prather et al., 2003). 
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  1.3.2.1 Cell lysis 
Large scale productions of pDNA are normally conducted via fermentation, 
using E. coli as the production host. The efficiency of fermentation process is strongly 
influenced by the host strain, fermentation mode, the medium compositions and harvesting 
point (Urthaler et al., 2005a). After fermentation, harvested cells undergo the lysis step where 
the cells are disintegrated in order to release the intracellular components (Fig. 1.14). 
Currently, most of bacterial cell lysis techniques (homogenization, freeze/thaw, lysozyme 
digestion etc.) have been optimized for the purification of recombinant proteins and mostly, 
are not suitable to plasmid DNA purification. Homogenization operates at high shear rate 
therefore, inapplicable on shear-sensitive polynucleotide such as pDNA  (Carlson et al., 
1995). Freeze/thaw process was reported for causing the loss of supercoiled form pDNA 
(Kong et al., 2008). Lysozyme digestion is not applicable for therapeutic proposes since it 
relies on the use of lysozymes which are normally acquired from animal origins, i.e. egg 
white. For therapeutic DNA production, animal originated substances are prohibited by 
regulatory agencies due to safety concerns. Considering these disadvantages of the other 
methods, chemical lysis seems to be the method of choice for industrial-scale production of 
pDNA. Usually, bacterial cell disruption is performed using alkaline lysis method, first 
introduced by Birnboim and Doly (1979). This procedure is based on the cell disruption by 
the combination of sodium hydroxide and the detergent, sodium dodecyl sulfate (SDS) which 
leads to cell lysis and release of the intracellular components. Proteins and genomic DNA are 
subsequently precipitated by the following neutralization step involving potassium acetate 
addition (Birnboim and Doly, 1979). During neutralization, supercoiled plasmid DNA 
anneals from its pH-denatured state while large molecular weight (~200 kb) genomic DNA 
cannot diffuse and anneal properly, resulting in single-stranded genomic DNA precipitation 
(Prather et al., 2003) which can be removed by filtration or centrifugation. The clarified cell 
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lysates normally appear as a  diluted, viscous plasmid mixture in the presence of high salt 
concentration containing plasmid DNA at concentrations of < 3% of the clarified cell lysate 
even when high copy number plasmid was applied (Kepka et al., 2004b, Stadler et al., 2004, 
Sousa et al., 2008). The downfall of this method is the conversion of supercoiled pDNA to 
the alternative forms (e.g. denatured supercoiled, multimeric, open circle, and linear) since 
the DNA had actually denatured during this process. Also, if vigorous mixing was applied, 
shear force can cause fragmentation of genomic DNA which leads to the difficulty in the 
subsequence purification (Prather et al., 2003). Hence, it is critical to avoid shearing the 
chromosomal DNA into small fragments or breaking the precipitate network to prevent 
contamination of gDNA into the cleared lysate. This can be accomplished by avoiding 
vigorous mixing after addition of the alkaline detergent and potassium acetate solutions. At 
large scales, thorough mixing without substantial shearing presents a challenge. Once the 
precipitate has been removed, there is less concern about shearing unless the shear stress is 
very high or the plasmid is large (>15 kb) (Durland and Eastman, 1998, Levy et al., 1999). 
 
Fig. 1.14 Electron micrograph of DNA from a lysed E. coli cell. White arrows indicate 
circular plasmid DNA. (Nelson and Cox, 2008) 
 
33 
 
 
  1.3.2.2 Chromatography 
  After alkaline lysis, the major impurities remaining in the process stream are 
RNA, gDNA fragments, endotoxins, and proteins. Generally, RNA can be reduced by 
addition of RNA-digesting enzymes, such as RNase. However, this approach cannot be used 
for the purification of therapeutic pDNA since the application of animal-derived materials, 
such as commercially available RNases, is prohibited by regulatory organizations (Sousa et 
al., 2008). The removal of endotoxins is particularly critical since these lipopolysaccharide 
components of the E. coli cell wall can produce symptoms of toxic shock syndrome if present 
in sufficient quantities in vivo (Wei et al., 2007). Moreover, in terms of physiochemical 
properties, the similarities of these impurities’ molecules to plasmid DNA and their wide 
molecular weight range makes purification difficult (Prazeres et al., 1999). Apart from 
impurities, the separation of the undesirable pDNA isoforms to achieve high purity 
supercoiled plasmid is also essential (Urthaler et al., 2005a, Sousa et al., 2008). For pDNA 
purification, most of the available processes for pDNA purification i.e. organic solvent 
precipitation (Murphy et al., 1999), organic solvent extraction or ultrafiltration are time-
consuming and lack of scalability (Han et al., 2009). Moreover, product specification 
guidelines stated by the regulatory authorities dictate that the application of materials that are 
not certified for administration in human or application of enzymes of animal origins or toxic 
reagents such as phenol, CsCl, CsBr, etc., are unacceptable (Miller et al., 1997; Ferreira et al., 
2000; Shamlou, 2003; Prather et al., 2003; Eon-Duval and Burke, 2004). Hence, 
chromatography, considered as the method with highest resolution , becomes essential for 
production of pDNA suitable for therapeutic applications (Urthaler et al., 2005a). Moreover, 
chromatography processes are well established, scalable and normally provide proven track 
record which make it highly preferable for pharmaceutical products (Przybylowski et al., 
2007).  
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The most commonly used chromatography techniques for therapeutic pDNA 
purification are anion exchange (AEC), size-exclusion (SEC), hydrophobic interaction (HIC) 
and affinity chromatography (AC) (Eon-Duval and Burke, 2004, Diogo et al., 2000a, Horn et 
al., 1995). These chromatography techniques are fundamentally discussed as presented 
below, along with their advantages and disadvantages towards pDNA purification. 
 
1.3.2.2.1 Anion exchange chromatography (AEC) 
   Ion-exchange chromatography plays an important role in downstream 
processing of bio-molecules by offering the advantages of robustness, rapid separation, no 
solvent requirement, and a wide selection of process-grade stationary phases (Hanora et al., 
2006, Diogo et al., 2005). Since DNA displays the negatively-charged property, anion 
exchange chromatography (AEC) mode is applied. 
   AEC is based on the interaction between positively charged-anion 
exchange ligands c.g. quaternary amine (Chandra et al., 1992), Diethylaminoethyl (DEAE) 
(Muller, 1986), on the stationary phase and negatively charged phosphate groups in the DNA 
backbone (Prazeres et al., 1998, Prazeres and Ferreira, 2004). Elution patterns of nucleic 
acids bound to supports are functional to increasing charge density and was also found to 
depend on nucleotide sequence and nitrogenous base composition (Yamakawa et al., 1996, 
Muller, 1986). In most cases, the more compact supercoiled pDNA binds more tightly to the 
supports therefore, elutes later than other forms due to its higher overall charge density 
(Prazeres et al., 1998). It has been reported that some other polyanionic molecules i.e. gDNA 
fragments (Prazeres and Ferreira, 2004) and endotoxins (Wicks et al., 1995) may co-purify 
with the plasmid due to their similar binding affinities and limited diffusion of the 
macromolecules inside the adsorbent pores (Lyddiatt and O'Sullivan, 1998, Prazeres and 
Ferreira, 2004). These high molecular weight impurities can also compete with target pDNA 
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for binding sites and tenaciously adhere to the anion-exchange matrices resulting in decreased 
binding capacity of target pDNA (Prazeres and Ferreira, 2004). Moreover, ion exchange 
chromatography can also suffer from low pDNA binding capacity since most of the IEC 
supports available commercially were designed for protein purification while pDNA is too 
large to enter the pores being restricted to bind only at the support surface (Eon-Duval and 
Burke, 2004, Prazeres et al., 1999, Gustavsson et al., 2004, Tiainen et al., 2007b, Mao et al., 
1993, Ljunglöf et al., 1999, Grunwald and Shields, 2001). It was reported that dynamic 
capacities higher than 3 mg/mL gel, as can be expected in the field of protein purification 
while pDNA binding capacity is much less due to the large size (Prather et al., 2003). 
Ljunglöf et al. (1999) reported a study on direct visualisation of plasmid DNA adsorption on 
individual Q Sepharose XL particles by employing confocal scanning laser microscopy. 
Plasmid DNA visualization was aided by the fluorescent dye, YOYO-1, which forms a highly 
fluorescent complex with double stranded DNA. The results revealed that adsorption of 
plasmid DNA mainly takes place in an outer layer of the particles (Fig. 1.15) (Ljunglöf et al., 
1999). Another disadvantage for ion exchange chromatography is similarity between the 
charge properties of target products and the charge properties of some impurities, resulting in 
binding and elution of impurity species alongside the targets (Diogo et al., 2005). 
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Fig. 1.15 A study on direct visualisation of plasmid DNA adsorption on individual Q 
Sepharose XL particles published by Ljunglöf et al. showing plasmid adsorption being 
restricted on the surface of the support. (a) Confocal image of Q Sepharose XL saturated with 
plasmid DNA. The rectangular box represents the area that was evaluated. (b) Fluorescence 
intensity profile after image analysis: x-axis shows distance along the axis of the particle (in 
pixels of 0.42 μm) and y-axis fluorescence intensity (in arbitrary units) (Ljunglöf et al., 
1999).  
   
   1.3.2.2.2 Size exclusion chromatography (SEC) 
   Size-exclusion chromatography (SEC) (also known as ‘gel filtration’) 
fractionates and purifies plasmids on the basis of size and conformation (Prazeres and 
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Ferreira, 2004, Sousa et al., 2008).  Typically, the different DNA isoforms are eluted as a 
broad, non-Gaussian peak i.e.; gDNA elutes first as the leading edge, followed by open 
circular and then supercoiled plasmid (Yoshinaga and Suzuki, 1983, Moreau et al., 1987). 
Smaller molecules such as RNA, DNA fragments, and salts can be easily separated from the 
leading DNA peak due to their differences in size affect their retention times. The choice of 
the fractions to be collected can be identified easily, enables the recovery of almost pure 
supercoiled plasmid (Prazeres and Ferreira, 2004); free from proteins, RNA, and gDNA 
(Moreau et al., 1987, Stadler et al., 2004, Urthaler et al., 2005b). Moreover, substantial 
reduction in endotoxin loads as well as isoforms separation between supercoiled and open 
circular form also achieve (Prazeres and Ferreira, 2004, Horn et al., 1995). 
Due to the compact structure which leads to a reduction in size, 
supercoiled pDNA tends to elute later than the other isoforms. Yoshinaga and Suzuki (1983) 
published the effect on retention time of plasmid isoforms by purifying different 4.36 kbp 
plasmid isoforms using a Toyopearl HW75S column and the greater retention volume of 
supercoiled isoform compared to the open-circular isoform was observed (Yoshinaga and 
Suzuki, 1983). Moreau et al. (1987) reported that separations of different plasmid isoforms 
showed a reduction in the resolution between the supercoiled and open-circular isoforms with 
increasing plasmid size when applied alkaline lysis-SEC purification procedure using 
Fractogel TSK75S column on different plasmids with the size ranging from 2.9 to 17.5 MDa 
(Moreau et al., 1987). Retention behaviors of different pDNA isoforms during SEC 
purification was found to depend on the effective molecular size (Potschka, 1991). 
Disadvantages of SEC are its limited capacity (< 2% column volume) 
(Diogo et al., 2005), reduced resolution at higher loading and the dilution of the plasmid 
product which consequently requires an extra step for concentration. Furthermore, few SEC 
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resins available commercially have limited selectivity to be used in plasmid purification 
(Prazeres and Ferreira, 2004). Gomez-Marquez et al (1987) reported an observation of a 
limited selectivity between plasmid isoforms obtained from purification of pDNA (2.7 kbp) 
from clarified bacterial lysates on a Sephacryl S-1000 column. All three isoforms eluted as a 
single peak (Gómez-Márquez et al., 1987). The same observations was noticed by Latulippe 
and Zydney (2009) when different isoforms of plasmids (sizes ranging from 3.0 -17.0 kbp) 
was purified by Sephacryl S-1000 SF. The elution peaks of the three isoforms overlapped on 
one another, indicated the limitation of isoform separation (Latulippe and Zydney, 2009).   
For pDNA purification, SEC can be applied alone (Horn et al., 1995, 
Bywater et al., 1983, Ferreira et al., 1997, McClung and Gonzales, 1989, Raymond et al., 
1988, Latulippe and Zydney, 2009) or in combination with other chromatographic techniques 
such as anion exchange (Varley et al., 1999, Prazeres and Ferreira, 2004). The use of a 
simulated moving bed chromatography system employing SEC for plasmid purification was 
also published (Paredes et al., 2005). 
 
   1.3.2.2.3  Affinity chromatography (AC) 
   Affinity chromatography is based on the specific reversible interaction 
between a particular structure in the target molecule and a ligand immobilised on the 
stationary phase (Prazeres and Ferreira, 2004, Diogo et al., 2005). This method specifically 
purifies biomolecules on the basis of their specific biological function or individual chemical 
structure (Lowe et al., 2001, Kanoun et al., 1986, Sousa et al., 2008). The specific 
interactions occurring between the ligand and target molecule can occur by electrostatic 
interactions, hydrophobic interactions, van der Waals forces and/or hydrogen bonding (Sousa 
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et al., 2008). As a consequence, the specific nature of the employed interactions resulting in a 
high selectivity and resolution, the major advantage of AC (Platonova and Tennikova, 2005).  
The choice of stationary phase and operating conditions depend on 
the molecular properties of target biomolecules and the physicochemical and thermodynamic 
nature of the molecular interactions between the two (Mallik and Hage, 2006, Sousa et al., 
2008). Elution can be performed either specifically by using a competitive ligand or non-
specifically by changing the pH, ionic strength or polarity depending on the support used and 
the chemical characteristics of the biomolecules in which perform the interaction (Sousa et 
al., 2008). Different types of AC have been reported and are briefly discussed below; 
i). Triple-helix affinity chromatography (THAC) 
Triple-helix affinity chromatography is based on the formation 
of a triplex between an oligonucleotide covalently linked to a chromatographic matrix, and a 
specific duplex sequence in the target pDNA (Wils et al., 1997, Diogo et al., 2005). This 
triple-helix interaction is only possible if a suitable target homopurine sequence has been 
previously inserted into the pDNA (Wils et al., 1997, Schluep and Cooney, 1998). Stationary 
phase is covalently attached by pyrimidine oligonucleotide in order to bind to duplex DNA 
via the major groove and through the formation of Hoogsteen hydrogen bonds (Sousa et al., 
2008). The preferable operating pH is mild acidic since cytosine protonation is required to 
maintain stability of the triple-helices (Schluep and Cooney, 1998). In alkaline condition, the 
dissociation of triple-helices occurs (Sousa et al., 2008). 
THAC is claimed to purify plasmid DNA in one step while 
significantly reduce the levels of impurities (Prazeres et al., 1999). Despite highly selective 
property, THAC has a low versatility since each ligand targets only specific base sequence 
which can lead to a prohibitively high cost for scaling-up. Moreover, low binding kinetics 
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was also noticed. (Prazeres and Ferreira, 2004, Han et al., 2009). Another limitation is that 
when the ligands of biological origin were used, a safety issue arises since these ligands tend 
to be fragile and may leak out and contaminate the product (Kanoun et al., 1986, Diogo et al., 
2005, Sousa et al., 2008). 
ii). Protein–DNA affinity chromatography 
A bi-functional protein was prepared by fusing a zinc finger 
(ZF) DNA binding domain with glutathione S-transferase (GST) as the N-terminal domain 
(Woodgate et al., 2002). The ZF protein is a consensus sequence ZF protein that binds to the 
sequence 5-GGG-GCG-GCT-3, while the GST domain is able to bind to matrix immobilised 
glutathione. In this way, a complex can be formed between a target pDNA, containing the 
recognition sequence and glutathione-Sepharose. The protein–pDNA complexes can then be 
recovered from glutathione-Sepharose by competitive elution with reduced glutathione buffer 
(Diogo et al., 2005).  
 
iii). Immobilised metal affinity chromatography (IMAC) 
Immobilised metal affinity chromatography has been recently 
applied to pDNA purification, using an imino diacetic acid (IDA) resin charged with Cu(II) 
(Murphy et al., 2003). The resin was found to bind exposed purine bases in solution. In this 
way, denatured DNA and RNA bind to the IMAC column whereas the pDNA, not having 
exposed purine, is not absorbed (Diogo et al., 2005).  
 
iv). Boronate affinity chromatography (BAC) 
One of the few differences between RNA and DNA which can 
be used to facilitate the separation is the presence of a vicinal 2,3cis-diol at the 3’ end of 
RNA molecules  but absent in DNA molecules (Singh and Willson, 1999). Boronate ligands 
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(e.g. m-aminophenylboronic acid) attached to chromatographic matrices are able to recognise 
and bind RNA molecules via this feature. BAC has been used essentially in applications in 
which RNA is the desired product (e.g. ribozyme science and rRNA probe methods). 
Although the use of BAC has not been described in the context of pDNA purification, its 
application as a way of reducing the RNA content in pDNA-containing clarified or pre-
purified lysates should not be overlooked (Liu, 2006, Singh and Willson, 1999, Diogo et al., 
2005). 
 
v). Polymyxin B affinity chromatography 
Polymyxin B is a cationic polypeptide antibiotic that has 
bactericidal activity against gram-negative bacteria. This activity is based on the ability to 
disorganize the bacterial cell wall due to the specific interaction of polymyxin B with the 
lipidic structure of endotoxins (Lipid A) (Petsch and Anspach, 2000). This ability has been 
explored by affinity chromatography with polymyxin B functionalized onto Sepharose to 
significantly reduce endotoxin contamination (200–100,000-fold) in pDNA solutions 
(Montbriand and Malone, 1996, Wicks et al., 1995).  However, low yields were obtained as a 
result of non-specific ionic interactions between pDNA and polymyxin B (Wicks et al., 
1995). Another disadvantage of the technique is related with the neuro- and nephrotoxicity  
of polymyxin B and stimulation of monocytes to release interleukin-1(Petsch and Anspach, 
2000). 
 
   1.3.2.2.4 Hydrophobic interaction chromatography (HIC)   
Hydrophobic interaction chromatography (HIC) has been used for 
pDNA purification (Diogo et al., 2000a, Diogo et al., 2001, Diogo et al., 2000b) and is 
considered to be the methods of choice for selective separation of pDNA isoforms and 
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endotoxin reduction (Stadler et al., 2004). Stationary phases derivatised with mildly 
hydrophobic ligands allow the separation of supercoiled and open circular plasmid DNA 
from protein, RNA, gDNA, endotoxins, denatured plasmid forms and oligonucleotides 
(Latulippe and Zydney, 2009, Prazeres and Ferreira, 2004, Iuliano et al., 2002b). HIC 
separates pDNA from these impurities by relying on their difference in hydrophobicity. 
Double helix structure of plasmid are formed by exposing hydrophilic sugar-phosphate 
backbone to the outside while hydrophobic aromatic bases are packed and shielded inside (Li 
et al., 2005). As long as double strand of the plasmids remain intact (i.e. in supercoiled or 
open circular form), their interactions with the HIC support are minimal (Prazeres and 
Ferreira, 2004). Contrarily, denatured gDNA and RNA are single-stranded having 
hydrophobic bases exposed, resulting in higher hydrophobicity and stronger interactions with 
the hydrophobic ligands compared to circular or supercoiled pDNA (Li et al., 2005). 
Endotoxins are polyanionic amphiphilic molecules that can form multimolecular aggregates 
with a complex supramolecular structure. High hydrophobicity content enables endotoxins to 
interact with the HIC media even more strongly via the lipidic moiety (Diogo et al., 2000a, 
Petsch and Anspach, 2000, Li et al., 2005). This endotoxin binding property make HIC 
become attractive for endotoxin removal. Since the hydrophobicity of pDNA are rather small, 
binding to stationary phases requires high salt concentration which is commonly considered 
as a disadvantage, especially for industrial application since the use of salt elevates the cost 
and associates with environmental impact. Elution is generally performed by decreasing the 
salt concentration of the mobile phase in order to weaken the hydrophobic interactions 
(Jungbauer et al., 2005, Iuliano et al., 2002a, Xiao et al., 2007, Diogo et al., 2005). In the 
cases of nucleic acids, retention on HIC is mainly affected by their size, base composition 
and structure (Ferreira et al., 2000). 
43 
 
 
During purification process, HIC media mainly adsorb impurities 
(protein, RNA, gDNA, endotoxins, denatured plasmid forms and oligonucleotides) while 
intact pDNA does not bind due to its low hydrophobicity (Li et al., 2005). Diogo et al. 
described the application of HIC for purification of supercoiled plasmid DNA by using 
sepharose gel derivatized with 1,4-butanedioldiglycidylether under non-denaturing condition. 
All contaminants were absorbed on HIC matrices and separated from non-binding plasmid 
DNA (Diogo et al., 2001, Diogo et al., 2000b). Other cellulose and Sepharose-based HIC 
matrices were also found to promote the binding of poly A, denatured DNA and viral RNA 
via hydrophobic interactions (Cashion et al., 1980). This binding behavior may become a 
solution for the commonly encountered problem of low DNA binding on common media 
caused by inadequate pore sizes as discuss earlier by facilitating the ‘negative mode’ 
chromatography where impurities bind to supports while target DNA appears in the 
flowthrough.   
 
1.4 Bilayered SEC/IEC supports 
Many efforts on chromatography support development have been made by researchers in 
order to solve the surface-restricted binding of such large biomolecules as nanoplexes on 
particulate chromatographic supports. Matrices properties have been improved by various 
approaches such as; extending the support’s surface area by grafting extender polymers to the 
beads (Theodossiou et al., 2001, Müller, 1990, Theodossiou et al., 2000a), using small non 
porous support particles to get rid of pore flow problem (Levy et al., 2000, Sumita et al., 
1994, Tiainen et al., 2007b). Another attempt has been made on exploring new choices of 
matrix formats which contain networks of large flow pores to allow plasmids to be 
transported into the interior of the supports by convective flow i.e.; ‘superporous’ matrices 
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(Deshmukh and Lali, 2005, Tiainen et al., 2007a), membranes (Teeters et al., 2003, Chang et 
al., 2008, Grunwald and Shields, 2001), non porous silica fibre (Tiainen et al., 2007b) and 
monolith (Urthaler et al., 2005c, Yamamoto et al., 2009, Sousa et al., 2011, Savina et al., 
2005, Branovic et al., 2004, Plieva et al., 2004). However, these solutions still have some 
drawbacks. Small beads lead to pressure drop limitation (Teeters et al., 2003). Membranes 
possess problems such as uniform flow distribution, a relatively large dead volume and 
scalability (Urthaler et al., 2005c). Large pore monoliths only provide limited surface areas 
on their pore walls (Plieva et al., 2004) and the high operation pressure leads to high shear 
rate which may harm some fragile target molecules.  
Amongst the various chromatography modes available for the purification of nanoplexes, ion 
exchange (IEC) and size exclusion (SEC) chromatography have been the most widely used 
(Ferreira et al., 2000, Gustavsson et al., 2004). However, due to the disadvantages of these 
techniques as mentioned earlier, an increase interest in ‘negative modes’ of adsorption 
chromatography has emerged. In negative mode chromatography, small impurities are bound 
and target species pass through the column (Jahanshahi et al., 2005). The negative mode also 
benefits pDNA purification due to the minimal interaction between nanoplexes and matrices 
resulting in the minimal changes on target nanoplex structure. HIC also provide a satisfying 
separation power but the main disadvantage is the use of high salt concentration. Hence, the 
idea of bilayered SEC/IEC supports which combine the strengths of SEC and IEC, possessing 
a functionalized core to capture small impurities and inert, non-stick surface to exclude large 
charged micromolecules (Fig. 1.16) becomes more attractive.  
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Fig. 1.16 Schematic showing separation of nanoplex from smaller chemically similar 
contaminants using bi-layered SEC-AEC hybrid chromatography supports. 
 
Existing approaches to produce bilayered SEC/IEC supports in order to exclude large 
biomolecules mostly have been done on expanded bed adsorption (EBA) supports i.e. 
laminating IEX base matrices with a non- charged polymer layer i.e. agarose and cross-linked 
agarose. Dainiak et al. (2002) reported coating Amberlite resins with cell-repelling polymer, 
polyacrylic acid (PAA) for a direct capture of shikimic acid from fermentation broth. The 
negatively charged polymer, PAA, was physically absorbed onto the anion exchanger surface 
followed by a covalent cross-linking. The target molecule, shikimic acid, is small enough to 
travel across the PAA layer while large negatively charged structures such as cell and cell 
debris are repelled from binding to the support (Dainiak et al., 2002). In 2004, Viloria-Cols et 
al. reported the effect of shielding an adsorbent with a layer of agarose on reducing the cell 
binding while still allowing the low-molecular-mass bioproducts to be adsorbed. An AEX 
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resin, Amberlite IRA-400, was coated with agarose followed by cross-linking the agarose 
layer. Resulting SEC/IEC support was seen to effectively prevent the binding of E. coli, 
Saccharomyces cerevisiae, and Lactobacillus casei cells but at the same time, allowed the 
binding of lactic acid to the adsorbent (Viloria-Cols et al., 2004). Jahanshahi et al. (2008) 
introduced a novel prototype polymer-coated adsorbent (PCA) manufactured by using the 
three-phase emulsification process to laminate anion exchange base matrix with agarose gel. 
The non-stick exterior coating acts as a sieve reducing the non-specific binding of cell and 
cell debris without diminution of selective capture of target protein from complex particulate 
feedstocks such as whole microbial broths and cell debris (Jahanshahi et al., 2008). However, 
the lamination of adsorbents with gel forming polymer possesses a fundamental problem of 
difficulty in casting sufficiently thin, uniform, mechanically robust layers around core 
particles, resulting in the compromised bed expansion properties, hydrodynamics and 
intraparticle mass transfer (Arpanaei et al., 2010). 
Another approach to created bilayered SEC/IEC supports is applying low temperature plasma 
discharge treatment. In 2010, Arpanaei et al. introduced the application of low temperature 
glow discharge plasma for preparation of bilayered SEC/IEC from commercial strong anion 
exchanger, Q HyperZ. Plasma treatments were employed to either: (i) shave off the surface 
charges from the support particles (plasma etching): or (ii) coat the support particles with 
nano-thin polymer (plasma polymerization). The modified Q Hyper Z exhibited surface 
charge elimination without any damage on support structure. The DNA induced inter-particle 
cross-linking was not observed during dynamic binding study in EBA mode while the core 
protein binding capacity remained unchanged (Arpanaei et al., 2010). 
 
However, these existing approaches are based on EBA systems while only few researches 
were published on packed bed column chromatography systems. In 2004, using the AGE 
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activation-partial bromination approach based on Bergstorm’s methods (Bergstrom, 2002), 
Gustavsson et al. produced a bilayered SEC/IEC for packed bed chromatography. This so-
called ‘lid bead’ was produced by chemically functionalisation of commercially available 
SEC base matrix, Sephacryl S500 HR. Conclusively, this process consists of (i) introduction 
of allyl groups (CH2=CH-CH2-) throughout the structure of supports by reaction of allyl 
glycidyl ether (AGE) with hydroxyl groups on the support; (ii) partial bromination of allyl 
groups on the surface of each particle to create an outer layer via addition reaction; (iii) 
hydrolysis of the resulting outer layer of bromo-alkyl groups to create an inert outer layer; 
(iv) full bromination of the remaining allyl groups on support’s core; and finally (v) coupling 
of a quaternary amine ligand, trimethylamine (Q), to the core. This lid bead was further 
applied to an integrated process for purification of a 6.1 kbp plasmid from a clarified E. coli 
lysate. This integrated process consisted of ultra/diafiltration step combined with 
polymer/polymer aqueous two-phase system and finally, lid bead was used for polishing step. 
The overall process yield for plasmid DNA of 69% was achieved (Kepka et al., 2004a, 
Gustavsson et al., 2004). However, some problems were noticed in these bi-functional 
supports. For example, in tests with clarified alkaline lysate feedstocks at high ionic strength, 
it was necessary to sacrifice over 30% of the support’s RNA binding capacity in order to 
prevent pDNA binding. Such problem appears to result from an imperfect ability to control 
the thickness and inertness of the outer size excluding layer, combined with a lower than 
ideal definition between the inert outer layer and charged core. Due to the poor control of the 
thickness of inert outer layer, the ineffective mass transfer is also expected  (Arpanaei et al., 
2010). 
It has been realized that for AGE activation- partial bromination approach, in order to obtain 
the maximum elimination of surface pDNA binding while maintain the maximum core 
binding for impurities, the inert outer layer needs to be very thin where charge elimination 
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occurs densely and restricted on the outermost surface of support particle. Therefore, core 
binding is not compromised. This can be achieved by optimization of the bilayer-defining 
step, partial bromination. 
 
1.5 Aims 
The aim of this study is to explore the preparation of SEC/IEC support for ‘one column-one 
bead’ nanoplex purification using AGE activation/partial bromination route via two different 
approaches; viscosity enhancement-reaction/diffusion balancing (VE-RD) and microwave 
assisted reaction diffusion balancing. Plasmid DNA, representing the nanoplexes, was used as 
a test system. Parameters affecting the properties of SEC/IEC matrices produced were 
assessed for the impacts on supports’ characteristics. Characterizations of SEC/IEC supports 
were performed by means of physical, chemical and biological approaches to determine the 
most effective production conditions. Supports candidates were further evaluated by 
application on column chromatography for plasmid DNA purification from neutralized E. 
coli cleared lysate. Effects of different chromatographic operating parameters on the 
performance of SEC/IEC columns were also tested.   
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Chapter 2 
Viscosity enhanced, reaction-diffusion balancing for the 
preparation of SEC/IEC supports 
 
Abstract 
SEC/IEC support preparation via an AGE activation-partial bromination route, using viscosity 
enhancement to achieve a balanced reaction-diffusion rate (VE-RD), was studied on 
Sepharose CL-6B. Parameters examined included: types of solvent and viscosity enhancers, 
viscosities, and temperatures used for partial bromination reaction as well as degrees of partial 
bromination and numbers of bromination-hydrolysis cycles. Single 10% partial bromination 
at room temperature in 64% (w/v) aqueous sucrose without sodium acetate addition was 
found to be the the most suitable condition for SEC/IEC Sepharose CL-6B production due to 
the high selectivity indices seen in the bilayered SEC/IEC products and the simplicity of 
process scale up compared to double 10% bromination. 
 
2.1 Introduction 
Since the success of the first approved trial on a four year-old girl suffering from severe 
combined immunodeficiency (SCID) in 1990 (Blaese et al., 1995, Sheridan, 2011), gene 
therapy and DNA vaccination have raised huge interest as techniques for prevention of 
treatment of diseases via gene transfer, and show great promise for fulfilling current 
worldwide requirements for therapeutic usage. DNA vaccines bases on plasmid DNA 
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containing specific genes encoding target proteins and can activate both cell-mediated 
immunity and humoral responses (Prather et al., 2003). DNA vaccinations have yielded 
highly attractive results against parasitic infections (Ivory and Chadee, 2004, Carvalho et al., 
2010) such as malaria (Doolan and Hoffman, 2001, Doolan et al., 2003) and viral infections 
such as AIDS (Mascola and Nabel, 2001, Smith et al., 2004). Recent developments of DNA 
vaccine for cancer treatment have been also reported (Anderson and Schneider, 2007, Cohen, 
2001, Ma and Yang, 2010). Gene therapy aims to treat genetic defects such as severe 
combined immunodeficiency (SCID) (FISCHER et al., 2011, Blaese et al., 1995, Fischer et 
al., 2010) i.e. cystic fibrosis (Desigaux et al., 2005, Diogo et al., 2000a, Prazeres et al., 1999), 
or acquired diseases i.e. cancer (Frederiksen et al., 1999, Horn et al., 1995, Jia et al., 2012, 
Wysocki et al., 2002), AIDS (Lisziewicz, 1997, Sorg and Methali, 1997, Zaia, 2003), 
Parkinson’s disease (Dass and Kordower, 2007, Fiandaca et al., 2008, Lewis and Standaert, 
2008, Lim et al., 2010, Rodnitzky, 2012) etc. 
Although the therapeutic genes can be transferred by several types of viral vectors, plasmid 
DNA (pDNA) vectors have been considered to be safer, simpler to use and easier to produce 
on a large scale at reasonable cost (Diogo et al., 2005, Wolf et al., 2009).  The safety aspect of 
pDNA vector has been emphasized by several cases of viral vector-associated toxicity during 
clinical trials. In 1999, an 18 year-old volunteer, Jesse Gelsinger was the first person who died 
on a gene therapy trial using adenoviral vector (Glover et al., 2005, Sheridan, 2011). In 2008, 
Hacein-Bey-Abina et al. reported that 4 out of 10 patients developed T cell leukemia 31-68 
months after a gene therapy using retroviral vector (Hacein-Bey-Abina et al., 2008). The 
increasing use of pDNA vectors in pre-clinical and clinical trials of gene therapy and DNA 
vaccination has raised the demand for manufacture of large amounts of high-purity 
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therapeutic or pharmaceutical grade supercoiled-form pDNA. Therefore, a need for more 
effective processes for large scale pDNA purification has arisen. 
Liquid chromatography plays an important role in process-scale manufacturing of therapeutic 
macromolecules for downstream processing due to its high resolution, capacity and the ability 
to provide the product purity required (Tiainen et al., 2007b).  Chromatography has come a 
long way since the 1950’s, when Sober and Peterson first introduced a cellulose based ion 
exchanger for protein separation (Sober and Peterson, 1958). However, despite five 
subsequent decades of chromatographic process development, commercially available 
chromatography supports still perform only one function for one given purpose. From this 
perspective, the development of chromatographic support design could be considered to be 
static. With the development of improved methods for including high-level expression of 
recombinant E. coli, combined with successful production process optimization, it can be 
predicted that feedstock yield in biopharmaceutical processes may soon be too high for 
current chromatographic techniques to deal with (Przybycien et al., 2004, Lyddiatt and 
O'Sullivan, 1998). For example, it has been considered possible that the yearly production of 
pDNA would reach the scale of kilograms or even tonnes. Therefore, downstream processing 
has become the bottleneck for pharmaceutical production and accounts for the majority of the 
manufacturing costs (Aldridge, 2006, Prazeres et al., 1999). 
Of the various chromatography modes available for the purification of plasmid DNA, ion 
exchange (IEC) and size exclusion (SEC) chromatography have been the most widely used 
(Ferreira et al., 2000, Gustavsson et al., 2004). However, each technique possesses some 
disadvantages. Ion exchange chromatography can suffer from low pDNA binding capacity 
since most of the IEC supports available commercially were designed for protein purification 
while pDNA is too large to enter the pores being restricted to bind only at the support surface 
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(Eon-Duval and Burke, 2004, Prazeres et al., 1999, Gustavsson et al., 2004, Tiainen et al., 
2007b, Mao et al., 1993, Ljunglöf et al., 1999, Zöchling et al., 2004). As the result, binding 
capacities for pDNA are usually at approximately hundreds of micrograms of plasmid per mL 
of chromatographic support while the binding capacity of ~200 mg/mL was reported for 
proteins (Shamlou, 2003). Another disadvantage for ion exchange chromatography is 
similarity between the charge properties of target molecules and the charge properties of some 
impurities, resulting in binding of impurity species alongside the targets (Diogo et al., 2005). 
 
In order to solve the problems caused by surface-restricted binding of pDNA, many efforts on 
chromatography support development have been made. Various approaches have been studied 
in order to improve the matrices properties. For example, grafting the extending polymers on 
to the support particle (Theodossiou et al., 2001, Müller, 1990). Small non-porous particles 
were also applied to solve the pore flow problem (Levy et al., 2000, Sumita et al., 1994, 
Tiainen et al., 2007b) New choices of matrix formats which contain networks of large flow 
pores to allow plasmids to be transported into the interior of the beads by convective flow  
also have been explored i.e.; ‘superporous’ matrices (Deshmukh and Lali, 2005, Tiainen et al., 
2007a), membranes (Teeters et al., 2003, Chang et al., 2008, Grunwald and Shields, 2001), 
non porous silica fibre (Tiainen et al., 2007b) and monolith (Urthaler et al., 2005c, Yamamoto 
et al., 2009, Sousa et al., 2011, Savina et al., 2005, Branovic et al., 2004, Plieva et al., 2004). 
However, these matrixes still have some drawbacks. Small particles lead to pressure drop 
(Teeters et al., 2003), disadvantages of membranes are the lack of uniform flow distribution, a 
relatively large dead volume and scalability (Urthaler et al., 2005c). Large pore monoliths 
only provide limited surface areas on their pore walls (Plieva et al., 2004) and the high 
operation pressure leads to high shear rate which may harm target molecules.  
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Size exclusion chromatography separates large biomolecules from smaller impurities based 
on their size differences, regardless of charges. However, problems still exist due to the 
comparatively low selectivity toward different isoforms of pDNA, limited capacity,  reduced 
resolution at higher loading and dilution of the plasmid product which consequently requires 
an extra step for concentration (Lemmens et al., 2003). Co-purification of the other pDNA 
species along with the most desirable form, supercoiled pDNA has been reported by many 
researchers (Gómez-Márquez et al., 1987, Latulippe and Zydney, 2009, Prazeres and Ferreira, 
2004).  
The drawbacks of both chromatographic techniques, combined with difficulties in the 
production of adsorbent material with sufficiently high capacities have increased interest in 
‘negative modes’ of adsorption chromatography in which small impurities are bound and 
target species pass through the column (Jahanshahi et al., 2005). The negative mode also 
benefits pDNA purification due to the minimal interaction between pDNA and matrices 
resulting in the minimal changes on target pDNA structure. For subtractive adsorption 
chromatography to be successful in the separation of large biomolecules from smaller 
contaminants sharing similar or identical surface chemistry, new matrices to be produced 
should possess ‘non-stick’ exteriors or barriers to exclude large entities (such as pDNA) while 
leaving the charged cores freely accessible to smaller impurities. The idea of a bilayered 
SEC/IEC support involves combining the strengths of IEC and SEC, having charged core 
which absorbs negatively charged small impurities while inert outer layer excludes pDNA, 
resulting in an effective ‘one column-one bead’ separation where impurities are ionically 
captured inside the beads while target plasmids are excluded by size and instantly come out in 
the flowthrough. Attempts to achieve a complete separation between small and large 
biomolecules possessing the same charge properties have resulted in different bilayered 
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SEC/IEC support prototypes reported, mostly on EBA system. For example, Viloria-Cols et 
al. (2004) and Jahanshahi et al (2008) reported laminating IEX base matrices with a non- 
charged polymer layer i.e. agarose and cross-linked agarose in order to exclude large 
biomolecules. Only small target molecules are allowed to enter the pores and bind to the 
support’s ligands (Viloria-Cols et al., 2004, Jahanshahi et al., 2008). The application of low 
temperature plasma discharge treatment was reported by Arpanaei et al. in 2010. This 
treatment eliminates the support’s surface charges by either (i) shaving off the surface charges 
from support particles (plasma etching) or (ii) coating the support particles with nano-thin 
polymer (plasma polymerization) (Arpanaei et al., 2010). Although these methods have 
shown some promising results, only EBA supports have been applied and tested on these 
studies while only a few publications dedicated to column chromatography systems. In 2004, 
a bilayered SEC/IEC for column purification of plasmid DNA was introduced by Gustavsson 
et al. This so-called lid-bead was produced by functionalising a commercially available SEC 
matrix, Sephacryl S500HR using via AGE activation-partial bromination approach.  
Conclusively, this process consists of (i) introduction of allyl groups (CH2=CH-CH2-) 
throughout the structure of supports by reaction of allyl glycidyl ether (AGE) with hydroxyl 
groups on the support; (ii) partial bromination of allyl groups on the surface of each particle to 
create an outer layer via addition reaction; (iii) hydrolysis of the resulting outer layer of 
bromo-alkyl groups to create an inert outer layer; (iv) full bromination of the remaining allyl 
groups on support’s core; and finally (v) coupling of a quaternary amine ligand, 
trimethylamine (Q), to the core. This lid bead was further applied to polishing step in an 
integrated process for pDNA purification from a clarified E. coli lysate. (Kepka et al., 2004a, 
Gustavsson et al., 2004). However, in order to prevent pDNA binding, over 30% loss in core 
binding capacity was necessary. Such problem seemed to caused by the inability to control the 
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thickness and inertness of the outer size excluding layer and the lack of definition between the 
outer layer and the core. Clearly, the production procedure needs to be improved. 
For AGE activation-partial bromination approach, it is important to achieve a thin brominated 
outer layer in partial bromination step in order to minimize compromisation of core charge by 
deeper penetration of bromine into the supports. This can be accomplished by, in this chapter, 
slowing the diffusion of bromine into the pores so that the bromination reaction only occurs 
on the outermost site of the supports. Fine-tuning of viscosity and temperature of the solution 
used in partial bromination reactions can aid in optimization of conditions for creating an 
SEC/IEC support structure with a thin inert outer layer to exclude pDNA without 
compromising the core binding capacity. Viscosity enhancement was mentioned in 
Gustavsson’s report (2004) by applying high concentration of sucrose during partial 
bromination. However, the effects of different viscosity values on performances of SEC/IEC 
supports have not been studied. In this chapter, the effects of different viscosity values applied 
during partial bromination on surface and core binding capacities were systematically 
examined and discussed.  
 Against the above, the aim of this study is to optimise the conditions used for SEC/IEC 
supports preparation using VE-RD balancing approaches on a commercially available 
underivatised chromatographic support, Sepharose CL-6B. Various solvents, viscosity 
enhancers and temperature conditions were tested for partial brominations, as well as different 
degrees of partial bromination and numbers of bromination-hydrolysis cycles. The SEC/IEC 
supports produced were characterised physically, chemically and biologically by means of 
electron scanning microscopy (SEM), chemical assays and binding studies with pDNA and 
bovine serum albumin (BSA).  
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2.2 Materials and methods 
2.2.1 Materials     
The SEC base matrix, Sepharose CL-6B, was purchased from GE Healthcare Bio-
Sciences (Lot number 10027527, Uppsala, Sweden). Viscosity enhancers; sucrose and 
glycerol, were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). Allyl 
glycidyl ether (AGE), 50% (w/v) sodium hydroxide solution, sodium hydroxide pellets, 
sodium borohydride (NaBH4, 99%), bromine,  sodium acetate anhydrous, sodium chloride, 
trimethylamine hydrochloride (Q) and Dimethyl sulfoxide (DMSO) used in SEC/IEC 
supports preparations were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, 
USA). Ethanol was purchased from Fisher Scientific (Loughborough, UK). 
E. coli DH5α containing the 27379 bp plasmid pITT3 was kindly provided by Dr. 
Eirini Theodosiou, Department of Chemical Engineering, Loughborough University, UK. 
This plasmid is a pPR633-based high copy number plasmid (4579 bp) and containing a 22800 
bp insert from Saccharomyces cerevisiae chromosome III at BamHI site. Luria Bertani (LB) 
broth, LB agar, D-glucose, ampicillin, polypropylene glycol (PPG) antifoam used for culture 
and fermentation were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). 
QIAfilter Plasmid Giga Kits for plasmid purification were purchased from Qiagen GmbH 
(Hilden, Germany). 
For bromine assay, standard potassium bromate solution (0.1 M) was purchased from 
Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). H2SO4 was purchased from Fisher 
Scientific (Loughborough, UK). For ionic capacity assay, mercury II thiocyanate was 
purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA) and ammonium iron III 
sulphate was purchased from Fisher Scientific (Loughborough, UK).  For binding studies, 
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bovine serum albumin (BSA), Tris HCl and Trizma base were purchased from Sigma-Aldrich 
Company Ltd. (St. Louis, MO, USA). For diphenylamine assay, diphenylamine, perchloric 
acid, acetaldehyde, glacial acetic acid and calf thymus DNA were purchased from Sigma-
Aldrich Company Ltd. (St. Louis, MO, USA). Pierce® BCA Protein Assay Kit was purchased 
from Thermo Scientific (Rockford, IL, USA). For agarose gel electrophoresis, 100x TE (10 
mM Tris-Cl, pH 7.5. 1 mM EDTA) buffer, agarose, Lambda- HinDIII marker, 6x gel loading 
dye, 10x Tris borate EDTA (TBE) buffer and ethidium bromide were purchased from Sigma-
Aldrich Company Ltd. (St. Louis, MO, USA). Distilled water was used in all experiment 
unless stated otherwise. 
 
2.2.2 Viscosity measurements 
  Rheological behavior of solutions used for viscosity enhancing was measured 
using an Advanced Rheometer AR1000 from TA Instruments (New Castle, Delaware, USA) 
equipped with a 40 mm, 2o angle stainless steel cone geometry. Viscosity changes were 
measured during the increasing temperature from 2 oC to 90 oC (applying a temperature ramp 
rate of 4oC/min) at a shear rate of 10 s-1.  
 
2.2.3 Preparation of SEC/IEC supports 
SEC/IEC supports can be produced by employing an AGE activation/ partial 
bromination route, briefly described in Fig. 2.1. The detailed procedures are also presented 
hereby.   
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Fig.2.1  Schematic diagram of SEC/IEC supports preparation via AGE activation-
partial bromination route, using VE/RD approach. Trimethylamine chloride (Q) was used for 
ligand coupling in this experiment. 
 
2.2.3.1 AGE activation  
  AGE activation (Adapted from Gustavsson et al., 2004) was carried out by 
washing 60 mL settled volume of Sepharose CL-6B with MilliQ water under vacuum. The 
suction drained support was then transferred to a 250 mL conical flask containing 0.25 g of 
AGE activation 
Partial bromination 
VE/RD balancing  
Hydrolysis  
Full bromination  
Q-coupling  
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sodium borohydride and 6.7 g of sodium sulphate in 24 mL of 50% (w/v) NaOH. The flask 
was immediately immersed in a 50oC reciprocal water bath shaker (Grant OLS 200, Grant 
Instruments Ltd., Cambridge, UK), and was left to mix at 170 rpm for 1 h. Supports slurry 
was then suction dried to remove exceed NaOH solution and transferred back to the flask. 
Fifty one millilitres of AGE was then added to the supports and the reaction was left to 
proceeded overnight (16 h) in the water bath at 40oC and 170 rpm. The AGE activated support 
was subsequently washed with: water; 70% (v/v) ethanol; and finally water once again, in 
order to eliminate the residual chemicals and solvents used in the reaction. The suction 
drained support was assayed for allyl groups content by the bromine assay. The AGE 
activated support was stored in 20% ethanol at 4oC. Allyl contents of AGE activated supports 
were 0.341 + 0.026 µg/mL supports (n=16, + standard deviation). 
 
 2.2.3.2 Partial bromination 
  A 15 mL portion of allylated supports was equilibrated 3 times in a viscosity 
enhanced solution. The equilibrated supports were then suction dried, added to a screw cap 
tube containing 12 mL of viscosity enhanced solution and mixed thoroughly. For partial 
brominations performed in the presence of sodium acetate, 0.33 g of sodium acetate was 
added at this point with thorough mixing. A calculated amount of 1% (v/v) bromine solution 
in water, aiming for 10% elimination of total allyl content, was added. The tube was 
immediately sealed and shaken vigorously until the yellow colour disappeared. Supports were 
then washed thoroughly with water. The remaining allyl content of the supports was measured 
by bromine assay.  
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  The variations of viscosity in experiments using sucrose as a sole viscosity 
enhancer were conducted by varying sucrose concentrations from 0-80% (w/v). Viscosities at 
these concentrations were further increased by reduction of temperature from room 
temperature to 2oC by placing reaction vessels in an ice bath. 
 
  2.2.3.3 Hydrolysis of the partially brominated Sepharose CL-6B  
 Ten millilitres of partially brominated supports were suction dried and added 
to a screw cap tube containing 10 mL of water. An aliquot of 1.12 mL of 50% (w/v) sodium 
hydroxide solution was added, followed by addition of 0.04 g sodium borohydride. The tube 
was sealed immediately and left to be shaken overnight at 40oC in an orbital shaker incubator 
(New Brunswick Scientific, New Jersey, USA). After time elapse, hydrolysed supports were 
washed thoroughly with water. 
 
 2.2.3.4 Full bromination of hydrolysed supports and coupling of 
trimethylamine chloride (Q) 
 Eight millilitres of hydrolysed supports were transferred to a screw cap tube 
containing 3.48 mL of water. After mixing, 0.39 g of sodium acetate was added and 
dissolved. Bromine was added to the mixture until a permanent yellow colour was obtained. 
The supports were then washed thoroughly with water and transferred to a clean screw cap 
tube containing 3.48 mL of water. A 2.61 mL portion of 50% (w/v) sodium hydroxide was 
added to the mixture followed by 0.035 g of sodium borohydride. After mixing, 5.07 mL of 
65% (w/v) trimethylamine chloride was added. The tube was sealed immediately and was left 
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at room temperature overnight on a blood tube rotator SB1 (Stuart Scientific, Staffordshire, 
UK).The supports were then washed with water, 1 M NaCl and water once again. Modified 
supports were stored at 4oC in 20% (v/v) ethanol. 
 Fully Q-coupled supports were produced by directly applying the full bromination and 
Q-coupling step step (Method 2.2.3.4) to allylated supports directly after AGE activation.  
 
2.2.4 Production of plasmid used for binding studies 
Starting cultures were prepared by inoculating 10 mL aliquots of Luria Bertani (LB) 
broth containing 50 µg/mL ampicillin with a fresh single colony of Escherichia coli DH5α 
cells containing the plasmid pITT3 and shaking overnight at 37°C and 220 rpm. A 1 mL 
portion of inoculum culture was then added to a 0.25 L shake flask containing 80 mL of LB 
broth supplemented with 50 µg/mL ampicillin and the contents were shaken on an orbital 
shaker at 220 rpm at 37°C until an OD600nm of 0.59. LB broth (final volume of 4 L) containing 
30 g/L glucose, 100 µg/mL ampicillin and Prolypropylene glycol (PPG) antifoam was used 
for the growth of E. coli in a 5 L fermenter (FerMac 360, Electrolab, Tewkesbury, UK) 
equipped with two six-blade Ruston turbines. The fermenter was operated in batch mode and 
the starting conditions employed were: temperature 37°C; agitator speed  400 rpm; air–flow 
rate 1.0 VVM; pH 7. The pH was maintained at 7.0 throughout the fermentation by the 
automatic addition of either 2 N H2SO4 or 4 N NaOH. The dissolved oxygen tension (DOT) 
was maintained above 50% by increasing the aeration and agitation. After the cells reached 
late exponential phase, the fermentation was terminated.  
Cells were harvested by centrifugation in a J2-21 centrifuge (Beckman, High 
Wycombe, UK) operated at 10,000 rpm and 4oC for 0.25 h. The cell paste (total wet weight of  
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19 g; dry cell weight of 0.872 g/L; plasmid yield of 476.76 µg/g wet cell) was stored at -20oC. 
The plasmid produced at the end of the fermentation was purified by QIAfilter Plasmid Giga 
Kit. Purified plasmid was visualised by agarose gel electrophoresis and measured for pDNA 
content using diphenylamine (DPA) assay. 
 
2.2.5 Analysis 
 2.2.5.1 Environmental scanning electron microscopy (ESEM) 
  ESEM visualization of SEC/IEC supports was kindly assisted by Mrs Theresa 
Morris, School of Metallurgy and Materials, University of Birmingham. Samples were 
prepared by dehydrating in ethanol followed by critical point drying. Imaging of samples was 
carried out on Philips XL-30 FEG Environmental SEM (FEI Company, OR, USA). 
 
  2.2.5.2 Bromine assay 
  One millilitre of an acidified bromine solution was added to 0.05 mL samples 
of suction dried supports. The mixture was shaken vigorously by a vortex mixer for 10s, the 
supports were separated by centrifugation at 10,000 g for 10s and the supernatants were 
measured for absorbance at 410 nm using a Cecil CE2040, 2000 series spectrophotometer 
(Cecil Instruments, Cambridge, UK). Sulfuric acid solution at a concentration of 0.5 M was 
used for dilutions. Sepharose CL-6B supports were used as a control and the original acidified 
bromine solution was used as blank. A bromine standard curve was prepared by measuring 
A410 of bromine in water at a concentration range of 0-10 mM with the number of moles of 
bromine that disappeared corresponding to the number of mols of allyl groups present on 1 
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mL settled bed of allylated support. The acidified bromine solution was prepared by mixing 4 
mL of standard potassium bromate solution (0.1 M) with 8 mL of 0.5 M H2S04, leave to 
develop the yellow colour for 600 s. The solution was mixed again by 3-4 times inversion.  
   
  2.2.5.3 Ionic capacity assay (Adapted from Theodossiou and Thomas, 2002) 
Half millilitre of settled bed volume of support was incubated with 25 mL of   
2 M NaCl for 1.5 h. Supports were then washed five times under vacuum with 25 mL water 
on a sintered glass filter funnel (16-40 μm nominal max. pore size) to remove excess acid. 
The drained supports were subsequently transferred to 50 mL centrifuge tubes containing 25 
mL of 0.1 M NaOH and left overnight on a blood tubes rotator SB1 at room temperature. 
During incubation with NaOH, the excess hydroxide ions (OH-) displace the Cl- ions on the 
beads. The supports were left to settle and 1 mL of liquid phase was taken for Cl- ion 
determination. 
Cl- ion determination was performed as follows: 100 µL of 0.25 M ammonium 
iron (III) sulphate in 9 M HNO3 and 100 µL of mercury (II) thiocyanate saturated in 96% 
ethanol were added to 1 mL samples, then mixed vigorously using a VM20 vortex mixer 
(Chil Tern Scientific Instrumentation, London, UK). The reaction was allowed to proceed for 
600 s at room temperature and then the absorbance of each sample was measured at 460 nm 
using UVIKON 922 spectrophotometer (KONTRON Instruments, Bletchley, UK).  
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 2.2.5.4 Static binding studies   
 Supports (0.05 mL settled bed volume) were equilibrated 3 times with 1 mL of 
0.05 mM Tris-HCl pH 8.0. Drained supports were then incubated for 0.5 h at room 
temperature on a blood tube rotator SB1 with either 15 µg/mL pITT3 plasmid solution or 5 
mg/mL BSA solution in 0.05 mM Tris-HCl pH 8.0. The supernatants were then taken to be 
analysed for DNA or protein contents using DPA assay or BCA assay, respectively.  
 
  2.2.5.5 Diphenylamine (DPA) assay 
 A 175 µL portion of pDNA binding supernatant was added to a 1.5 mL 
microcentrifuge tube followed by 25 µL of 2 mg/mL BSA solution. After vigorous mixing by 
a vortex mixer, 200 µL of 0.4 M perchloric acid (PCA) was added. The samples were 
vigorously mixed again before being incubated at 4oC for 0.5 h. Samples were then 
centrifuged at 10,000 g for 1200 s and supernatant was discarded. A 250 µL portion of  1 M 
PCA was then added to the pellet, followed by vigorous mixing on a vortex mixer and 
incubation in a water bath at 70oC for 0.5 h. Samples were then cooled to room temperature 
and 500 µL of freshly prepared chromogenic reagent was added followed by vigorous mixing. 
Samples were then incubated for 18 h in a water bath at 37oC.  Following incubation, the 
samples were measured for absorbance at 600 nm. Calf thymus DNA solutions in TE buffer, 
pH 8.0 at concentration range of 0-16 µg/mL were used to construct a standard curve for 
DNA. Water was used as blank. Chromogenic reagent was prepared by mixing 20 mL of 
diphenylamine solution (contains 1.5 g  of diphenylamine, 100 mL of glacial acetic acid and 
1.5 mL of conc. H2SO4) with 0.1 mL of 2% (v/v) acetaldehyde. 
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  2.2.5.6 Bicinchoninic acid (BCA) assay   
BCA assay for protein was carried out using a Pierce® BCA Protein Assay Kit 
(Pierce, USA) in accordance with the assay kit manual. A working reagent was prepared by 
mixing 50 parts of reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) with 1 part of reagent B 
(containing 4% cupric sulfate). To perform the assay, 1 mL of working reagent was added to a 
1.5 mL microcentrifuge tube containing 50 µL of sample. The tubes were then vigorously 
mixed by a vortex mixer and incubated in a water bath at 37oC for 0.5 h. After cooling down 
to room temperature, samples were measured for absorbance at 562 nm using a UVIKON 922 
spectrophotometer (KONTRON Instruments, Bletchley, UK). A standard curve was 
constructed as described in the assay kit manual using the standard 2 mg/mL BSA solution 
provided. 
 
  2.2.5.7 Agarose gel electrophoresis 
  Agarose gel electrophoresis was performed on 0.8% (w/v) agarose gel 
prepared with 1x TBE buffer. The gel was run in 0.5x TBE buffer in an iMyRun gel tank 
(Helixx Technologies, Ontario, Canada). Three µL of samples or Lambda- HinDIII marker 
was mixed with 7 µL of 0.5x TBE buffer and 2 µL of 6x loading dye. Twelve µL of the 
mixture was loaded onto 18 µL well. Horizontal electrophoresis was operated at 75 V for 2.5 
h. The gel was then stained in 0.5 µg/ml ethidium bromide for 0.5 h. The ethidium bromide 
stained gel was visualised using a UVP UV-transilluminator at a wavelength of 304 nm. 
Images were taken by a Kodak DC290 digital camera (Kodak, NY, USA) via Kodak 1D 
software (Eastman Kodak Company; SIS, NY, USA).   
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2.3 Results and discussion 
The preparation of SEC/IEC supports via an AGE activation/ partial bromination route 
involves: (i) allylation of the supports, introducing allyl groups (CH2=CH-CH2-) throughout 
the structure of Sepharose CL-6B by reaction of allyl glycidyl ether (AGE) with hydroxyl 
groups on the support; (ii) partial bromination of allyl groups on the surface of each particle to 
create an outer layer via addition reaction; (iii) hydrolysis of the resulting outer layer of 
bromo-alkyl groups to create an inert outer layer; (iv) full bromination of the remaining allyl 
groups on the support; and finally (v) coupling of trimethylamine (Q), a quaternary amine 
ligand, to the support’s inner core.  
In the partial bromination step, it is important to achieve a thin brominated outer layer in order 
to minimize compromisation of core charge by deeper penetration of bromine into the 
supports. This can be accomplished by, in this experiment, slowing the diffusion of bromine 
into the pores so that the bromination reaction only occurs on the outermost site of the 
supports. The idea of viscosity enhancement to facilitate reaction-diffusion rate (VE-RD) 
balancing can be explained by the Arrhenius equation, Einstein-Stoke equation and 
Arrhenius-Guzman equation as shown below; 
Arrhenius equation 
     𝑘𝑘 = 𝐴𝐴 𝑒𝑒𝑒𝑒𝑒𝑒(−𝐸𝐸𝑎𝑎/𝑅𝑅𝑅𝑅)    (Eq. 2.1)  
Einstein-Stoke equation 
     𝐷𝐷 =  kB𝑅𝑅6𝜋𝜋𝜋𝜋𝜋𝜋     (Eq. 2.2)  
Arrhenius-Guzman equation  
     𝜋𝜋 =  0.5 𝑒𝑒 10−3exp( 𝐵𝐵𝑅𝑅𝑅𝑅 )  (Eq. 2.3) 
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Where; k is the rate coefficient (mol/L.s) 
  A  is the frequency factor (s-1) 
  Ea  is the activation energy, ~ -120 kJ/mol   for bromination of  
   double bond (Lister, 1941, Conn et al., 1938) 
  R  is the gas constant (8.314 x 10-3 kJ/mol/K) 
  T is a temperature (K)     
D is the diffusion constant (m2/s) 
  kB is Boltzmann’s constant (1.381 x 10−23 J/K) 
  η is viscosity (kg/m/s) 
  r is the radius of the spherical diffusing species, 228 pm for Br2  
   (Mountain, 2000) 
  B is an emphirical constant related to nature of the liquid (K) 
 
In this chapter, Sepharose CL-6B was modified by the AGE activation-partial bromination 
route with VE-RD balancing to create SEC/IEC supports. Several parameters affecting 
thickness and inertness of supports’ outer layer were investigated. The supports were analysed 
at various stages of preparation for allyl contents, ionic binding capacity as well as pDNA and 
protein binding capacities. The relative values, % reduction, were used to express the changes 
in each parameter after modifications as described below; 
The reductions in allyl content was calculated by comparing the allyl content of 
partially brominated supports to that of the original allylated supports as shown in Eq. 2.4. 
% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅 =
(allyl  contents  of  original  allylated  supports )−(allyl  contents  of  partially  brominated  supports )allyl  contents  of  original  allylated  supports  x 100%  
(Eq. 2.4) 
% Reductions in ionic capacity were calculated by comparing ionic capacities of 
modified supports to fully Q-coupled supports as shown in Eq. 2.5. 
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% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑎𝑎𝑒𝑒𝑎𝑎𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎 =
(ionic  capacity  of  fully  Q−coupled  supports )−(ionic  capacity  of  sample )ionic  capacity  of  fully  Q−coupled  supports  x 100%    (Eq. 2.5) 
Effectiveness of surface or core charge elimination is expressed by % reductions in 
pDNA or protein binding capacities, respectively. % Reductions in binding capacity were 
calculated by comparing the binding capacities of modified supports to fully Q-coupled 
supports as shown in Eq. 2.6. 
% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑏𝑏𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑏𝑏 𝑅𝑅𝑎𝑎𝑒𝑒𝑎𝑎𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎 =
(binding  capacity  of  fully  Q−coupled  supports )−(binding  capacity  of  sample )binding  capacity  of  fully  Q−coupled  supports  x 100%   (Eq. 2.6) 
For Eq. 2.5 and 2.6, fully Q-coupled supports were produced by directly applying the 
full bromination and Q-coupling steps to the supports directly after AGE activation. 
The effectiveness of the bilayer creations can be indicated by selectivity index (SI) 
value. SI value was expressed by comparing the remaining protein binding capacity to the 
remaining DNA binding capacity which therefore, indicates the ratio of residual core charge 
to the degree of surface charge elimination, respectively. From this aspect, SI can therefore be 
used to virtually demonstrate the ‘thinness’ of the inert outer layer as well as the depth of 
bromine penetration into support’s pores. Selectivity indices (SI) were calculated using 
equation; 
 𝑆𝑆𝑆𝑆 = 100%−(% reduction  in  protein  binding  capacity  )100%−(% reduction  in  pDNA  binding  capacity  )    (Eq. 2.7) 
 
ESEM visualisations of SEC/IEC Sepharose CL-6B confirm that support’s structure remain 
unchanged compared to unmodified support even at a magnification as high as 8000x (Fig. 
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2.2). Unbound pDNA supernatants collected from static binding studies were visualised by 
agarose gel electrophoresis to check the stability of plasmid forms after binding (Fig. 2.3), 
with results indicating that plasmid following binding to SEC/IEC Sepharose CL-6B 
compared were the same as those seen following binding to unmodified supports. Plasmid 
band intensities on agarose gel after binding to SEC/IEC and unmodified supports were fairly 
similar, suggesting that surface exclusion of pDNA by the SEC/IEC supports was successful. 
In contrast, a large proportion of the pDNA applied to fully Q-coupled Sepharose CL-6B was 
bound. 
 
 
Fig.2.2  ESEM images of SEC/IEC Sepharose CL-6B, modified by VE-RD approach 
at; a) 1000x; b) 2000x; c) 8000x magnification and d) unmodified Sepharose CL-6B at 2000x 
magnification. 
 
a) b) 
c) d) 
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Fig.2.3   Agarose gel electrophoresis of unbound pITT3 plasmid after binding to 
SEC/IEC Sepharose CL-6B. Lane; M) Lambda HinD III marker; 1) fully Q-coupled; 2) 10% 
partial bromination in 64% (w/v) sucrose; 3) unmodified. Electrophoresis was operated in 
0.8% (w/v) agarose at 75 V for 2.5 h. The gel was stained with 0.5 µg/mL ethidium bromide. 
 
2.3.1 Effects of different viscosity enhancers, solvents and sodium acetate 
addition 
In previous work by Liddy (2009), DMSO was reported to be the best solvent used for 
partial bromination reaction (Liddy, 2009). Therefore, two solvent systems were tested: (i) 
water or (ii) 85% (v/v) DMSO. Two viscosity enhancers tested in this experiment were 
sucrose and glycerol. Sucrose solution at concentrations as high as 2 g/mL was used during 
partial bromination reaction to produce bilayered Sephacryl S-500 HR by Gustavsson et al. in 
order to increase viscosity of reaction mixture (Gustavsson et al., 2004). Glycerol was chosen 
due to its inertness, water solubility and low toxicity. In this experiment, viscosity enhancers 
were added to the solvent to obtain a viscosity of 0.1 Pa.s. The effect of sodium acetate 
addition was also tested at a concentration of 2.75% (w/v) as described by Liddy (2009). In 
water, viscosity enhancement by either sucrose or glycerol addition resulted in dramatic 
improvement of surface charge elimination, as indicated by an improved reduction of pDNA 
binding capacities of supports (Fig. 2.4). Only a small difference was observed when using 
OC 
SC 
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40% (w/v) sucrose as a viscosity enhancer with a 85% (v/v) DMSO solvent. These results 
indicate that sucrose is a preferable choice compared to glycerol for viscosity enhancement. 
The best compositions for reaction mixture are 80% w/v sucrose in water without sodium 
acetate, yielding 60.8% reduction in pDNA binding capacity, 10.5% reduction in protein 
binding and SI of 2.28. 
Sodium acetate addition was investigated due to its inclusion in previous partial 
bromination studies. The very first reports on chromatographic support modification using 
partial bromination reaction i.e. Bergstorm et al. (2002) and Gustavsson et al. (2004) added 
sodium acetate at a final concentration of 1% (w/v); a final concentration of 0.11% (w/v) was 
used by Berg et al. (2007) and 2.75% (w/v) final concentration was reported by Liddy (2009). 
In this study, it was observed that sodium acetate has a negative effect on the partial 
bromination reaction, resulting in less effective elimination as reflected by a smaller % 
reduction in pDNA binding capacities and allyl contents (Fig. 2.4).    
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Fig.2.4  Chemical and biochemical characterisation of SEC/IEC supports produced at 
10% bromination in different solvents, viscosity enhancers (VE) and NaAc addition. The 
concentrations of sucrose in water and DMSO are 80% and 40% (w/v), respectively. Glycerol 
was added to obtain the concentrations of 98.5% (v/v) in both solvents. 
 
Bromine colour was observed to disappear more rapidly during partial bromination in 
some reaction mixtures than in others. This suggested that some bromine might be being 
consumed before it can react with the support allyl groups. As a result, two sets of 
experiments were carried out to determine bromine loss caused by the presence of sodium 
acetate. Reaction solvents with the same compositions as those being used in partial 
brominations, with or without viscosity enhancers and sodium acetate, were rapidly mixed 
with bromine to obtain a starting concentration of 200 mM bromine. Samples were taken 
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every 30 s to measure A410 in the first 900 s and were taken every 300 s until a total time of 
0.5 h elapsed. The results revealed that sodium acetate causes a drastic reduction in bromine 
concentration in 80% (w/v) sucrose solution (Fig. 2.5). To determine whether the loss of 
bromine resulted from pH change caused by sodium acetate addition, a second experiment 
was conducted. NaOH was used to adjust the pH of 80% (w/v) sucrose solution to 7.84, 
similar to the pH obtained from sodium acetate addition. From this result, it was proven that 
pH was not the main cause of bromine loss (Fig. 2.5) but the reaction between bromine and 
sucrose took responsibility. Andersson, et al., (1980) reported that sucrose can be oxidised by 
bromine in aqueous solution at pH 7 and room temperature (Andersson et al., 1980). 
 
Fig.2.5  Bromine stability in water at room temperature.  Symbols;  : water;  : 
water with sodium acetate addition;  : 80% (w/v) sucrose;  : 80% (w/v) sucrose with 
sodium acetate addition and; Δ : 80% (w/v) sucrose with NaOH addition. 
 
Similar experiments were conducted on 85% (v/v) DMSO system (Fig. 2.6). In the 
presence of sodium acetate, bromine concentration rapidly dropped to zero in both 85% (v/v) 
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DMSO and 40% (w/v) sucrose in 85% (v/v) DMSO, indicating that the presence of sodium 
acetate has a strong effect on bromine loss. Supporting literature reported that DMSO can be 
halogenated with chlorine or bromine in the presence of a base (Iriuchijima and Tsuchihashi, 
1970).  
 
Fig.2.6  Bromine stability in 85% (v/v) DMSO at room temperature.  Symbols;  : 
85% (v/v) DMSO;  : 85% (v/v) DMSO with sodium acetate addition;  : (40% w/v) 
sucrose in 85% (v/v) DMSO and ;  : (40% w/v) sucrose in 85% (v/v) DMSO with sodium 
acetate addition. 
 
2.3.2 Effects of viscosity and temperature 
 
Sucrose was selected as the preferable viscosity enhancer for further studies. Room 
temperature (21oC) partial bromination reactions were carried out in sucrose solutions with 
viscosities ranging from 0.001-0.104 Pa.s. Cold partial brominations (2oC) were performed by 
placing the reaction vessels in iced water, allowing operating viscosities of 0.001-0.451 Pa.s 
to be achieved. Increased reaction solution viscosities led to dramatic increase of %reductions 
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in pDNA binding and increased SI values for the resulting SEC/IEC supports at viscosities 
lower than 0.032 Pa.s and the declines were observed at higher viscosity (Fig. 2.8 and 2.9). 
However, at viscosities above 0.1 Pa.s a plateau for % reduction in pDNA binding capacity 
was observed (Fig. 2.7). The data plots at different temperatures seemed to collapse on the 
same lines suggesting that temperature may not affect the bromination reaction in this system. 
It was again observed that sodium acetate has disruptive effect on partial bromination 
reaction, and use of sodium acetate was avoided in subsequent experiments.  
 
Fig.2.7  Effects of viscosity and temperature on % reduction in binding capacity of 
pDNA and protein. Symbols;  : pDNA without sodium acetate addition;  : pDNA with 
sodium acetate addition;  : protein without sodium acetate addition and ;  : protein with 
sodium acetate addition. 
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Fig.2.8  Chemical and biochemical characteristics of SEC/IEC supports produced by 
10% partial bromination at room temperature (21oC), a) with; b) without addition of 0.75% 
(w/v) sodium acetate. 
a) 
b) 
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Fig.2.9  Chemical and biochemical characteristics of SEC/IEC supports produced by 
10% partial bromination at 2oC; a) with; b) without addition of 0.75% (w/v) sodium acetate. 
a) 
b) 
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2.3.3 Effects of different degrees of partial bromination and numbers of 
bromination-hydrolysis cycles 
Preparations of SEC/IEC supports via single partial bromination/hydrolysis cycle were 
performed at a range of viscosities at room temperature as described in section 2.2.3, without 
the addition of sodium acetate. For 20% single bromination/hydrolysis, support modification 
was carried out in the same fashion as described in section2.2.3 except that the quantity of 
bromine added was now aimed at achieving 20% elimination of allyl content on AGE 
activated supports. Double partial bromination/hydrolysis cycles were performed by 
completing a first partial bromination and hydrolysis process, thoroughly washing the 
supports and then applying a second partial bromination/hydrolysis cycle followed by Q-
coupling.  When the degree of partial bromination was increased from 10 to 20% in single 
bromination, improvement of % reduction in pDNA binding was observed at viscosities lower 
than 0.032 Pa.s. Again, the % reduction in pDNA binding in both cases were declined at the 
viscosity above 0.032 Pa.s and reached a plateau at viscosities higher than 0.047 Pa.s (Fig. 
2.10). The possible explanation is that when sucrose concentration exceed a certain point, the 
viscosity dominated the reaction rate and prevented the access of bromine to the allyl group 
and resulted in the oxidation of sucrose by bromine competing with the bromination of allyl 
groups (Trombotto et al., 2004). In contrast, no decline was observed in supports produced by 
double 10% bromination (Fig. 2.10). A plateau was reached at viscosities higher than 0.047 
Pa.s, giving a wider operation window for production compared to those seen for single 
bromination processes. The absence of decrease in % reduction in pDNA binding may be 
caused by the reinforcements of surface elimination of allyl groups on AGE activated 
supports when bromine can attack surface allyl groups twice. Second partial bromination 
allows bromine to attack leftover allyl group again from the outermost site of support particles 
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while in single 20% bromination, large amount of bromine allowed the further diffusion into 
support’s pores, causing core elimination instead of surface elimination.  
Although double 10% partial bromination gave higher maximum % reduction in 
pDNA binding (81.25%) and higher maximum SI (4.48) compared to supports prepared with 
single 10% partial bromination (Fig. 2.11). Single bromination possesses an advantage over 
double bromination in terms of simpler process scaling-up. It was concluded that the most 
suitable condition for SEC/IEC Sepharose CL-6B production was single 10% partial 
bromination at room temperature in 64% (w/v) aqueous sucrose (giving a viscosity of 0.032 
Pa.s) without sodium acetate addition.     
 
Fig.2.10 Effects of different degrees of partial bromination and numbers of 
bromination-hydrolysis (PB/Hy) cycles on % reduction in binding capacity of pDNA and 
protein at room temperature (21oC). Symbols;  : pDNA, single 10% PB/Hy;  : pDNA, 
single 20% PB/Hy;  : pDNA double 10+10% PB/Hy;  : protein, single 10% PB/Hy;  : 
protein, single 20% PB/Hy;  : protein, double 10+10% PB/Hy. 
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Fig.2.11 Chemical and biochemical characteristics of SEC/IEC supports produced by; 
a) single 10%, b) single 20% and c) double 10+10%, PB/Hy cycle at room temperature (21oC) 
without sodium acetate addition.  
a) 
b) 
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Fig.2.11 (continued) Chemical and biochemical characteristics of SEC/IEC supports 
produced by; a) single 10%, b) single 20% and c) double 10+10%, PB/Hy cycle at room 
temperature (21oC) without sodium acetate addition.  
 
2.4 Conclusions 
Viscosity enhancement was found to slow down the diffusion rate of bromine into support’s 
pore, resulting in the condensed charge elimination restricted on the outermost surface of 
support’s particle. It was observed during partial bromination reactions that bromine colour 
took long time to completely disappear when viscosity enhancers were applied (without 
presence of sodium acetate), especially sucrose which confirmed the slower access of bromine 
to allyl group. However, without direct visualization, it was difficult to point out the pattern of 
charge distribution on support particles after modification based on the binding behaviors 
alone. Attempts to monitor the changes of surface elements by SEM-EDS technique had been 
c) 
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made but the results were unreliable due to the small size of the element of interest (nitrogen). 
The direct visualization technique according to Gustavsson’s report was applied in an attempt 
to identify the thickness of the outer layer by viewing the SEC/IEC support dyed with a 
negative dye, Congo red under a light microscopy. Congo red binds to the positively charged 
core and leaves the inert outer layer unattached, resulting in a clear halo surrounding the red 
colour core. However, this method was found to have high chance to yield false positive 
‘halo’ caused by the light refraction under light microscope, even with the fully Q-coupled 
support. Hence, this visualization was not applied further in this study. Confocal scanning 
laser microscopy of supports bound with fluorescent-tagged protein in order to visualize the 
core area was also considered. However, due to the nature of SEC/IEC supports, it is 
presumably impossible to attach fluorescent probes onto the surface via binding. The confocal 
scanning laser microscopy, therefore, cannot pick up the fluorescent signals to identify the 
edge of the inert outer layer. For the future work, the development of visualization techniques 
to identify the thickness of inert outer layer and the patterns of charge elimination might be 
one of the aspects worth further investigation. 
In single bromination approach, the increase in viscosity resulted in the better performance of 
SEC/IEC supports until a certain point where the %reduction in DNA binding started to 
decline. The reason behind this is still unclear but it was believed that when sucrose 
concentration exceed a certain point, the viscosity dominate the reaction rate and instead, 
prevent the access of bromine to the allyl group and resulted in the oxidation of sucrose by 
bromine competing with the bromination of allyl groups (Trombotto et al., 2004). An 
experiment focused on sucrose oxidation by bromine may help addressing the cause of this 
behavior. However, this decline was not observe in SEC/IEC supports produced by double 
bromination which may be resulted from the reinforcements of surface elimination of allyl 
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groups on AGE activated supports when bromine can attack surface allyl groups twice. 
Second partial bromination allows bromine to attack leftover allyl group again from the 
outermost site of support particles without the deeper diffusion of bromine into support pores 
compared to 20% single bromination. The improved performances of SEC/IEC supports 
seemed to be mostly caused by the effect of viscosity regardless the reaction temperature. 
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Chapter 3 
Evaluation of SEC/IEC supports prepared by         
viscosity enhanced, reaction-diffusion balancing for the 
separation of RNA from E. coli neutralised lysates 
containing pDNA 
 
Abstract 
SEC/IEC supports produced via VE-RD approach was proven to effectively separate pDNA 
from the major contaminant, RNA, in the ‘one column-one bead’ purification of pDNA from 
E. coli cleared lysate feedstock.  Commercially available, underivatised base matrices 
modified by the AGE activation-partial bromination route prepared in chapter 2 were further 
evaluated by applying to packed bed chromatography system in order to purify target pDNA; 
pITT3 (27379 bp), from neutralized E.coli cleared lysates. SEC/IEC Sepharose CL-6B 
exhibited a better performance compared to Sephacryl S-400 HR with the pDNA 
breakthrough readily observed, confirming its pDNA exclusion property due to the successful 
elimination of surface charges during the preparation while Sephacryl S-400 HR showed the 
complete adsorption of pDNA for the first 20 CV of loading and a breakthrough was 
gradually observed in 30 CV suggesting the remain of surface charges. SEC/IEC Sepharose-
CL 6B also exhibited the more efficient RNA removal with the higher RNA breakthrough 
volume. SEC/IEC Sepharose-CL 6B modified by 10% single partial bromination at room 
temperature in 64% (w/v) sucrose was examine for the effects of loading conductivity, linear 
flow rate and target plasmid DNA size. The RNA breakthrough volume was seen to decrease 
113 
 
with the increased conductivity (23-54 mS/cm) and no RNA binding was observed at the 
highest conductivity of 54 mS/cm while the pDNA breakthrough curves reached plateau at 
C/Co of ~ 1 at all conductivities applied except for at 23 mS/cm where breakthrough curves 
reached a C/Co plateau of ~ 0.8. Breakthrough volume of RNA and pDNA showed the 
decrease when linear flow rate was increased from 30 to 90 cm/h. RNA breakthrough curves 
at 30 and 60 cm/h were almost completely overlapped and pDNA breakthrough curves 
achieved maximum at the same CV of 15, suggesting flexibility on flow rate application at 
30-60 cm/h. Two plasmid species (pITT3; 27379 bp and pORT3a-Bam2k; 4109 bp) loaded 
gave the similar pattern of pDNA breakthrough curves. RNA breakthrough was slightly 
steeper for pITT3 compared to pORT3a-BAM2k. After column purification, no alteration of 
plasmid forms was observed. ~ 
 
3.1 Introduction 
Since the success of the first approved trial on a four year-old girl suffering from severe 
combined immunodeficiency (SCID) in 1990 (Blaese et al., 1995, Sheridan, 2011), the 
interest in gene therapy was skyrocketed. Although therapeutic gene can be transported by 
several types of viral vectors (Mountain, 2000, Bergen and Schaffer, 2011, Cearley and 
Wolfe, 2009, Coura and Nardi, 2008) the safety issues involving gene transfer vectors 
especially viruses has been widely concerned and was emphasized by the death of an 18 year-
old patient caused by viral vector-associated toxicity in 1999 (Sheridan, 2011). The viral 
vector was also reported to cause insertion oncogenesis in patients after the treatment using 
Murine leukaemia-based retroviral vector in 2008 (Hacein-Bey-Abina et al., 2008).  Unlike 
viral vectors, plasmid vectors are considered to be a safer choice with no toxicity observed in 
host. The increased use of pDNA vectors in recent pre-clinical and clinical trials of gene 
114 
 
therapy and DNA vaccination has resulted in an increased demand for high-purity therapeutic 
or pharmaceutical grade supercoiled-form pDNA. In comparison to viral vectors, pDNA 
vectors are considered to be safer, simpler to use and easier to produce on a large-scale at 
reasonable cost (Diogo et al., 2005, Wolf et al., 2009), typically via E. coli fermentation. 
However, production of pDNA in E. coli cells poses a number of challenges for purification. 
E. coli lysates are usually heavily contaminated with anionic species of very similar structure, 
charge and physical behaviour (chromosomal DNA, RNA and endotoxin) (Varley et al., 
1999) which may result in co-purification alongside the target pDNA (Prazeres and Ferreira, 
2004, Wicks et al., 1995). Regarding product safety issues, each of these contaminants needs 
to be minimised according to the guidelines stated by regulatory organizations, such as the 
World Health Organization (WHO), Food and Drug Administration (FDA) and the European 
Agency for the Evaluation of Medical Products (EMEA) (Prazeres et al., 2001, Stadler et al., 
2004). This can be achieved by employing effective processes of purification. 
 
Liquid chromatography has been a potent workhorse for pDNA purification due to its 
resolution, scalability and ability to provide the product purity required (Han et al., 2009, 
Tiainen et al., 2007b). Amongst the various chromatography modes available for the 
purification of pDNA, ion exchange (IEC) and size exclusion (SEC) chromatography have 
been the most widely used (Ferreira et al., 2000, Gustavsson et al., 2004). However, each 
approach holds some disadvantages. Ion exchange supports are designed for capturing 
proteins (2–10 nm largest diameter) (Thwaites et al., 2002, Theodossiou et al., 2000a) while 
larger plasmid species are unable to enter the support’s pores to bind (Theodossiou et al., 
2000b, Gustavsson et al., 2004). Therefore, pDNA binding is restricted to the outermost 
surface of support particles, resulting in a reduced of binding capacity which is 2-3 order of 
magnitude compared to proteins (Chandra et al., 1992, Prazeres et al., 1999, Theodossiou et 
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al., 2001). Moreover, similarity of charge properties between major impurities and target 
pDNA leads to a low selectivity where impurity species are bound and eluted alongside the 
targets (Diogo et al., 2005). Apart from impurities, the separation of the undesirable pDNA 
isoforms to achieve high purity supercoiled plasmid is also essential (Urthaler et al., 2005a, 
Sousa et al., 2008). 
 
Despite the fact that size exclusion chromatography separates biomolecules based on 
difference in sizes, regardless of charges, problems still exist due to its comparatively limited 
capacity (< 2% column volume) (Diogo et al., 2005), reduced resolution at higher loading 
and the dilution of the plasmid product which consequently requires an extra step for 
concentration. Furthermore, few SEC resins available commercially have limited selectivity 
toward different plasmid isoforms resulting in co-purification of the other pDNA species 
along with the most desirable form, supercoiled pDNA (Gómez-Márquez et al., 1987, 
Latulippe and Zydney, 2009, Prazeres and Ferreira, 2004).  
 
To overcome these drawbacks underlying in both IEC and SEC supports, the idea of 
bilayered SEC/IEC supports which combine the strengths of SEC and IEC, possessing a 
functionalized core to capture small impurities and inert, non-stick surface to exclude large 
charged micromolecules becomes more attractive. Existing approaches, mainly focused on 
EBA system, to produce bilayered SEC/IEC supports in order to exclude large biomolecules 
include; laminating IEX base matrices with a non- charged polymer layer i.e. agarose and 
cross-linked agarose (Dainiak et al., 2002, Jahanshahi et al., 2008, Viloria-Cols et al., 2004). 
However, the compromisation of bed expansion properties, hydrodynamics and intraparticle 
mass transfer were normally observed. The lamination of support particles with gel forming 
polymer naturally possesses a difficulty in casting sufficiently thin, uniform, mechanically 
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robust layers around core particles. (Arpanaei et al., 2010). Another approach to created 
bilayered SEC/IEC supports is applying low temperature plasma discharge treatment to 
either: (i) shave off the surface charges from the support particles (plasma etching): or (ii) 
coat the support particles with nano-thin polymer (plasma polymerization) (Arpanaei et al., 
2010). However, these existing approaches are based on EBA systems while only few 
researches were published on packed bed column chromatography systems. In 2004, 
Gustavsson et al. introduced a ‘lid bead’ produced by chemically functionalisation of 
commercially available SEC matrix, Sephacryl S500 HR via AGE activation-partial 
bromination approach based on Bergstorm’s methods (Bergstrom, 2002). Conclusively, this 
process consists of (i) introduction of allyl groups (CH2=CH-CH2-) throughout the structure 
of supports by reaction of allyl glycidyl ether (AGE) with hydroxyl groups on the support; 
(ii) partial bromination of allyl groups on the surface of each particle to create an outer layer 
via addition reaction; (iii) hydrolysis of the resulting outer layer of bromo-alkyl groups to 
create an inert outer layer; (iv) full bromination of the remaining allyl groups on support’s 
core; and finally (v) coupling of a quaternary amine ligand, trimethylamine (Q), to the core. 
This lid bead was further evaluated by applying to an integrated process for purification of 
plasmid from a clarified E. coli lysate as the polishing step (Kepka et al., 2004a, Gustavsson 
et al., 2004). However, in tests with clarified alkaline lysate feedstocks at high ionic strength, 
in order to prevent pDNA binding, it was necessary to sacrifice over 30% of the support’s 
RNA binding capacity. This indicates the lower than ideal definition between the inert outer 
layer and charged core due to the lack of ability to control the thickness and inertness of the 
outer size excluding layer during production process which clearly, needs improvements. 
 
In order to improve the SEC/IEC support preparation via AGE activation-partial bromination 
method, the idea of viscosity enhancement to facilitate reaction-diffusion rate (VE-RD) 
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balancing, explained in chapter 2, was applied to partial bromination step in order to achieve 
a thin brominated outer layer to minimize compromisation of core charge by deeper 
penetration of bromine into the supports. Fine-tuning of viscosity and temperature of the 
solution used in partial bromination reactions can aid in balancing of diffusion and reaction 
rate for creating an SEC/IEC support structure with a thin inert outer layer to exclude pDNA 
without compromising the core binding capacity. 
 
In chapter 2, processes for SEC/IEC supports production by VE-RD balancing approach were 
optimized. In this chapter, selected SEC/IEC supports from chapter 2 were further evaluated 
by ‘one column-one bead’ applications in chromatography systems for pDNA purification to 
separate the main contaminant, RNA, from neutralized E. coli cleared lysate. Variations of 
parameters such as pDNA sizes, bed volumes, bed heights, flow rates, ionic strengths and 
dilution factors of E. coli cleared lysate as well as different support produced were 
investigated. Chromatography fractions were monitored for pDNA, RNA and protein 
contents using UV traces, agarose gel electrophoresis and chemical assays.  
 
3.2 Materials and methods 
 
3.2.1 Materials     
The SEC base matrices, Sepharose CL-6B and Sephacryl S400 HR, were purchased 
from GE Healthcare Bio-Sciences (Uppsala, Sweden).  
E. coli DH5α containing the 27379 bp plasmid pITT3 was kindly provided by Dr. 
Eirini Theodosiou, Department of Chemical Engineering, Loughborough University, UK. 
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This plasmid is a pPR633-based high copy number plasmid (4579 bp) and containing a 22800 
bp insert from Saccharomyces cerevisiae chromosome III at BamHI site. 
The plasmid pORT3a-BAM2k (4109 bp) was provided by Dr. Rocky Cranenburgh, 
Molecular Biology, Recipharm Cobra Biologics, UK. Competent  E. coli JM109 cells 
prepared using a protocol demonstrated by Nishimura et al. (Nishimura et al., 1990) were 
kindly provided by Mr. Chia-Chang Hsu, School of Chemical Engineering, University of 
Birmingham. 
 Luria Bertani (LB) broth, LB agar, D-glucose, ampicillin, kanamycin, prolypropylene 
glycol (PPG) antifoam used for culture and fermentation and transformation were purchased 
from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). QIAfilter Plasmid Giga Kits and 
QIAprep Spin MiniPrep Kits for plasmid purification were purchased from Qiagen GmbH 
(Hilden, Germany).H2SO4 and sodium hydroxide were purchased from Fisher Scientific 
(Loughborough, UK). EDTA, sodium dodecyl sulphate (SDS), 3 M potassium acetate pH 5.5 
used for cell lysis and loading buffer preparation were purchased from Sigma-Aldrich 
Company Ltd. (St. Louis, MO, USA). 
Tricorn 5/50 column was purchased from GE Healthcare Bio-Sciences (Uppsala, 
Sweden). All chromatography was performed on an ÄKTA Explorer 100 system controlled 
by UNICORN 4.11 software (GE Healthcare, Uppsala, Sweden). Sodium chloride used for 
buffer preparation was purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA).  
Diphenylamine, perchloric acid, acetaldehyde, glacial acetic acid and calf thymus 
DNA used for diphenylamine assay was purchased from Sigma-Aldrich Company Ltd. (St. 
Louis, MO, USA). Pierce® BCA Protein Assay Kit was purchased from Thermo Scientific 
(Rockford, IL, USA). Orcinol, FeCl3, ribonucleic acid from baker's yeast (S. cerevisiae) used 
in Orcinol assay were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). 
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For phenol-chloroform extraction of nucleic acids and agarose gel electrophoresis, 
Phenol: Chloroform: Isoamyl alcohol (25:24:1) solution, 0.2 µm filtered 3 M sodium acetate 
pH 7.0, 100x TE buffer, agarose, Lambda- HinDIII marker, 6x gel loading dye and 10x TBE 
buffer were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). Kb DNA 
ladder (250 bp-12 kbp) was purchased from Agilent Technologies (Santa Clara, CA, USA). 
SYBR® safe DNA gel stain (Invitrogen, CA, USA) was purchased from Life Technologies 
Ltd (Paisley, UK). Restriction endonuclease, Bam HI and topoisomerase I from vaccinia 
virus were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). 
Distilled water was used in all experiment unless stated otherwise. 
 
3.2.2 Transformation of plasmid pORT3a-BAM2k 
 Plasmid pORT3a-BAM2k was introduced into competent E. coli JM109 cells via heat 
shock transformation as described by Nishimura et al. (Nishimura et al., 1990). Competent 
cells were thawed on ice, 50 µL of thawed cells were transferred to a microcentrifuge tube 
containing 5 µL (or ~100 pg) of plasmid DNA and incubated on ice up to 0.5 h. A 60 s heat 
pulse at 42oC was applied to induce the cells to take in plasmids. The tubes were then 
immediately chilled on ice for 120 s followed by addition of 0.5 mL of 42oC prewarmed LB 
broth. Resulting transformants were grown overnight at 37oC on LB agar containing 50 
µg/mL kanamycin. The cells were extracted for plasmid DNA using QIAprep Spin MiniPrep 
Kit to check the effectiveness of transformations. Extracted pDNA was visualised using 
agarose gel electrophoresis as mentioned in section 3.2.6.5.  
In order to prepare cell banks, a single colony was transferred to 8 mL LB broth 
containing 50 µg/mL kanamycin and incubated overnight on an incubator shaker (New 
Brunswick Scientific, New Jersey, USA) at 37oC, 200 rpm. Two millilitres of sterile glycerol 
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was added and mixed thoroughly. An aliquot of 0.5 mL was transferred to a cryotube vial and 
stored at -80oC. 
 
3.2.3 Production of plasmid–containing cells 
Preparation of starting cultures and fermentations of plasmid containing E. coli cells 
containing either pITT3 or pORT3a-BAM2k were carried out in the same manners as 
described in section 2.2.4, chapter 2 but with 50 µg/mL kanamycin being used for pORT3a-
BAM2k cultures instead of 100 µg/mL ampicillin. Cells were harvested by centrifugation in a 
J2-21 centrifuge (Beckman, High Wycombe, UK) operated at 10,000 g and 4oC for 0.25 h. 
The cell paste was weighed and stored at -20oC. 
 
3.2.4 Cell lysis 
Cell lysis was performed using alkaline lysis as described by Gustavsson et al. 
(Gustavsson et al., 2004). Five grams of cell paste was thawed and resuspended in 36 mL of 
10 mM Tris-HCl, pH 8 containing 61 mM glucose and 50 mM EDTA by vortex mixing in a 
500 mL screw cap glass bottle. Subsequently, 78 mL of 0.2 M NaOH containing 1% SDS 
was added followed by 4-6 times inversion and left at room temperature for 600 s. After this 
incubation period, 59 mL of cold (5oC) 3 M potassium acetate, pH 5.5 was added followed by 
gently mixing by 4-6 times inversion. White precipitate (floc) containing potassium dodecyl 
sulfate, genomic DNA and cell debris was removed by centrifugation at 10,000 g, 4oC for 0.5 
h. The supernatant was then transferred to a clean container and stored at -20oC. DNA and 
RNA contents of lysates prepared from pITT3 containing cells were 22.94 + 0.75 µg/mL and 
1069.69 + 47.26 µg/mL, respectively (n=8). For the lysate prepared from pORT3a-BAM2k 
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containing cells, DNA and RNA contents were 16.44 µg/mL and 843.00 µg/mL, respectively 
(n=1).  
 
3.2.5 Chromatography 
All chromatography was performed on an ÄKTA Explorer 100 system controlled by 
UNICORN 4.11 software (GE Healthcare, Uppsala, Sweden) at room temperature (~ 21oC). 
SEC/IEC Sepharose CL-6B and Sephacryl S-400 HR were produced by employing a VE-RD 
balancing approach as described and discussed in chapter 2. Buffer A used for equilibration, 
loading and washing was prepared to mimic the compositions of clarified neutralised alkaline 
lysate by mixing 36 mL of 10 mM Tris-HCl, pH 8 containing 61 mM glucose and 50 mM 
EDTA with 78 mL of 0.2 M NaOH containing 1% SDS. Subsequently, 59 mL of cold (5oC) 3 
M potassium acetate, pH 5.5 was added followed by 4-6 times inversion. White precipitate 
was removed by filtration through a 0.2 µm membrane filter. 
 
SEC/IEC supports being evaluated were packed into Tricorn 5/50 column (GE Healthcare, 
Uppsala, Sweden). A bed volume of 1 mL was applied in order to obtain a 5 cm bed height. 
Chromatographic runs were performed as follows. A packed column was equilibrated with 5 
column volumes of diluted buffer A (dilution factor corresponding to the dilution factor 
applied to E. coli lysate for feedstock preparation) at a flow rate of 30 cm/h. The loading 
feedstock was prepared by diluting clarified neutralised E. coli lysate with distilled water to 
obtain the conductivity required for the loading phase. A specified volume (35-80 CV) of 
diluted lysate was loaded onto column using P-960 sample pump at a determined flow rate 
(30-90 cm/h). After the loading phase was complete, the column was washed with 4 CV 
diluted buffer A used for equilibration. The column was then eluted with a linear salt gradient 
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(gradient length of 20 CV) of 2 M NaCl, 1 mM EDTA, 25 mM Tris–HCl, pH 8. Finally, 
stripping was performed using 25 CV of a 0.2 M NaOH, 2 M NaCl solution. The 
chromatography runs were monitored for UV absorbance at 260 and 280 nm. The 
flowthrough, washed and eluted fractions were subsequently analysed by agarose gel 
electrophoresis, chemical assays for DNA, RNA and protein contents. Restriction enzyme 
digestions and topoisomerase reactions were performed to identify plasmid topology. 
 
Variation of loading conductivity was conducted by dilution of buffer A as followed; 
 23 mS/cm : 1 : 4 dilution of buffer A by water  
 33 mS/cm : 1 : 2 dilution of buffer A by water 
 44 mS/cm: 1 : 1 dilution of buffer A by water 
 54 mS/cm: 2 : 1 dilution of buffer A by water  
 
 
3.2.6 Analysis 
  3.2.6.1 Diphenylamine (DPA) assay 
  DPA assay for DNA content was performed as described in section 2.2.5.5, 
chapter 2. 
 
3.2.6.2 Orcinol assay (Almog and Shirey, 1978) 
Orcinol assay for RNA content used in this study was modified from the 
method reported by (Almog and Shirey, 1978). Working reagent was prepared by mixing 70 
mL of solution A with 2.45 mL of solution B. Solution A was prepared by dissolving 100 mg 
of FeCl3 in 100 mL concentrated HCl. Solution B was prepared by dissolving 300 mg of 
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orcinol in 5 mL H2O. Samples were diluted 1:2 with water, 200 µL of each diluted sample 
was transferred to a 1.5 mL microcentrifuge tube followed by addition of 300 µL freshly 
prepared working reagent. The tubes containing samples and working reagent were mixed by 
a vortex mixer and incubated in a water bath at 95oC for 1200 s. After incubation, the tubes 
were left to cool at room temperature and centrifuged at 600 rpm for 0.25 h. The supernatants 
were measured for A665 using a UVIKON 922 spectrophotometer (KONTRON Instruments, 
Bletchley, UK). Standard curves were constructed using ribonucleic acid from baker's yeast 
(S. cerevisiae) at a concentration range of 0-100 µg/mL. Water was used as blank. 
 
  3.2.6.3 Bicinchoninic acid (BCA) assay   
BCA assay for protein was carried out in a 96-well microplate using a Pierce® 
BCA Protein Assay Kit in accordance with the assay kit manual. A working reagent was 
prepared by mixing 50 parts of reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) with 1 part of reagent B 
(containing 4% cupric sulfate). To perform the assay, 200 µL of working reagent along with 
25 µL of sample was added to each well. The tubes were then incubated in a DTS-2 
Microplate Thermoshaker (ATR, Laurel, MD, USA) at 37oC, 200 rpm for 0.5 h. After 
cooling down to room temperature, samples were measured for absorbance at 562 nm using a 
Modulus II Microplate Multimode Reader (Turner Biosystems, Sunnyvale,   CA, USA). A 
standard curve was constructed as described in the assay kit manual using standard 2 mg/mL 
BSA solution provided with the kit.  
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3.2.6.4 Phenol chloroform extraction of nucleic acids 
Before applying to agarose gel electrophoresis, nucleic acid species in 
chromatography fractions were extracted using a phenol-chloroform extraction method. Two-
hundred microlitres of chromatography fraction was mixed with 200 µL of Phenol: 
Chloroform: Isoamyl alcohol (25:24:1) solution then centrifuged at 10,000g for 600 s. The 
top aqueous phase was transfered to a clean microcentrifuge tube and 20 µL of 0.2 µm 
filtered 3 M sodium acetate pH 7.0 was added followed by addition of 0.5 mL ice cold 
absolute ethanol. The tubes were mixed gently by inverting 7 times, then left at -20 oC 
overnight and centrifuged at 10,000g for 600 s. The pellet was washed with ice cold 70% 
(v/v) ethanol and centrifuged at 10,000g for 600 s. The pellet was then air dried for 0.5 h and 
resuspended in 20 µL of Tris EDTA pH 8. The extracted nucleic acid solution was stored at -
20 oC. 
 
  3.2.6.5 Agarose gel electrophoresis 
  Agarose gel at a concentration of 0.8 % (w/v) was pre-stained using SYBR 
safe stain as follows; 10 µL of SYBR safe stain was mixed with 100 mL of 1x TBE buffer 
prior to addition of 0.8 g agarose powder. After melting the agarose by heating in a 
microwave oven, the gel was casted on a casting box equipped with an 18 µL, 26-well comb. 
Agarose gel electrophoresis and imaging were performed in similar manners as described in 
section 2.2.5.7, chapter 2 but the gel was processed directly to visualization step without  
ethidium bromide staining after electrophoresis. 
 
  3.2.6.6 Restriction enzyme digestions 
  Restriction endonuclease, Bam HI was used for digest pITT3 at insertion 
points. Digestion was performed by mixing 10 µL of Bam HI (containing 100 U of enzyme 
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activity) with 3µL of 10x digestion buffer SB and 3 µL of water. The mixture was then added 
with 14 µL (~ 1 µg DNA) of phenol-chloroform extracted flowthrough fraction. Enzyme-
sample mixture was then incubated at 37oC for 2.5 h. The enzyme was inactivated by 
incubation at 65oC for 0.5 h. Resulting cut fractions were visualised by agarose gel 
electrophoresis as described in section 3.2.6.5. 
 
  3.2.6.7 Topoisomerase reaction  
  One microlitre (~ 10 units) of topoisomerase I from vaccinia virus was added 
to 14 µL (~ 1 µg DNA) of phenol-chloroform extracted flowthrough fraction. The reaction 
was preceded at 37oC for 1 h. Resulting relaxed plasmid samples were visualised by agarose 
gel electrophoresis as described in section 3.2.6.5. 
 
  
3.3 Results and discussion 
Commercially available, underivatised base matrices modified by the AGE activation-partial 
bromination route using VE-RD approach prepared in chapter 2 were further evaluated by 
applying to packed bed chromatography system in order to purify target pDNA; pITT3, from 
neutralized E.coli cleared lysates. Plasmid DNA, RNA and protein contents were monitored 
by UV traces and chemical assays as well as agarose gel electrophoresis. Plasmid topology of 
pDNA in the flowthrough was identified using restriction enzyme digestions topoisomerase 
reactions. 
 
Bam HI digestion of the flowthrough fraction containing pITT3 yielded a 22800 bp fragment 
of Saccharomyces cerevisiae chromosome III and a 4579 bp fragment of pPR633 plasmid 
vector as demonstrated in Fig. 3.1a, confirming the circular form of plasmid in the 
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flowthrough which can be either supercoiled (SC) or open circular (OC) forms. This result 
indicated that there was no contamination of linear pDNA after column purification, 
suggested the mild purification property of SEC/IEC support without damaging the pDNA. 
Result from topoisomerase relaxation of pDNA in the flowthrough showed that supercoiled 
(SC) band migrated faster on the gel compared to the open circular form. After relaxation by 
topoisomerase, supercoil pDNA was unwound to yield one band representing the open 
circular (OC) form (Fig. 3.1b).    
          
a)                                                           b) 
Fig. 3.1 Agarose gel electrophoresis images of; a) BamHI digestion of pITT3 in 
flowthrough fraction after applying to SEC/IEC column.  Lanes; M: Lambda HinDIII marker, 
1: uncut pITT3, 2: pITT3 cut by BamHI. b) Topoisomerase relaxation of pITT3 in 
flowthrough fraction after applying to SEC/IEC column.  Lanes; M: Lambda HinDIII marker, 
1: native pITT3, 2: pITT3 after topoisomerase reaction. 
 
3.3.1 Effects of different base matrices 
SEC/IEC supports based on Sepharose CL-6B and Sephacryl S-400 HR modified by 
20% single partial bromination at room temperature in 80% (w/v) sucrose were loaded with 
60 column volumes of neutralized E.coli lysate with a conductivity of 33 mS/cm at a linear 
flow rate of 30 cm/h. DNA and high molecular weight RNA (HM-RNA) breakthrough curves 
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(Fig. 3.2) show a better performance for Sepharose CL-6B than Sephacryl S400 HR, as 
indicated by a shallower slope for RNA and a steeper curve for pDNA. Shallower RNA 
breakthrough curve of Sepharose CL-6B suggests a higher RNA binding capacity which is 
confirmed by the UV260 trace on the chromatogram and total RNA content measured by 
orcinol assay (Fig. 3.3) as well as agarose gel electrophoresis (Fig.3.4). A steeper pDNA 
breakthrough indicates a lower pDNA binding capacity on Sepharose CL-6B compared to 
Sephacryl S-400 HR. Moreover, pDNA breakthrough was observed readily after loading, 
confirming pDNA exclusion due to successful elimination of surface charges during support 
preparation. In contrast, pDNA content (Fig 3.3) and agarose gel electrophoresis showed a 
complete adsorption of pDNA on Sephacryl S-400 HR for the first 20 CV of loading and a 
breakthrough was gradually observed in 30 CV. Plasmid adsorption on this support was 
evident by significant amounts of pDNA in elution fractions (Fig. 3.3 and 3.4). The different 
performance on pDNA binding was thought to be caused by difference in pore sizes between 
Sepharose CL-6B and Sephacryl S-400 HR (24 nm and 31 nm, respectively) (Hagel et al., 
1996). However, with large biomolecules such as plasmids which normally are larger than 
0.2 µm (Fishman and Patterson, 1996) and much larger the pore sizes of these two supports. 
Conclusively, the difference in pore sizes of supports does not cause the difference in 
absorption behaviour of pDNA in this case. Therefore, it is possible that modified Sephacryl 
S400 HR tested still possesses surface charges, high enough to still be presence at high 
conductivity applied and resulting in a later breakthrough compared to modified Sepharose 
CL-6B.  
Protein contents measured by BCA assay from each chromatography runs were stable 
during loading phase and declined after washing (Fig. 3.3). However, BCA assay results did 
not correspond to UV280 traces. This may be caused by the low selectivity of UV260 and 
UV280 adsorption signals between protein and nucleic acid.  
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Fig. 3.2 Influence of different base matrices on breakthrough curves for; a) HM-RNA 
(open symbols) and b) pDNA (closed symbols) binding in packed bed chromatography.  
Symbols; Squares : Sepharose CL-6B; Circles : Sephacryl S400 HR. Chromatography runs 
were performed at a conductivity of 33 mS/cm, linear flow rate of 30 cm/h. 
 
a) 
b) 
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Fig. 3.3 Chromatograms (left) and chemical measurements of chromatographic 
fractions (right) obtained from packed bed chromatography of a) Sepharose CL-6B and b) 
Sephacryl S-400 HR. Chromatography runs were performed at a conductivity of 33 mS/cm, 
linear flow rate of 30 cm/h. 
       
a)               b) 
 
Fig. 3.4 Agarose gel eletrophoresis of chromatographic fractions obtained from a) 
Sepharose CL-6B and b) Sephacryl S-400 HR. Fraction sizes were 5 CV for the run 
performed on Sepharose CL-6B and 10 CV for the run performed on Sephacryl S-400 HR. 
Abbreviations; M : Lambda HindIII marker, L : cleared lysate fed onto column, F : 
flowthrough, W : wash fraction, E : elution fractions and S : stripped fraction. 
b) 
a) 
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3.3.2 Effects of loading conductivities  
Feedstock with loading conductivities of 23-54 mS/cm were applied to 
chromatography runs using SEC/IEC Sepharose CL-6B modified by 10% partial bromination 
at room temperature in 64% (w/v) sucrose. 1 mL of supports was packed in a Tricorn 5/50 
column to obtain a bed height of 5 cm. Chromatography runs were operated at a flow rate of 
30 cm/h. Breakthrough curves of HM-RNA and pDNA are shown in Fig. 3.5. RNA 
breakthrough increased when conductivities were decreased.  Small amount of RNA in 
elution and stripped fractions indicated that almost no binding was observed when the 
conductivity was increased to 54 mS/cm (Fig. 3.6 and 3.7). It was reported that under 
conditions of relatively high ionic strength (> 50 mS/cm), almost no RNA binding occur and 
most of the RNA elutes in the flow through (Stadler et al., 2004). Plasmid DNA 
breakthroughs showed similar trends where pDNA binding increased when conductivity was 
decreased. At all conductivities applied, pDNA breakthrough curves reached plateau at C/Co 
of ~ 1 except for at 23 mS/cm where breakthrough curves reached a C/Co plateau of ~ 0.8. 
This observation suggested pDNA loss during loading phase via binding, which was 
promoted by low conductivity. These findings on various conductivities applied are 
supported by chromatograms and chemical measurements as shown in Fig. 3.6 as well as gel 
electrophoresis results shown in Fig. 3.7. Protein contents measured by BCA assay from each 
chromatography runs were stable during loading phase and declined after washing (Fig. 3.6).  
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Fig. 3.5 Influence of different loading conductivities on breakthrough curves for; a) 
HM-RNA (open symbols) and b) pDNA (closed symbols) in packed bed chromatography. 
Symbols; squares : 23 mS/cm; circles : 33 mS/cm;  up-triangles : 44 mS/cm and diamonds : 
54 mS/cm. Chromatography runs were operated at a flow rate of 30 cm/h using SEC/IEC 
Sepharose CL-6B modified by 10% partial bromination at room temperature in 64% (w/v) 
sucrose. 
   
 
 
a) 
b) 
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Fig. 3.6 Chromatograms (left) and chemical measurements of chromatographic 
fractions (right) obtained from packed bed chromatography at different loading conductivities 
of a) 23 mS/cm, b) 33 mS/cm, c) 44 mS/cm and d) 54 mS/cm. Chromatography runs were 
operated at a flow rate of 30 cm/h using SEC/IEC Sepharose CL-6B modified by 10% partial 
bromination at room temperature in 64% (w/v) sucrose. 
 
a) 
b) 
c) 
d) 
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a)                                                                     b) 
                
                                c)                                                               d) 
Fig. 3.7 Agarose gel eletrophoresis of chromatographic fractions obtained from packed 
bed chromatography at different loading conductivities of a) 23 mS/cm, b) 33 mS/cm, c) 44 
mS/cm and d) 54 mS/cm. Fraction size was 5 CV. Abbreviations; M : Kb DNA ladder (250 
bp-12kbp), (gel a) or Lambda HindIII marker (gel b-d), L : cleared lysate fed onto column, F 
: flowthrough, W : wash fraction, E : elution fractions and S : stripped fraction.  
 
 
 
3.3.3 Effects of linear flow rates 
Various linear flow rates of 30-90 cm/h were applied to chromatography runs using 
SEC/IEC Sepharose CL-6B modified by 10% partial bromination at room temperature in 
64% (w/v) sucrose. Loading conductivity of 33 mS/cm was obtained by 3 times dilution of 
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neutralized E.coli cleared lysates or loading buffer with water. One millilitre of support was 
packed into a Tricorn 5/50 column to obtain a bed height of 5 cm. Breakthrough curves of 
HM-RNA and pDNA bindings showed a reduction in both pDNA and RNA binding 
capacities when linear flow rate was increased (Fig. 3.8). Plasmid DNA breakthrough curves 
of all flow rates reached the maximum of C/C0 = 1. Interestingly, RNA breakthrough curves 
at 60 cm/h almost overlapped with breakthrough curve at 30 cm/h and pDNA breakthrough 
curves achieved maximum at the same CV of 10, suggesting flexibility on flow rate 
application at 30-60 cm/h. While the flow rate of 90 cm/h showed earlier RNA breakthrough 
at 30-35 CV. Agarose gel images presented in Fig 3.10 confirmed the results observed in 
breakthrough curves and suggested the same trends. 
Protein contents measured by BCA assay from each chromatography runs were stable 
during loading phase and were decreased after washing (Fig. 3.9).  
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Fig. 3.8 Influence of different linear flow rates on breakthrough curves for; a) HM-
RNA (open symbols) and b) pDNA (closed symbols) in packed bed chromatography.  
Symbols; squares: 30 cm/h; circles: 60 cm/h; and up-triangles: 90 cm/h. Chromatography 
runs were operated at a loading conductivity of 33 mS/cm using SEC/IEC Sepharose CL-6B 
modified by 10% partial bromination at room temperature in 64% (w/v) sucrose.  
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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Fig. 3.9 Chromatograms (left) and chemical measurements of chromatographic 
fractions (right) obtained from packed bed chromatography at linear flow rates of a) 30 cm/h, 
b) 60 cm/h, c) 90 cm/h. Chromatography runs were operated at a loading conductivity of 33 
mS/cm using SEC/IEC Sepharose CL-6B modified by 10% partial bromination at room 
temperature in 64% (w/v) sucrose. 
 
a) 
b) 
c) 
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          a)           b) 
 
          c) 
 
Fig. 3.10 Agarose gel eletrophoresis of chromatographic fractions obtained from packed 
bed chromatography at linear flow rates of; a) 30 cm/h, b) 60 cm/h and c) 90 cm/h. Fraction 
size was 5 CV. Abbreviations; M: Lambda HindIII marker, L: cleared lysate applied onto 
column, F: flowthrough, W: wash fraction, E: elution fractions and S: stripped fraction. 
 
 
 3.3.4 Performances on different plasmids 
To further assess the pDNA exclusion properties of SEC/IEC supports, neutralized E. 
coli cleared lysate containing a smaller plasmid; pORT3a-BAM2k (4109 bp) was applied to a 
Tricorn 5/50 column packed with 1 mL SEC/IEC Sepharose CL-6B modified by 10% partial 
bromination at room temperature in 64% (w/v) sucrose to obtain a 5 cm bed height. Loading 
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conductivity of 33 mS/cm was obtained by 3 times dilution of neutralized E.coli cleared 
lysates or loading buffer with water. Diluted lysate was loaded onto the column at a linear 
flow rate of 30 cm/h. Breakthrough curves for pDNA showed similar pattern for both plasmid 
species despite the fact that the curve representing pORT3a-BAM2k reached a plateau at a 
C/C0 < 1 (Fig. 3.11). This observation is confirmed by pDNA content measured by DPA 
assay (Fig. 3.12) and agarose gel electrophoresis result of pORT3a-BAM2k (Fig. 3.13) 
showing pDNA in elution and stripped fractions, especially the bands located at high 
molecular weights region on gel. The higher molecular weight pDNA are generally bind 
more tighly with anion ligands on support. HM-RNA breakthrough was slightly steeper for 
pITT3 and RNA appeared in the flowthrough earlier at 50 CV on agarose gel while pORT3a-
BAM2k appeared later on the gel at 55 CV (Fig. 3.11 and 3.13). The possible cause of 
various molecular weights for pORT3a-BAM2k will be discussed later on.  
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Fig. 3.11 Influence of different plasmid species on breakthrough curves for; a) HM-
RNA (open symbols) and b) pDNA (closed symbols) in packed bed chromatography. 
Symbols; squares: clarified E. coli lysate containing pITT3 (27379 bp); circles: clarified E. 
coli lysate containing pORT3a-BAM2k (4109 bp). Chromatography runs were performed at a 
loading conductivity of 33 mS/cm using SEC/IEC Sepharose CL-6B modified by 10% partial 
bromination at room temperature in 64% (w/v) sucrose. 
 
 
 
a) 
b) 
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Fig. 3.12 Chromatograms (left) and chemical measurements of chromatographic 
fractions (right) obtained from packed bed chromatography applied with lysates containing 
different species of plasmid; a) pITT3 and b) pORT3a-BAM2k. Chromatography runs were 
performed at a loading conductivity of 33 mS/cm using SEC/IEC Sepharose CL-6B modified 
by 10% partial bromination at room temperature in 64% (w/v) sucrose. 
 
     a)          b) 
Fig. 3.13 Agarose gel eletrophoresis of chromatographic fractions obtained from packed 
bed chromatography applied with lysates containing different species of plasmid; a) pITT3 
and b) pORT3a-BAM2k. Fraction size was 5 CV. Abbreviations; M: Lambda HindIII 
marker, L: cleared lysate fed onto column, F: flowthrough, W: wash fraction, E: elution 
fractions and S: stripped fraction. 
a) 
b) 
141 
 
It was also noted that the different forms of pORT3a-BAM2k remain unaltered 
throughout the loading phase (Fig. 3.13). The pDNA bands of various molecular weights 
other than SC and OC bands are possibly caused by catenanes formation. 
Generally, it is likely that two or more circular DNA molecules can interlink. Circular 
DNAs that link together one or more times are called catenanes (Mirkin, 2001, Levene et al., 
1995, Laurie et al., 1998) as shown in Fig. 3.14. Catenanes are routinely detected inside 
living cells and are believed to form at the late stages of DNA replication and can be 
subsequently resolved by topoisomerases (Mirkin, 2001). 
 
 
Fig. 3.14 Crossover points between fully catenated DNA molecules are clearly 
demonstrated using Atomic force microscopy (AFM) in a publication by Harmon et al. In 
order to aid visualization, DNA molecules in the catenane sample were coated with RecA 
protein. AFM provides height information (Z), in addition to length and width measurements 
(X). (Harmon et al., 2003) 
 
Fig. 3.15 Restriction map of pORT3a-BAM2k, constructed by using computational 
processing of DNA sequence by artemis software (Wellcome Trust Sanger Institution) 
followed by pDRAW32 1.0 (revision 1.1.112, Accaclone software). 
142 
 
 In order to confirm catananes formations, one-site cutting by Bam HI was applied to 
pORT3a-BAM2k plasmid. From plasmid restriction map, pORT3a-BAM2K only contains 1 
restriction site for Bam HI (Fig. 3.15). Therefore, cutting catananes rings of this plasmid 
specie should result in 1 band of 4109 bp linear DNA, not various bands with assorted size 
which may result from contamination. As expected, the result reveals that pDNA bands that 
are larger than normal plasmid size are likely to be caused by catananes formations (Fig. 
3.16).  
 
Fig. 3.16 One-site cutting of pORT3a-Bam2K using Bam HI. Lane 1: Lamba HinD III 
marker; Lane 2: pORT3a-Bam2K before cutting; Lane 3: pORT3a-Bam2K after cutting, 
showing 1 band of 4109 bp linear DNA. 
  
Protein contents, as measured by BCA assay, were stable during the loading phase 
and were decreased after washing (Fig. 3.12).  
 
3.3.5 Performances of different SEC/IEC Sepharose CL-6B  
 Three SEC/IEC supports based on Sepharose CL-6B, produced at room temperature 
using the VE-RD balancing approach described in chapter 2, were packed into a Tricorn 5/50 
column at a bed volume of 1mL and bed height of 5 cm (Table 3.1). Neutralized E. coli 
cleared lysate was diluted three times with water (~ conductivity of 33 mS/cm) and applied to 
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the column at a flow rate of 30 cm/h. Preparation conditions, % reduction in binding 
capacities and selectivity indices for the supports are shown in Table 3.1. 
 
Table 3.1 Characteristics of SEC/IEC supports applied to column in section 4.3.5 
Support % (w/v) 
sucrose 
% 
Bromination 
% 
Reduction 
in DNA 
binding 
 
% 
Reduction 
in protein 
binding 
 
SI 
64s10 64 10 77.50 11.49 3.93 
70d10 70 10+10 81.25 16.31 4.46 
80s20 80 20 92.45 17.23 10.96 
 
 From existing data, HM-RNA breakthrough curves (Fig. 3.17a) suggested that RNA 
binding capacity followed SI values, except for 70d10 support which showed earliest RNA 
breakthrough while having 2nd highest SI. The 70d10 supports also show distinct pDNA 
breakthrough behaviour (Fig. 3.17b), with a more delayed pDNA breakthrough, whereas the 
breakthrough curves for 64s10 and 80s20 largely overlap one another. Distinctive pDNA 
breakthrough behaviour of 70d10 support is also evidenced by the DPA assay shown in Fig. 
3.18 and agarose gel electrophoresis image shown in Fig. 3.19 and may be caused by the 
different bromination mechanism of double bromination applied for this support preparation 
while the other two supports were prepared by single bromination. Double bromination also 
exhibited different surface binding behaviour with the increased viscosity used for support 
preparation compared to single bromination (see chapter 2). 
 SI value were used to evaluate the effectiveness of bilayering methods in the creation 
of SEC/IEC supports and in this respect SI might be expected to correlate with a supports 
ability to discriminate between DNA and RNA binding during chromatographic operation. 
However, the static binding studies employed for SI calculations were performed in relatively 
low ionic strength buffer, 0.05 mM Tris-HCl pH 8.0 (~ 4.8 mS/cm) compared to loading 
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buffer used for column experiment. High conductivity compromises binding capacity of 
target biomolecules (Harinarayan et al., 2006) and therefore, nucleic acids binding behaviour 
might be quite different to that expected from SI values. 
  
 
 
Fig. 3.17 Influence of different SEC/IEC Sepharose CL-6B on breakthrough curves for; 
a) HM-RNA (open symbols) and b) pDNA (closed symbols) in packed bed chromatography. 
Symbols; squares: 64s10; circles: 70d10; and up-triangle: 80s20. Chromatography runs were 
performed at a loading conductivity of 33 mS/cm using SEC/IEC Sepharose CL-6B modified 
by 10% partial bromination at room temperature in 64% (w/v) sucrose. 
 
 
 
a) 
b) 
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Fig. 3.18 Chromatograms (left) and chemical measurements of chromatographic 
fractions (right) obtained from packed bed chromatography using different SEC/IEC 
Sepharose CL-6B ; a) 64s10, b) 70d10 and c) 80s20. Chromatography runs were performed at 
a loading conductivity of 33 mS/cm using SEC/IEC Sepharose CL-6B modified by 10% 
partial bromination at room temperature in 64% (w/v) sucrose. 
 
 
a) 
b) 
c) 
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   a)           b) 
 
   c)       
Fig. 3.19 Agarose gel eletrophoresis of chromatographic fractions obtained from packed 
bed chromatography using SEC/IEC supports based on Sepharose CL-6B; a) 64s10, b) 70d10 
and c) 80s20. Fraction size was 5 CV. Abbreviations; M: Lambda HindIII marker, L: cleared 
lysate applied onto column, F: flowthrough, W: wash fraction, E: elution fractions and S: 
stripped fraction. 
 
 
3.4 Conclusions 
Generally, RNA is the main contaminant to be focused on since it can escape cell lysis and 
possesses similar characteristic as pDNA. RNA can be reduced by addition of RNA-digesting 
enzymes, such as RNase. However, this approach cannot be used for the purification of 
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therapeutic pDNA since the application of animal-derived materials, such as commercially 
available RNases, is prohibited by regulatory organizations (Sousa et al., 2008) In this 
chapter, the selected SEC/IEC supports produced in chapter 2 were evaluated in column 
chromatography system to separate RNA from E. coli cleared lysate. SEC/IEC Sepharose 
CL-6B modified by 10% single bromination exhibited a better performance especially on 
pDNA exclusion compared to SEC/IEC Sephacryl S400 HR. The pore sizes of both supports 
are considerably similar and are small enough to exclude plasmid pITT3 (27379 bp) used, 
suggesting that the binding of pDNA on SEC/IEC Sephacryl S400 HR, evident by large 
amount of pDNA in eluted fractions, may be caused by the remaining surface charge. 
Variations of operating parameters (conductivity, linear flow rate, plasmid size) were tested 
using SEC/IEC Sepharose CL-6B. The increase in conductivity resulted in the reduced 
binding capacity for both RNA and pDNA. Ideally, a successful pDNA-RNA separation 
requires minimum pDNA binding and maximum RNA binding. From this result, it is possible 
to fine-tune the conductivity to assist the separation. A flexible operating flow rate range of 
30-60 cm/h was observed which means that the chromatography can be operated at twice the 
standard flow rate (30 cm/h) which helps shorten operation period. The smaller plasmid 
(4109 bp) show similar pattern during chromatography proved the flexibility of this support 
towards different plasmid sizes. The SEC/IEC Sepharose CL-6B modified by double partial 
bromination/hydrolysis was seen to have different binding behaviours especially for RNA 
compared to those modified by single bromination (10 or 20%). It is worth mentioning that 
no change in plasmid form was observed in every chromatography runs using SEC/IEC 
supports. 
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Chapter 4 
Microwave assisted reaction-diffusion balancing for the 
preparation of SEC/IEC supports to separate RNA from   
E. coli neutralised lysates containing pDNA 
  
Abstract 
Microwave heating provided a fast, effective and controlled process for production of 
bilayered SEC/IEC supports containing non-charged surfaces and anionic cores for pDNA 
purification via AGE activation – partial bromination route. Partial bromination reactions on 
allylated supports were heated up by microwave irradiation in a monomodal microwave 
reactor to the target temperatures of 70-90oC in 55-70 s which were much faster than 
conventional heatings. SEC/IEC Sepharose CL-6B supports produced at 80-90oC with 10% 
partial bromination showed almost complete surface charge eliminations indicated by high 
values of % reduction in pDNA binding capacity of 95-98% and a highest selectivity index 
(SI) value of 57.4 was achieved at 80oC. Also, SEC/IEC Sephacryl S400 HR produced at 70-
90oC with 10% partial bromination exhibited high values of % reduction in pDNA binding 
capacity of 69-83% and a highest SI value of 10.2 was achieved at 70oC. These high SI 
values indicated efficient bilayer creations on both base matrices, resulted from the effect of 
increased temperature on reaction rate as described by Arrhenius equation. The relationship 
between reaction/diffusion rate ratio (k/D) and temperature for this bromination reaction 
suggested that a dramatic increase in reaction rate can be achieved when the temperature is 
raised to above 60oC and that ratio of reaction vs. that of diffusion (k/D) increase 
approximately fourfold per 10oC increase in temperature. These results proved the 
effectiveness of microwave heating on the production of bilayered SEC/IEC supports from 
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underivatised base matrices. The best SEC/IEC support, Sepharose CL-6B modified by 10% 
bromination at 83oC was further evaluated in a packed bed chromatography system using a 
Tricorn 5/50 column to purify a 6336 bp plasmid from E. coli cleared lysate. This support 
showed the high core binding capacity suggested by the absence of RNA breakthrough even a 
large volume of lysate (90 CV) was loaded. However, a delayed pDNA was also observed 
which may due to the remained surface charge. 
 
4.1 Introduction 
An increase in demand for high-purity therapeutic supercoiled-form plasmid DNA has arisen 
due to the increase application in pre-clinical and clinical trials for gene therapy and DNA 
vaccination. Therapeutic pDNA is widely produced in large scale by E. coli fermentation 
which possesses a number of challenges during purification process due to its high level of 
anionic contaminant with similar properties (i.e. charge, size and physical behaviours) to 
target pDNA such as chromosomal DNA, RNA and endotoxin (Varley et al., 1999). 
Moreover, for clinical trials where therapeutic DNA products are administered to patients, 
extremely high purity pDNA is required. This requirement leads to attempts to achieve an 
effective purification process. 
Ion exchange (IEC) and size exclusion (SEC) chromatography have been the most widely 
used for pDNA purification (Ferreira et al., 2000, Gustavsson et al., 2004). Still, each 
technique possesses some disadvantages. Ion exchange chromatography suffers from low 
pDNA binding capacity since most of the IEC supports available commercially were 
designed for protein purification (2–10 nm diameter) (Theodossiou et al., 2000a, Thwaites et 
al., 2002) while large target biomolecules such as pDNA are too large to enter the pores and 
bind only at the support’s surface (Eon-Duval and Burke, 2004, Prazeres et al., 1999, 
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Gustavsson et al., 2004, Tiainen et al., 2007b, Mao et al., 1993, Ljunglöf et al., 1999, 
Grunwald and Shields, 2001). Moreover, similarity of charge properties between major 
impurities and target pDNA resulting in binding and co-elution of impurity species alongside 
the targets (Diogo et al., 2005). Apart from impurities, the separation of the undesirable 
pDNA isoforms to achieve high purity supercoiled plasmid is also essential (Urthaler et al., 
2005a, Sousa et al., 2008).  In contrast, size exclusion chromatography can tackle the 
problems caused by similar charge property by separating large biomolecules from smaller 
impurities based on their size differences, regardless of charges. However, problems still 
exist due to the comparatively low selectivity of the technique and limitations of the 
feedstock volume that can be processed (Lemmens et al., 2003).  
In order to overcome these issues, the idea of a bifunctional restricted access SEC/IEC 
support consists of a positively charged core and an inert outer layer for ‘one column- one 
bead’ purification has become more and more attractive. SEC/IEC supports combine the 
strengths of IEC and SEC by having charged core which absorbs negatively charged small 
impurities while inert outer layer excludes pDNA, resulting in an effective separation where 
impurities are captured inside the beads and target plasmids come out in the flowthrough. 
Existing approaches to produce bilayered SEC/IEC supports are mainly focused in EBA 
system. The attempts to develop SEC/IEC supports in order to exclude large biomolecules 
include; coating IEX base matrices with a non- charged polymer i.e. agarose and cross-linked 
agarose (Viloria-Cols et al., 2004, Jahanshahi et al., 2008). Low temperature glow discharge 
plasma treatment was applied on functionalized base matrices to either (i) shave off the 
surface charges from the support particles (plasma etching): or (ii) coat the support particles 
with nano-thin polymer (plasma polymerization) (Arpanaei et al., 2010). However, these 
approaches mentioned are based on EBA systems while only few researches were published 
based on packed bed column chromatography systems. In 2004, Gustavsson et al. introduced 
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a SEC/IEC matrix called ‘lid bead’ produced by chemically functionalisation of 
commercially available SEC matrix, Sephacryl S500 HR via AGE activation-partial 
bromination approach. Conclusively, this process consists of (i) introduction of allyl groups 
(CH2=CH-CH2-) throughout the structure of supports by reaction of allyl glycidyl ether 
(AGE) with hydroxyl groups on the support; (ii) partial bromination of allyl groups on the 
surface of each particle to create an outer layer via addition reaction; (iii) hydrolysis of the 
resulting outer layer of bromo-alkyl groups to create an inert outer layer; (iv) full bromination 
of the remaining allyl groups on support’s core; and finally (v) coupling of a quaternary 
amine ligand, trimethylamine (Q), to the core. This lid bead was further evaluated by 
applying to polishing step in an integrated process for pDNA purification from a clarified E. 
coli lysate. (Kepka et al., 2004a, Gustavsson et al., 2004). However, these bi-functional 
supports seemed to lack the sharp definition between the inert outer layer and the charged 
core. For example, in tests with clarified alkaline lysate feedstocks at high ionic strength, 
over 30% of the support’s RNA binding capacity needed to be sacrificed in order to prevent 
pDNA binding. This problem appears to caused by the imperfect ability to control the 
thickness and inertness of the outer size excluding layer during the production process in 
which therefore, needs to be improved. 
It has been realized that  in order to obtain the maximum elimination of surface pDNA 
binding while maintain the maximum core binding for impurities for AGE activation- partial 
bromination approach, the inert outer layer needs to be very thin where charge elimination 
occurs densely and restricted on the outermost surface of support particle therefore, core 
binding is not compromised. This can be achieved by employing ‘reaction-diffusion 
balancing’ approach which involves increasing the reaction rate of the outer layer defining 
step, partial bromination, by increasing temperature (according to the Arrhenius equation) to 
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be fast enough that the reaction occurs only at the outermost part of adsorbent particle with 
minimal diffusion of reactant (bromine) deeper into support’s interior.  
The aim of this chapter is to optimise the conditions used for SEC/IEC supports preparation 
using microwave-assisted, reaction-diffusion balancing approaches on a commercially 
available underivatised chromatographic supports, Sepharose CL-6B and Sephacryl S400 HR 
for application on ‘one column-one bead’ pDNA purification. Microwave heating by a bench 
top monomodal microwave reactor was applied during partial bromination step prior to 
addition of bromine in order to rapidly ramp up the reaction rate to be much faster than 
diffusion rate. The effects of various temperatures during partial bromination reaction on the 
properties of SEC/IEC support produced were studied. The resulting SEC/IEC adsorbents 
were also characterised physically, chemically and biologically by means of scanning 
electron microscopy (SEM), chemical assays and binding studies with pDNA and bovine 
serum albumin (BSA) to identify the changes in surface and core binding capacity, 
respectively. The best SEC/IEC support was further evaluated in a packed bed 
chromatography system in order to purify pDNA from E. coli cleared lysate. 
 
4.2 Microwave principles 
Microwave heating possesses a number of advantages over conventional heating including 
non-contact heating, transfer of energy instead of heat (Fig. 4.1), higher heating rate (> 
400 oC/min (Agrawal, 1998)), rapid start-up and stopping of the heating, uniform heating 
with minimal energy loss (almost 100% conversion of electromagnetic energy into heat 
(Agrawal, 1998), selective heating properties, reverse heating profile (heating starting from 
the interior of the material body) which eliminates limitations cased by thermal conductivity 
of the vessel (Mallakpour and Rafiee, 2011, Çalışkan et al., 2012), reduction in the amount of 
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solvent required (Koroskenyi and McCarthy, 2002), energy savings and improved product 
yield results in a reduction in manufacturing cost (Pääkkönen et al., 2010). Due to these 
advantages, microwaves are widely used in various organic synthesis to heat up different 
types of reactions from library syntheses (Gelens et al., 2006), drug discoveries and syntheses 
(Frank et al., 2007, Alexandre et al., 2003), ceramic syntheses (Agrawal, 1998, Victor and 
Kumar, 2008, Naik et al., 2004), polymer syntheses and grafting (Koroskenyi and McCarthy, 
2002, Wiesbrock et al., 2004b, Singh et al., 2012, Wan et al., 2011) to regeneration of 
activated carbon (Çalışkan et al., 2012, Ania et al., 2005, Menéndez et al., 2010) and so on. 
The first published reports on the application of microwave irradiation to carry out organic 
chemical transformation were produced by the groups of Gedye (1986) and Giguere (1986) 
(Gedye et al., 1986, Giguere et al., 1986).  
 
Fig. 4.1 Schematic diagram of sample heating by a) conventional heating; and b) 
microwave irradiation (Hayes, 2002). 
 
 
Microwaves are nonionising electromagnetic radiation  (Banik et al., 2003) having the 
frequency range of 0.3-300 GHz, corresponding to wavelength of 0.001 – 1 m, which lies in 
the electromagnetic spectrum between infrared radiation and radio frequency (Mallakpour 
and Rafiee, 2011, Menéndez et al., 2010). Generally, microwave heating is usually applied at 
0.915 GHz (0.896 GHz in the UK) and 2.450 GHz which are the most popular of the 
frequencies allowed for ISM (industrial, scientific and medical) applications, set aside for 
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non-communication proposes (Das et al., 2009). Operating frequency of 2⋅45 GHz, 
corresponding to a wavelength of 12.2 cm and energy of 1.02×10−5 eV (Jones et al., 2002),  
is mostly used for domestic and laboratory scale microwave ovens while 0.915-2.45 can be 
found in industrial microwave ovens (Das et al., 2009, Nóbrega et al., 2002). 
 
Fig. 4.2  A typical spectrum of common electromagnetic radiation (Hayes, 2002). 
  
Microwave energy is transferred to the material by interaction of the electromagnetic field at 
the molecular level. Microwave heating is based on two fundamental mechanisms; dipole 
rotation and ionic conduction. Dipole rotation is an interaction of polar molecules trying to 
align in the alternating electric field, resulting in an energy loss in the form of heat through 
molecular friction and dielectric loss. The amount of heat generated depends on nature of the 
dipole (shape, size, dielectric constant, etc.) and frequency of the radiation applied. Under 
low frequency irradiation, dipole rotates in synchronized fashion with electric field but the 
motion is not enough to generate heat. On the other hand, under high frequency electric field 
the dipole does not have enough time to respond to the oscillation field and does not rotate. In 
both cases, no heating occurs. The assigned frequency of 2.45 GHz used in commercial 
systems lies between these two extremes cases, and gives the molecular dipole time to align 
in the field but not to follow the alternating field precisely. Under such conditions, rapid 
heating of chemical reaction mixtures to high temperatures can be obtained (Thostenson and 
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Chou, 1999, Das et al., 2009, Kappe and Dallinger, 2006, Figueiredo et al., 2011, Mallakpour 
and Rafiee, 2011, Lidström et al., 2001). Alternatively, ionic conduction occurs with the 
presence of free ions or ionic species, even a single isolated ion with hydrogen bond cluster, 
in substance being heated. The electric field generates ionic motion as the molecules try to 
orient themselves to the rapidly changing field, leads to an increased collision rate and 
finally, converts the kinetic energy to heat. The temperature of material affects ionic 
conduction by enhancing energy transfer efficiency when the temperature increased 
(Lidström et al., 2001, Hayes, 2002). Considering their heat generating capacity, ionic 
conductivity mechanism is a much stronger interaction than dipole rotation mechanism. Both 
mechanisms cooperate each other synergistically, resulting in an enhanced heat production 
(Lidström et al., 2001). Schematic diagrams of dipole rotation and ionic conduction during 
microwave irradiation are shown in Fig. 4.3 and 4.4, respectively. 
 
Fig. 4.3 Dipole rotation mechanism. Dipolar molecules tries to align with an 
oscillating electric field (Lidström et al., 2001). 
 
 
 
Fig. 4.4 Ionic conduction mechanism. Charged particles in a solution follows the 
applied electric field (Lidström et al., 2001). 
 
 
 
Materials can be classified into three categories based on their interaction with microwaves 
(Fig. 4.5): (i) materials that reflect microwaves which are called ‘conductor’, example of 
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these materials are bulk metals and alloys, e.g. copper, graphite and highly graphitized 
carbons; (ii) materials that are transparent to microwaves, namely ‘insulator’, typified by 
fused quartz, several glasses, ceramics, Teflon, etc.; and (iii) materials that absorb 
microwaves as known as ‘absorber’ which constitute the most important class of materials for 
microwave synthesis, e.g. aqueous solution, polar solvent, etc (Li and Yang, 2008, Menéndez 
et al., 2010, Jones et al., 2002).  
 
Fig. 4.5 Microwave absorption characteristic of conductor, insulator and absorber 
(Jones et al., 2002). 
 
The ability of a material to be heated in the presence of a microwave field is defined by its 
dielectric loss tangent (also known as dissipation factor); tan δ which is normally used to 
predict the behaviours of materials under a microwave field. The microwave absorption 
ability of a material is directly proportional to its tan δ value (Li and Yang, 2008). 
tan δ = ε″ / ε′       (Eq. 4.1) 
The dielectric loss tangent is composed of two parameters, the dielectric constant (or real 
permittivity); ε′, and the dielectric loss factor (or imaginary permittivity); ε″. The dielectric 
constant (ε′) indicates how much of microwave energy is reflected and how much is 
absorbed, while the dielectric loss factor (ε″) represents the dissipation of electric energy in 
form of heat within the material. To achieve an optimum microwave energy coupling, a 
combination of moderate value of ε′ and a high value of ε″ (yielding a high tanδ value) is 
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required to convert microwave energy into thermal energy effectively. This explains the 
heating property of some microwave transparent materials which do not possess a sufficiently 
high loss factor to allow dielectric heating while other materials such as some inorganic 
oxides and most carbon materials are excellent microwave absorbers. In general, materials 
can be classified as high (tan δ > 0.5), medium (tan δ = 0.1-0.5), and low microwave 
absorbing (tan δ < 0.1) (Kappe, 2004). Dielectric constants and loss tangents of solvents 
commonly used in organic synthesis is shown in Table 4.1. 
Table 4.1 Dielectric constants and loss tangents of solvents commonly used in organic 
synthesis (Lidström et al., 2001). 
Solvent Dielectric constant (ε’)a Loss tangent (tan δ)b 
Hexane 
Benzene 
Carbon tetrachloride 
Chloroform 
Acetic acid 
Ethyl acetate 
THF 
Methylene chloride 
Acetone 
Ethanol 
Methanol 
Acetronitrile 
Dimethylformamide 
DMSO 
Formic acid 
Water 
1.9 
2.3 
2.2 
4.8 
6.1 
6.2 
7.6 
9.1 
20.6 
24.6 
32.7 
36 
36.7 
47 
58 
80.4 
 
 
 
 
0.091 
0.174 
0.059 
0.047 
0.042 
0.054 
0.941 
0.659 
0.062 
0.161 
0.722 
0.123 
a Dielectric constant (ε’) at room temperature and under the influence of a static electric field. 
b Values determined at 2.45 GHz and room temperature. 
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The three dimensional stationary pattern of standing waves generated by the reflections of the 
wave within a cavity is called ‘mode’. In domestic microwave ovens, the cavities are 
designed to have typically 3-6 different modes in order to provide a uniform heating pattern 
(Lidström et al., 2001). In the very first chemical synthesis studies conducted on microwaves, 
most of the chemical reactions were performed using domestic microwave ovens (Yu et al., 
1988, Engelhart, 1990, Molina et al., 1993, Prasad et al., 2010, Banik et al., 1992, Kalyani et 
al., 2003, Dabirmanesh and Roberts, 1993, Giguere et al., 1986, Gedye et al., 1986, Bram et 
al., 1990, Ali et al., 1989, Baptistella et al., 1993, Banik et al., 1993, Komarneni et al., 1992, 
Liu et al., 2001) where generally the irradiation power was controlled by on/off cycles of the 
magnetron, the high-power generator of microwave power (Stuerga, 2008). These 
unmodified multimode microwave ovens were popular due to their easy accessibility and low 
cost. However, their use was not much encouraged due to the safety concerns, insufficient 
control over the reaction temperature and pressure as well as the lack of efficiency to process 
samples in small volume (Singh et al., 2012, Lidström et al., 2001, Bond et al., 1993, Kappe 
et al., 2009). ‘Hot and cold spots’ issue due to poor distribution of high and low field strength 
which resulting in a drastic variation of heating efficiency between different positions of 
samples, is also observed. In order to overcome these problems, several modifications to 
domestic microwave ovens for laboratory scale synthesis were made (Kappe, 2004, Ge and 
Luo, 2005, Huacai et al., 2006). Nowadays, all the specialized commercially available 
microwave reactors designed for chemical synthesis featured built-in magnetic stirrers, fibre-
optic probes or IR sensors for direct temperature control of the reaction mixture and software 
for on-line temperature/pressure control by regulation of microwave power output (Mingos, 
2009, Kappe and Dallinger, 2006, Singh et al., 2012). Currently, two different widely used 
microwave reactor designs are multimode and monomode (single mode) reactors. In the 
multimode reactors (employing similar concept to a domestic oven), the microwaves that 
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enter the typically large cavity (~ 40-50 L) are reflected by the walls of the cavity, and 
therefore interact with the sample in a chaotic manner (Kappe and Dallinger, 2006). The 
smaller monomodal reactors possess much smaller cavities where only one mode is present. 
Electromagnetic irradiation is directed through an accurately designed rectangular or circular 
wave guide onto the reaction vessel mounted at a fixed distance from the radiation source to 
creatie a standing wave (Kappe, 2004, Kappe and Dallinger, 2006). These features of a 
monomodal microwave reactor promote accurate temperature and pressure control with 
improved reliability, leading to better reproducibility of the results and also facilitating the 
scale-up of the reactions (Wiesbrock et al., 2004a, Huacai et al., 2006). 
 
.4.3 Materials and methods 
4.3.1 Materials     
The SEC base matrix, Sepharose CL-6B and Sephacryl S400 HR, were purchased 
from GE Healthcare Bio-Sciences (Uppsala, Sweden). Allyl glycidyl ether (AGE), 50% (w/v) 
sodium hydroxide solution, sodium hydroxide pellets, sodium borohydride (NaBH4, 99%), 
bromine, sodium chloride and trimethylamine hydrochloride (Q) used in SEC/IEC supports 
preparations were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). 
Ethanol was purchased from Fisher Scientific (Loughborough, UK). 
The monomodal microwave reactor used in this experiment was CEM Discover S-
Class (CEM Corporation, Matthews, NC, USA).  
E. coli DH5α containing the 27379 bp plasmid pITT3 was kindly provided by Dr. 
Eirini Theodosiou, Department of Chemical Engineering, Loughborough University, UK. 
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This plasmid is a pPR633-based high copy number plasmid (4579 bp) and containing a 22800 
bp insert from Saccharomyces cerevisiae chromosome III at BamHI site.  
E. coli DH1 carrying the 6335 bp plasmid pORT.mpt64 was provided by Dr. Rocky 
Cranenburgh, Molecular Biology, Recipharm Cobra Biologics, UK. 
Luria Bertani (LB) broth, LB agar, D-glucose, ampicillin, kanamycin, prolypropylene 
glycol (PPG) antifoam used for culture and fermentation were purchased from Sigma-Aldrich 
Company Ltd. (St. Louis, MO, USA). QIAfilter Plasmid Giga Kits for plasmid purification 
were purchased from Qiagen GmbH (Hilden, Germany). 
For bromine assay, standard potassium bromate solution (0.1 M) was purchased from 
Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). H2SO4 was purchased from Fisher 
Scientific (Loughborough, UK). For ionic capacity assay, mercury II thiocyanate was 
purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA) and ammonium iron III 
sulphate was purchased from Fisher Scientific (Loughborough, UK).  For binding studies, 
bovine serum albumin (BSA), Tris HCl and Trizma base were purchased from Sigma-Aldrich 
Company Ltd. (St. Louis, MO, USA). For diphenylamine assay, diphenylamine, perchloric 
acid, acetaldehyde, glacial acetic acid and calf thymus DNA were purchased from Sigma-
Aldrich Company Ltd. (St. Louis, MO, USA). Pierce® BCA Protein Assay Kit was 
purchased from Thermo Scientific (Rockford, IL, USA). Orcinol, FeCl3, ribonucleic acid 
from baker's yeast (S. cerevisiae) used in Orcinol assay were purchased from Sigma-Aldrich 
Company Ltd. (St. Louis, MO, USA). 
Tricorn 5/50 column was purchased from GE Healthcare Bio-Sciences (Uppsala, 
Sweden). All chromatography was performed on an ÄKTA Explorer 100 system controlled 
by UNICORN 4.11 software (GE Healthcare, Uppsala, Sweden). EDTA, sodium dodecyl 
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sulphate (SDS), 3 M potassium acetate pH 5.5 used for cell lysis and loading buffer 
preparation were purchased from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA).  
For phenol-chloroform extraction of nucleic acids and agarose gel electrophoresis, 
Phenol: Chloroform: Isoamyl alcohol (25:24:1) solution, 0.2 µm filtered 3 M sodium acetate 
pH 7.0, 100x TE buffer, agarose, 6x gel loading dye and 10x TBE buffer were purchased 
from Sigma-Aldrich Company Ltd. (St. Louis, MO, USA). Kb DNA ladder (250 bp-12 kbp) 
was purchased from Agilent Technologies (Santa Clara, CA, USA). SYBR® safe DNA gel 
stain (Invitrogen) was purchased from Life Technologies Ltd (Paisley, UK).  
Distilled water was used in all experiment unless stated otherwise. 
 
4.3.2 Viscosity measurement  
 Rheological behaviour of water was measured using an Advanced Rheometer 
AR1000 from TA Instruments (New Castle, DE, USA) equipped with a 40 mm, 2o angle 
stainless steel cone geometry. Viscosity changes were measured during the increasing 
temperature from 2 oC to 90 oC (applying a temperature ramp rate of 4oC/min) at a shear rate 
of 10 s-1.  
 
4.3.3 Preparation of SEC-IEC supports 
SEC/IEC supports can be produced by employing an AGE activation/ partial 
bromination route, briefly described in Fig. 4.6. The detailed procedures are also presented 
hereby.  
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Fig.4.6  Schematic diagram of SEC/IEC supports preparation via microwave-assisted 
AGE activation-partial bromination route. Trimethylamine chloride (Q) was used for ligand 
coupling in this experiment. 
 
4.3.3.1 AGE activation  
  AGE activation (Adapted from Gustavsson, 2004) was carried out in the same 
manner as described in section 2.2.3.1, chapter 2. The suction drained support was assayed 
for allyl groups content by the bromine assay. The AGE activated support was stored in 20% 
ethanol at 4oC. Allyl contents of AGE activated supports were 199 µg/mL supports for 
Sepharose CL-6B and 189 µg/mL supports for Sephacryl S400 HR.  
Partial bromination (70-90oC) 
Microwave assisted, reaction-
diffusion balancing  
AGE activation 
Full bromination  
Hydrolysis  
Q-coupling  
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 4.3.3.2 Partial bromination 
  A 30 mL portion of allylated supports was equilibrated 3 times in water. The 
equilibrated supports were then suction dried, added to a round bottom flask. Additional 
water (20 mL) was added to this flask, being used to rinse all support from the sides of the 
flask to ensure that all supports were collected at the bottom of the flask. A magnetic stirrer 
flea was added to the suspension and the flask was then placed in the CEM Discover 
microwave cavity (see Fig. 4.7). 
 
Fig. 4.7  Setup for microwave heating of chromatography support slurry in 100 mL 
round bottom flask. 
 
Microwave heating for partial bromination reactions was performed using 
the CEM Discover under ‘Dynamic’ heating mode. In this mode, a target temperature can be 
set by the user and the system uses temperature feedback data to control the amount of power 
supplied to allow the target temperature to be reached and maintained in a controlled fashion. 
The support slurries containing 60% support in water were heated using the dynamic mode, 
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with mixing by a magnetic stirrer.  A calculated amount of bromine, aiming for 10% or 20% 
elimination of total allyl content, was added as soon as the target temperature had been 
reached. The target temperature was held for a further 60 s, with continued mixing. The flask 
was then removed from microwave apparatus and leave to cool down at room temperature. 
The brominated supports were washed 3 times with 60 mL of water (60 mL x 3) on a sintered 
glass filter funnel under vacuum. A sample of support (0.2 g) was removed for analysis the 
remaining allyl content by bromine assay.  
 
  4.3.3.3 Hydrolysis of the partially brominated supports 
 The remaining of partially brominated supports were suction dried and added 
to a 100 mL screw cap bottle containing 25 mL of 1 M NaOH followed by addition of 0.08 g 
sodium borohydride. The bottle was sealed immediately and left to be shaken overnight at 
40oC in an orbital shaker incubator (New Brunswick Scientific, New Jersey, USA). After 
time elapse, hydrolysed supports were washed thoroughly with water. 
 
 4.3.3.4 Full bromination of hydrolysed supports and coupling of 
trimethylamine chloride (Q) 
 A whole portion of hydrolysed supports from hydrolysis step were transferred 
to a 100 mL screw cap bottle containing 13 mL of water. After mixing, 1.46 g of sodium 
acetate was added and dissolved. Bromine was added to the mixture until a permanent yellow 
colour was obtained. The supports were then washed thoroughly with water and transferred to 
a clean 100 mL screw cap bottle containing 13 mL of water. A 9.79 mL portion of 50% (w/v) 
sodium hydroxide was added to the mixture followed by 0.13 g of sodium borohydride. After 
mixing, 19 mL of 65% (w/v) trimethylamine chloride was added. The bottle was sealed 
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immediately and left to be shaken overnight at room temperature on a blood tube rotator SB1 
(Stuart Scientific, Staffordshire, UK). The supports were then washed with water, 1 M NaCl 
and water once again. Modified supports were stored at 4oC in 20% (v/v) ethanol. 
 
4.3.4 Production of plasmid–containing cells  
Preparation of starting cultures and fermentations of plasmid containing E. coli cells 
containing pITT3 (27379 bp) or pORT.mpt64 (6336 bp) were carried out in the same 
manners as described in section 2.2.4, chapter 2. For pITT3, 100 µg/mL ampicillin was used 
while 50 µg/mL kanamycin was added in case of pORT.mpt64. Cells were harvested by 
centrifugation in a J2-21 centrifuge (Beckman, High Wycombe, UK) operated at 10,000 g 
and 4oC for 0.25 h. The cell paste was weighed and stored at -20oC.  
Cells containing pITT3 were extracted for plasmid using QIAfilter Plasmid Giga Kits 
(Hilden, Germany) to be used for static binding study.  
 
4.3.5 Chromatography 
 4.3.5.1 Cell lysis 
 Cell lysis of E. coli DH1 containing pORT.mpt64 was performed using 
alkaline lysis method as described in section 3.2.4, chapter 3. DNA and RNA contents of 
lysate were 34.32 μg/mL and 661.47 μg/mL, respectively. 
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 4.3.5.2 Column operation 
 The chromatography was performed on an ÄKTA Explorer 100 system 
controlled by UNICORN 4.11 software (GE Healthcare, Uppsala, Sweden) at room 
temperature (~ 21oC). SEC/IEC Sepharose CL-6B modified by 10% bromination at 90oC was 
packed into Tricorn 5/50 column (GE Healthcare, Uppsala, Sweden). A bed volume of 1 mL 
was applied in order to obtain a 5 cm bed height.  Buffer A used for equilibration, loading 
and washing was prepared to mimic the compositions of clarified neutralised alkaline lysate 
by mixing 36 mL of 10 mM Tris-HCl, pH 8 containing 61 mM glucose and 50 mM EDTA 
with 78 mL of 0.2 M NaOH containing 1% SDS. Subsequently, 59 mL of cold (5oC) 3 M 
potassium acetate, pH 5.5 was added followed by 4-6 times inversion. White precipitate was 
removed by filtration through a 0.2 µm membrane filter. 
 
Chromatographic run was performed as follows. A packed column was 
equilibrated with 5 column volumes of diluted buffer A (dilution factor corresponding to the 
dilution factor applied to E. coli lysate for feedstock preparation) at a flow rate of 30 cm/h. 
The loading feedstock was prepared by three-fold dilution of clarified neutralised E. coli 
lysate with distilled water to obtain a conductivity of ~ 33 mS/cm. Ninety CV of diluted 
lysate was loaded onto column using P-960 sample pump at a flow rate of 30cm/h. After the 
loading phase was complete, the column was washed with 4 CV diluted buffer A used for 
equilibration. The column was then eluted with a linear salt gradient (gradient length of 20 
CV) of 1 M NaCl, 1 mM EDTA, 25 mM Tris-HCl, pH 8. Finally, stripping was performed 
using 25 CV of a 0.2 M NaOH, 2 M NaCl solution. The chromatography run was monitored 
for UV absorbance at 260 and 280 nm. The flowthrough, washed and eluted fractions were 
subsequently analysed by agarose gel electrophoresis, chemical assays for DNA and RNA 
contents.  
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4.3.6 Analysis 
 4.3.6.1 Environmental scanning electron microscopy (ESEM)  
  ESEM visualization of SEC/IEC supports was kindly assisted by Mrs Theresa 
morris, School of Metallurgy and Materials, University of Birmingham. Samples were 
prepared by dehydrating in ethanol followed by critical point drying. Imaging of samples was 
carried out on Philips XL-30 FEG Environmental SEM (FEI Company, OR, USA). 
 
  4.3.6.2  Bromine assay 
  Bromine assay was performed in the same manner as stated in section 2.2.5.2, 
chapter 2.   
 
  4.3.6.3 Ionic capacity assay (Theodossiou and Thomas, 2002) 
Ionic capacity of supports was measured by the method adapted from 
Theodossiou and Thomas (2002). The assay was performed as mentioned in section 2.2.5.3, 
chapter 2.  
 
  4.3.6.4 Static binding studies   
  The cell paste containing pITT3 obtained from fermentation was purified by 
QIAfilter Plasmid Giga Kit according to the product manual provided. Purified plasmid was 
visualised by agarose gel electrophoresis and measured for pDNA content using 
diphenylamine (DPA) assay. 
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 DNA and protein binding studies were performed in the same fashion as 
described in section 2.2.5.4, chapter 2.  
 
  4.3.6.5 Diphenylamine (DPA) assay 
  DPA assay for DNA content was performed as described in section 2.2.5.5, 
chapter 2. 
 
 4.3.6.6 Orcinol assay (Almog and Shirey, 1978) 
Orcinol assay for RNA content used in this study was modified from the 
method reported by Almog and Shirey (1978) as described in section 3.2.6.2, chapter 3. 
  
 4.3.6.7 Bicinchoninic acid (BCA) assay   
BCA assay for protein content was carried out using a Pierce® BCA Protein 
Assay Kit (Pierce, USA) in accordance with the assay kit manual. A working reagent was 
prepared by mixing 50 parts of reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) with 1 part of reagent B 
(containing 4% cupric sulfate). The assay was performed as stated in section 2.2.5.6, chapter 
2. 
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4.3.6.8 Phenol chloroform extraction of nucleic acids 
Before applying to agarose gel electrophoresis, nucleic acid species in 
chromatography fractions were extracted using a phenol-chloroform extraction method as 
described in section 3.2.6.4, chapter 3.  
 
  4.3.6.9 Agarose gel electrophoresis 
  Agarose gel at a concentration of 0.8 % (w/v) was pre-stained using SYBR 
safe stain as follows; 10 µL of SYBR safe stain was mixed with 100 mL of 1x TBE buffer 
prior to addition of 0.8 g agarose powder. After melting the agarose by heating in a 
microwave oven, the gel was casted on a casting box equipped with an 18 µL, 26-well comb. 
Agarose gel electrophoresis and imaging were performed in similar manners as described in 
section 2.2.5.7, chapter 2 but the gel was processed directly to visualization step without 
ethidium bromide staining after electrophoresis. 
 
 
4.4 Results and discussion 
Bilayered SEC/IEC supports were prepared by modification of two commercially available 
SEC supports, Sepharose CL-6B and Sephacryl S400 HR, via AGE activation-partial 
bromination route. Conclusively, this process consists of (i) introduction of allyl groups 
(CH2=CH-CH2-) throughout the structure of Sepharose CL-6B by reaction of allyl glycidyl 
ether (AGE) with hydroxyl groups on the support; (ii) partial bromination of allyl groups on 
the surface of each particle to create an outer layer via addition reaction; (iii) hydrolysis of 
the resulting outer layer of bromo-alkyl groups to create an inert outer layer; (iv) full 
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bromination of the remaining allyl groups on support’s core; and finally (v) coupling of a 
quaternary amine ligand, trimethylamine (Q), to the core.  
Amongst all steps, partial bromination is the most crucial step to determine the sharp 
discrimination between inert outer layer and charged core. Essentially, inert outer layer is 
preferred to be as thinnest as possible in order to minimize compromisation of core binding 
capacity. Thin inert outer layer can be achieved by minimizing bromine diffusion into 
support’s pores and simultaneously increase reaction rate between bromine and double bonds 
on allylated supports. By balancing bromine diffusion rate and bromine-allyl reaction, it 
should be possible to improve the separation of the ‘inert’ and anion-exchanging layers and to 
create more effective SEC/IEC supports. The idea of increasing temperature to facilitate 
reaction-diffusion balancing can be explained by the Arrhenius equation and Einstein-Stoke 
equation as shown below (Eq. 4.2 and 4.3).  
 
Arrhenius equation 
     𝑘𝑘 = 𝐴𝐴 𝑒𝑒𝑒𝑒𝑒𝑒(−𝐸𝐸𝑎𝑎/𝑅𝑅𝑅𝑅)    (Eq. 4.2)  
Einstein-Stoke equation 
     𝐷𝐷 =  kB𝑅𝑅6𝜋𝜋𝜋𝜋𝜋𝜋     (Eq. 4.3)  
Where; k is the rate coefficient (mol/L.s) 
  A  is the frequency factor (s-1) 
  Ea  is the activation energy, ~ -120 kJ/mol  for bromination of  
   double bond (Lister, 1941, Conn et al., 1938) 
  R  is the gas constant (8.314 x 10-3 kJ/mol/K) 
  T is a temperature (K)     
D is the diffusion constant (m2/s) 
  kB is Bolzmann’s constant (1.381 x 10−23 J/K) 
  η is viscosity (kg/m/s) 
  r is the radius of the spherical diffusing species, 228 pm for Br2  
   (Mountain, 2000) 
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Considering these equations, it is clear that temperature (T) plays an important role in both 
reaction and diffusion. Increasing temperature results in increased reaction and diffusion rates 
while high reaction rate and low diffusion rate are essential. By adjusting temperature,it is 
expected that the ‘balanced’ point can be achieved.  
 
 4.4.1 Effect of temperature on reaction/diffusion rates 
The viscosity of water was dramatically reduced when the temperature was reduced 
from 2-60oC and reached plateau after 60oC until the end of measurement at 90oC (Fig. 4.8).   
 
Fig. 4.8 Viscosity-temperature profile of water. Viscosity was measured during the 
increasing temperature from 2 oC to 90 oC (applying a temperature ramp rate of 4oC/min) at a 
shear rate of 10 s-1.  
 
Water viscosity values (η) at each temperature were used to calculate the 
reaction/diffusion rate ratio (k/D). k is the reaction rate coefficient, calculated by using the 
Arrhenius equation (Eq. 4.2) while D is the diffusion rate coefficient calculated by using the 
Stokes-Einstein equation (Eq. 4.3). The relationship between temperature and k/D is shown 
in Fig. 4.9. 
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Increasing temperature leads to an increase in the reaction/diffusion rate ratio (k/D) 
(Fig. 4.9).  Dramatic increase in k/D was observed when the temperature was increased to 
above 60oC. D was observed to be relatively constant over this temperature range (Fig. 4.8), 
with the increase in k/D coming from the significant increase in reaction rate seen as 
temperature is increased. Due to the lack of variation seen in D at the reaction temperatures 
which the studies in this chapter focus on (> 60oC), the effect of temperature on diffusion rate 
was neglected. 
 
Fig. 4.9 Relationship between reaction/diffusion rate ratio (k/D) and temperature for 
bromination reaction of double bond {Ea = ~ -120 kJ/mol (Lister, 1941, Conn et al., 1938)}. 
 
As shown in Fig. 4.9, in order to gain the full benefit of heating, reactions should be 
processed at temperature higher than 60oC. Therefore, temperatures for partial bromination 
reaction were pre-determined to be 70, 80 and 90oC. At these temperatures, reaction rate 
between bromine and allyl groups on allylated support was predicted to be very fast. At such 
high reaction rate, bromine added is expected to be completely reacted before diffusing 
further into support interior, yielding a SEC/IEC support with a high-definition, thin inert 
outer layer. 
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 4.4.2 Microwave heating curves during partial bromination reaction 
 Microwave-assisted partial bromination of Sepharose CL-6B was performed by 
heating up 50 mL of Sepharose CL-6B slurry (60% v/v support in water) using dynamic 
mode to 83 and 93 oC. Heating speeds of microwave irradiation were proved to be extremely 
fast compared to conventional heating. It has been reported that microwave heats up materials 
at extremely higher speed compared to conventional heating (Agrawal, 1998, Ania et al., 
2005, Mallakpour and Rafiee, 2011). For 10% bromination, microwave heating of Sepharose 
CL-6B in dynamic mode took 60 s to reach 83oC and 70 s to reach 93oC respectively (Fig. 
4.10).  Fast heating speeds were also observed during the heating of support slurry for 20% 
bromination. The slurries took 55 s to reach 71oc, 60 s to reach 81oc and 70 s to reach 92oC, 
respectively (Fig. 4.11).  Bromine was added at these target temperatures and bromine colour 
was seen to disappear almost immediately, indicating that the reaction between bromine and 
allyl groups was very rapid.  This was as expected, due to the increased reaction rates 
associated with the increased temperatures used as described by Arrhenius law (Eq. 4.2). 
 
Fig. 4.10    Changes in temperature during microwave heating for 10% bromination of 
Sepharose CL-6B under ‘dynamic mode’. The temperature was held constant after target 
temperature was reached.  Bromine was added at points indicated by arrows.  
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Fig. 4.11    Changes in temperature during microwave heating for 20% bromination of 
Sepharose CL-6B under ‘dynamic mode’. The temperature was held constant after target 
temperature was reached.  Bromine was added at points indicated by arrows.  
 
 For Sephacryl S-400 HR, microwave-assisted partial bromination reactions were 
performed by heating up 50 mL of support slurry (60% v/v support in water) to 79, 85 and 
89oC. Microwave heating of Sephacryl S400 HR in dynamic mode took 60 s to reach 79oC, 
65 s to reach 85oC and 70 s to reach 89oC respectively (Fig. 4.12). For 20% bromination, 
microwave heating of Sephacryl S400 HR in dynamic mode took 60 s to reach 80oC, 65 s to 
reach 85oC and 70 s to reach 91oC respectively (Fig. 4.13). Again, fast heating was observed 
and bromine colour disappeared almost instantly suggesting high reaction rates following the 
Arrhenius law. 
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Fig. 4.12    Change in temperature during microwave heating for 10% bromination of 
Sephacryl S400 HR under ‘dynamic mode’. The temperature was held constant after target 
temperature was reached.  Bromine was added at points indicated by arrows.  
 
 
 
Fig. 4.13    Change in temperature during microwave heating for 20% bromination of 
Sephacryl S400 HR under ‘dynamic mode’. The temperature was held constant after target 
temperature was reached.  Bromine was added at points indicated by arrows.  
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4.4.3 Characterisations of SEC/IEC supports produced 
 Sepharose CL-6B and Sephacryl S400 HR were modified by the AGE activation-
partial bromination route with reaction-diffusion balancing approach to create SEC/IEC 
supports. Microwave heating by a monomodal microwave reactor was applied to aid partial 
bromination reaction. Various temperature and degrees of partial bromination were 
investigated for their effects on thickness and inertness of supports’ outer layer. The supports 
were analysed at various stages of preparation for allyl contents, ionic binding capacity as 
well as pDNA and protein binding capacities.  
ESEM visualisations of SEC/IEC Sepharose CL-6B and Sephacryl S400 HR 
confirmed that microwave power does not affect support’s structure even at the highest 
temperature tested (90oC ) compared to unmodified supports (Fig. 4.14). 
 
Fig. 4.14 ESEM images of; a) unmodified Sepharose CL-6B, b) SEC/IEC Sepharose 
CL-6B, modified using microwave heating at 90oC, c) unmodified Sephacryl S400 HR and d) 
SEC/IEC Sephacryl S400 HR, modified using microwave heating at 90oC, 10% bromination.   
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SEC/IEC matrices produced were further characterised for allyl contents, ionic 
capacity as well as pDNA and protein binding capacities. The relative values, % reduction, 
were used to express the changes in each parameter after modifications as described below; 
The reductions in allyl contents were calculated by comparing the allyl content 
of partially brominated supports to that of the original allylated supports as shown in Eq. 4.4. 
% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑐𝑐 =
(allyl  contents  of  origina l allylated  supports )−(allyl  contents  of  partially  brominated  supports )allyl  contents  of  original  allylated  supports  x 100%  
(Eq. 4.4) 
% Reductions in ionic capacity were calculated by comparing ionic capacities 
of modified supports to fully Q-coupled supports as shown in Eq. 4.5. 
% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑎𝑎𝑒𝑒𝑎𝑎𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎 =
(ionic  capacity  of  fully  Q−coupled  supports )−(ionic  capacity  of  sample )ionic  capacity  of  fully  Q−coupled  supports  x 100%    (Eq. 4.5) 
Effectiveness of surface or core charge elimination is expressed by % 
reductions in pDNA or protein binding capacities, respectively. % Reductions in binding 
capacity were calculated by comparing the binding capacities of modified supports to fully 
Q-coupled supports as shown in Eq. 4.6. 
% 𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝑏𝑏𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑏𝑏 𝑅𝑅𝑎𝑎𝑒𝑒𝑎𝑎𝑅𝑅𝑅𝑅𝑅𝑅𝑎𝑎 =
(binding  capacity  of  fully  Q−coupled  supports )−(binding  capacity  of  sample )binding  capacity  of  fully  Q−coupled  supports  x 100%   (Eq. 4.6) 
For Eq. 4.5 and 4.6, fully Q-coupled supports were produced by directly 
applying the full bromination and Q-coupling steps (section 2.2.3.4) to the supports directly 
after AGE activation. 
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The effectiveness of the bilayer creations can be indicated by selectivity index 
(SI) value. SI value was expressed by comparing the remaining protein binding capacity to 
the remaining DNA binding capacity which therefore, indicates the ratio of residual core 
charge to the degree of surface charge elimination, respectively. From this aspect, SI can 
therefore be used to virtually demonstrate the ‘thinness’ of the inert outer layer as well as the 
depth of bromine penetration into support’s pores. Selectivity indices (SI) were calculated 
using equation; 
 𝑆𝑆𝑆𝑆 = 100%−(% reduction  in  protein  binding  capacity  )100%−(% reduction  in  pDNA  bi nding  capacity  )     (Eq. 4.7) 
Initially, microwave heating at 40oC was used to aid partial bromination 
reaction due to a promising result reported by Liddy (2010) obtained by heating Sepharose 
CL-6B slurry with a domestic microwave oven (Liddy, 2009). However, in the preliminary 
test using monomodal microwave reactor, modified Sepharose CL-6B produced at the same 
temperature of 40oC resulted in a rather disappointing result. Only 3.94% reduction in pDNA 
binding capacity and a relatively high % reduction in protein binding capacity of 12.86% 
were observed. This contradiction is believed to be caused by the insufficient temperature 
control and monitoring in the domestic microwave oven operation used by Liddy, in which 
heated samples were removed from the microwave oven and the temperatures were measured 
by a mercury thermometer, leaving a time delay between heating and measurement with a 
consequent temperature loss. The actual reaction temperature was, therefore, believed to be 
much higher than 40oC. According to the relationship between k/D and temperature shown in 
Fig.4.9, the value of k/D approximately doubles for every 5oC change in temperature, so from 
this it was surmised that higher temperatures would be more suitable for partial bromination, 
although not so high as to cause significant loss/damage of supports or loss of added bromine. 
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Hence, the raises in reaction temperatures to 71-93oC were applied later on in both Sepharose 
CL-6B and Sephacryl S400 HR. 
  As expected, increasing the reaction temperature to 71-93oC led to reduction 
in pDNA binding capacity at a range of 85-98% for modified Sepharose CL-6B supports, 
suggesting almost complete elimination of surface charge (Fig. 4.15). The highest SI value of 
48 was obtained when applying 10% partial bromination at 83oC.  This corresponds to a 
reduction in pDNA binding of 98.4% with only 4.3% reduction in protein binding was 
observed. Increased degree of partial bromination from 10-20% led to a greater decrease in 
allyl group contents (Fig. 4.15).  This decrease in the number of available allyl groups was 
seen to correlate with a decrease in the protein binding and ionic capacities. Strangely, the 
reductions in pDNA binding decreased when the degree of partial bromination was increased 
from 10-20% while an increase in % reduction for pDNA binding was expected. However, 
reductions in protein binding capacity seemed to follow the trend, along with reductions in 
allyl content and ionic capacity.  
  SEC/IEC Sephacryl S400 HR matrices produced were also characterised for 
allyl contents, ionic binding capacity as well as pDNA and protein binding capacities (Fig 
4.16). Again, an increased degree of partial bromination from 10-20% led to a greater 
decrease in allyl group content, correlating with an increase in the reduction in protein 
binding and ionic capacities. Reduction in pDNA binding capacity values at a range of 52-
83% was achieved. The highest SI value of 5.7 was obtained when applying 10% partial 
bromination at 79oC.  This corresponds to a reduction in pDNA binding of 83% with only 8% 
reduction in protein binding was observed. Once again, the reductions in pDNA binding 
decreased when the degree of partial bromination was increased from 10-20% while an 
increase in % reduction in pDNA binding was expected. Reduction of protein binding seemed 
to follow the trend, along with reductions in allyl content and ionic capacity. 
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Fig. 4.15 Chemical and biochemical characterisation of SEC/IEC Sepharose CL-6B 
produced via AGE activation-partial bromination route facilitated by microwave heating at 
various temperatures and degrees of partial bromination. 
 
Fig. 4.16 Chemical and biochemical characterisation of SEC/IEC Sephacryl S400 HR 
produced via AGE activation-partial bromination route facilitated by microwave heating at 
various temperatures and degrees of partial bromination. 
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Although high % reductions in DNA binding capacity were seen for the 
bilayered Sephacryl S400 HR, the associated SI values were not as high as those seen for 
Sepharose CL-6B in similar conditions due to the lower % reduction in pDNA binding 
capacity while % reduction in protein binding capacity seemed to be indifferent (Fig. 4.17). 
The different performances on pDNA binding was thought to be caused by difference in pore 
sizes between Sepharose CL-6B and Sephacryl S-400 HR (24 nm and 31 nm, respectively) 
(Kornberg and Baker, 2005). However, with large biomolecules such as plasmids which 
normally are larger than 0.2 µm (Fishman and Patterson, 1996) and much larger than the pore 
sizes of these two supports. Conclusively, the difference in pore sizes of supports does not 
cause the difference in absorption behaviour of pDNA in this case. Therefore, it is possible 
that modified Sephacryl S400 HR tested still possesses surface charges. Further column 
experiments on modified Sephacryl S400 HR may be able to help addressing the cause of this 
difference. 
 
4.4.4 Chromatography 
The SEC/IEC support exhibited the highest SI value, Sepharose CL-6B modified by 
microwave-assisted, 10% bromination at 83oC was chosen to be  further evaluated by 
applying to packed bed chromatography system in order to purify target pDNA; pORT.mpt64 
(6336 bp), from neutralized E.coli cleared lysates. Plasmid DNA and RNA contents were 
monitored by UV traces and chemical assays as well as agarose gel electrophoresis.  
From the gel electrophoresis and chemical assay results (Fig. 4.18a and 4.19), it was 
observed that HM-RNA breakthrough was not achieved even after a large loading volume of 
90 CV, suggesting the high core binding capacity of this support. After column purification, 
plasmid forms remain unchanged, reflecting the benefit of negative mode chromatography 
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where target molecules do not bind to the matrix. However, pDNA breakthrough was 
observed to be slightly delayed at 10 CV, suggested the possibility that the support still have 
surface charge. The agarose gel image of eluted and stripped fractions confirmed that a 
relatively large amount pDNA was bound to this support even at high conductivity. It was 
noted no change in plasmid forms was observed on agarose gel. 
 
 
Fig. 4.17 Chromatograms (a) and chemical measurements of chromatographic fractions 
(b) obtained from packed bed chromatography of Sepharose CL-6B modified by microwave-
assisted, 10% bromination at 83oC. Chromatography run was performed at a conductivity of 
33 mS/cm, flow rate of 30 cm/h. 
 
 
a) 
b) 
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Fig. 4.18 Agarose gel eletrophoresis of chromatographic fractions obtained from packed 
bed chromatography of Sepharose CL-6B modified by microwave-assisted, 10% bromination 
at 83oC. Fraction sizes was 5 CV. Abbreviations; M : Kb DNA Ladder (250bp-12Kb), L : 
cleared lysate fed onto column, F : flowthrough, W : wash fraction, E : elution fractions and S 
: stripped fraction. 
 
 
4.5 Conclusions 
The microwave-assisted reaction diffusion balancing approach was employed for SEC/IEC 
supports preparation. The monomodal microwave reactor provided a fast and controlled 
heating compared to conventional heating without damaging the supports. The high reaction 
temperature (70-90oC) resulted in almost complete surface charge elimination in SEC/IEC 
Sepharose CL-6B. The enhancement of reaction rate by the increased temperature can be 
explained by the Arrhenius equation. The calculation of reaction/diffusion rate ratio (k/D) for 
bromination reaction suggested that in order to gain the full benefit of heating, reactions 
should be processed at temperature higher than 60oC and double reaction rate can be achieve 
every 5oC increase in temperature. The SEC/IEC support with the highest SI was tested in 
column chromatography system for pDNA purification from E. coli cleared lysate. It was 
noted that the plasmid forms remain unchanged, suggesting the mild purification condition. 
This support exhibited the high core binding capacity, however, the delayed pDNA 
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breakthrough and the relatively large amount of pDNA in eluted and striped fractions 
reflected that the surface charges still remain. Again, it was difficult to point out the pattern 
of charge distribution on support particles after modification based on the binding behaviors 
alone. In order to identify the patterns of charge elimination on the support produced, the 
development of visualization techniques may be worth investigation.  
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Chapter 5 
Concluding remarks 
 
The worldwide growing demands for gene therapy products, especially for clinical trials 
where the large doses are required for each administration, has raised the requirement of the 
processes for the efficient large scale production of clinical grade gene transfer vectors with 
the high purity compliant with the specifications set by the governmental regulatory agency. 
For these gene therapy products to be administered safely in human, the purification process 
becomes the crucial step among the whole process. Generally, packed bed chromatography 
especially ion exchange chromatography, has been the method of choice for the purification 
of these gene transfer vectors ‘nanoplexes’ due to its high resolution, and selectivety. 
However, some problems still exist due to the similar charge properties between the target 
nanoplexes and impurities. Moreover, the large size of these nanoplexes led to the restricted 
binding only on support’s surface and the fragility of these molecules requires gentle 
handling methods. The idea of bilayered SEC/IEC supports can tackle these problems by 
providing negative mode purification where the charged core captures small impurities while 
the non-charged surface excludes the large target biomolecules without having chemical 
interaction therefore considerably more gentle than the general binding-elution approaches. 
In this thesis, the preparations of SEC/IEC supports from commercially available, 
underivatised base matrices by AGE activation-partial bromination technique via two 
different approaches; (i) viscosity enhanced-reaction diffusion (VE-RD) and (ii) microwave-
assisted reaction diffusion, were studied and optimised. The selected supports were further 
evaluated in column chromatography to purify pDNA from E. coli cleared lysate.  
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In chapter 2, preparation of SEC/IEC supports via VE-RD approach was optimised. The 
viscosity enhancement was found to greatly aid the creation of thin inert outer layer by 
slowing down the diffusion of bromine into support’s pores, resulted in the condensed charge 
elimination restricted on the outermost surface of support’s particle. The improved 
performances of SEC/IEC supports seemed to be mainly caused by the effect of viscosity 
regardless the reaction temperature. The decline of support’s performance at the sucrose 
viscosity above 0.032 Pa.s suggested the ‘balance’ point. After this point, the viscosity 
became excessive with excessive sucrose concentration which may led to another reaction 
between bromine and sucrose, competed with the bromination reaction of allyl group and 
resulted in bromine loss. 
In chapter 3, the selected SEC/IEC supports produced in chapter 2 were evaluated in column 
chromatography system to separate RNA from E. coli cleared lysate. SEC/IEC Sepharose 
CL-6B modified by 10% single bromination exhibited a better performance especially on 
pDNA exclusion compared to SEC/IEC Sephacryl S400 HR. The pore sizes of both supports 
are considerably similar and are small enough to exclude plasmid pITT3 (27379 bp) used, 
suggesting that the binding of pDNA on SEC/IEC Sephacryl S400 HR, evident by large 
amount of pDNA in eluted fractions, may be caused by the remaining surface charge. 
Variations of operating parameters (conductivity, linear flow rate, plasmid size) were tested 
using SEC/IEC Sepharose CL-6B. The increase in conductivity resulted in the reduced 
binding capacity for both RNA and pDNA. Ideally, a successful pDNA-RNA separation 
requires minimum pDNA binding and maximum RNA binding. From this result, it is possible 
to fine-tune the conductivity to assist the separation. A flexible operating flow rate range of 
30-60 cm/h was observed which means that the chromatography can be operated at twice the 
standard flow rate (30 cm/h) which helps shorten operation period. The smaller plasmid 
(4109 bp) show similar pattern during chromatography proved the flexibility of this support 
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towards different plasmid sizes. The SEC/IEC Sepharose CL-6B modified by double partial 
bromination/hydrolysis was seen to have different binding behaviours especially for RNA 
compared to those modified by single bromination (10 or 20%). It is worth mentioning that 
no change in plasmid form was observed in every chromatography runs using SEC/IEC 
supports. 
In chapter 4, the microwave-assisted reaction diffusion balancing approach was employed for 
SEC/IEC supports preparation. The monomodal microwave reactor provided a fast and 
controlled heating compared to conventional heating without damaging the supports. The 
high reaction temperature (70-90oC) resulted in almost complete surface charge elimination 
in SEC/IEC Sepharose CL-6B. The enhancement of reaction rate by the increased 
temperature can be explained by the Arrhenius Law. The calculation of reaction/diffusion 
rate ratio (k/D) for bromination reaction suggested that in order to gain the full benefit of 
heating, reactions should be processed at temperature higher than 60oC and double reaction 
rate can be achieve every 5oC increase in temperature. The SEC/IEC support with the highest 
SI was testes in column chromatography system for pDNA purification from E. coli cleared 
lysate. It was noted that the plasmid forms remain unchanged, suggesting the mild 
purification condition. This support exhibited the high core binding capacity, however, the 
delayed pDNA breakthrough and the relatively large amount of pDNA in eluted and striped 
fractions reflected that the surface charge still remain.  
Although the binding studies can be used to indirectly demonstrate the charge elimination 
patterns and the thickness of the inert outer layer. However, without direct visualization, it 
was difficult to point out the pattern of charge distribution on support particles after 
modification based on the binding behaviors alone. Attempts to monitor the changes of 
surface elements by SEM-EDS technique had been made but the results were unreliable due 
to the small size of the element of interest (nitrogen). The direct visualization technique 
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according to Gustavsson’s report was applied in an attempt to identify the thickness of the 
outer layer by viewing the SEC/IEC support dyed with a negative dye, Congo red under a 
light microscopy. Congo red binds to the positively charged core and leaves the inert outer 
layer unattached, resulting in a clear halo surrounding the red colour core. However, this 
method was found to have high chance to yield false positive ‘halo’ caused by the light 
refraction under light microscope, even with the fully Q-coupled support. Hence, this 
visualization was not applied further in this study. Confocal scanning laser microscopy of 
supports bound with fluorescent-tagged protein in order to visualize the core area was also 
considered. However, due to the nature of SEC/IEC supports, it is presumably impossible to 
attach fluorescent probes onto the surface via binding. The confocal scanning laser 
microscopy, therefore, cannot pick up the fluorescent signals to identify the edge of the inert 
outer layer. The development of visualization techniques to identify the thickness of inert 
outer layer and the patterns of charge elimination might lead to a better understanding on the 
mechanism of surface charge elimination via partial bromination reaction. 
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Future work 
1.  The patterns of charge distribution on support particles after modification are difficult 
to demonstrate based on the binding behaviours alone. The development of 
visualization techniques to identify the thickness of inert outer layer and the patterns 
of charge elimination/distribution might be one of the aspects worth further 
investigation. 
2. An experiment should be conducted to examine the possibility of the reaction between 
sucrose and bromine at the exact condition applied for support preparation as 
described in chapter 2 in order to determine the cause of decrease support 
performance at the viscosity above 0.032 Pa.s. 
3. The studies of integrated process by combining SEC/IEC column with other 
chromatographic column i.e. CIM™ DEAE (BIA Separation, Villach, Austria). 
SEC/IEC column may be applied first to capture impurities followed by CIM™ 
DEAE column for polishing and concentration or applied in polishing step to absorb 
small amount of impurities left after CIM™ DEAE column. 
4. Identification of plasmid isoforms by analytical pDNA column available 
commercially i.e. MiniQ from GE Healthcare (Uppsala, Sweden) or CIMac™ pDNA 
Analytical Columns from BIA Separations (Villach, Austria) is also a good choice to 
help confirming the plasmid isoforms in addition to gel electrophoresis visualisation, 
restriction enzyme digestion and topoisomerase relaxation used in this thesis. 
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Appendix 
 
 
A.1 Growth curve of E. coli containing pITT3 plasmid produced in 
Chapter 2 
 
The fermentation was terminated after the cells reached late exponential phase at an OD600nm 
of 2.13. The growth curve of E. coli was constructed using the software MicroFit v 1.0 
(Institute of Food Research (IFR), Norwich, UK). The maximum specific growth rate (µmax ) 
and lag time calculated using this software were 1.32 h-1 and 5.43 h, respectively.  
 
Fig. A.1  Growth curve of E. coli DH5α containing the pITT3 produced by fermentation 
in Chapter 2 
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A.2 Complete sequence of plasmid pORT3a-BAM2K 
BASE COUNT     1017 a       981 c      1025 g      1086 t  
ORIGIN 
        1 ctaggaaagc cacgttgtgt ctcaaaatct ctgatgttac attgcacaag ataaaaatat  
       61 atcatcatga acaataaaac tgtctgctta cataaacagt aatacaaggg gtgttatgag  
      121 ccatattcaa cgggaaacgt cttgctcgag gccgcgatta aattccaaca tggatgctga  
      181 tttatatggg tataaatggg ctcgcgataa tgtcgggcaa tcaggtgcga caatctatcg  
      241 attgtatggg aagcccgatg cgccagagtt gtttctgaaa catggcaaag gtagcgttgc  
      301 caatgatgtt acagatgaga tggtcagact aaactggctg acggaattta tgcctcttcc  
      361 gaccatcaag cattttatcc gtactcctga tgatgcatgg ttactcacca ctgcgatccc  
      421 cgggaaaaca gcattccagg tattagaaga atatcctgat tcaggtgaaa atattgttga  
      481 tgcgctggca gtgttcctgc gccggttgca ttcgattcct gtttgtaatt gtccttttaa  
      541 cagcgatcgc gtatttcgtc tcgctcaggc gcaatcacga atgaataacg gtttggttga  
      601 tgcgagtgat tttgatgacg agcgtaatgg ctggcctgtt gaacaagtct ggaaagaaat  
      661 gcataagctt ttgccattct caccggattc agtcgtcact catggtgatt tctcacttga  
      721 taaccttatt tttgacgagg ggaaattaat aggttgtatt gatgttggac gagtcggaat  
      781 cgcagaccga taccaggatc ttgccatcct atggaactgc ctcggtgagt tttctccttc  
      841 attacagaaa cggctttttc aaaaatatgg tattgataat cctgatatga ataaattgca  
      901 gtttcatttg atgctcgatg agtttttcta atcagaattg gttaattggt tgtaacactg  
      961 gcagagcatt acgctgactt gacgggacgg cggctttgtt gaataaatcg aacttttcct  
     1021 aggtaccccc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat  
     1081 taatgtgagt tagctcactc attaggcacc ccaggcttta cactttatgc ttccggctcg  
     1141 tatgttgtgt ggaattgtga gcggataaca atttcacaca ggaaacagct atgaccatga  
     1201 ttacgccaag cgcgcaatta accctcacta aagggaacaa aagctggagc gatgtacggg  
     1261 ccagatatac gcgttgacat tgattattga ctagttatta atagtaatca attacggggt  
     1321 cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc  
     1381 ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag  
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     1441 taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc  
     1501 acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg  
     1561 gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc  
     1621 agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca  
     1681 atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca  
     1741 atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg  
     1801 ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata agcagagctc  
     1861 tctggctaac tagagaaccc actgcttact ggcttatcga aattaatacg actcactata  
     1921 gggagaccca agctggctag caccatgctt gaaccgttcc aaattctctc tatctgctca  
     1981 tttatcttat ctgccctcca ttttatggcc tggaccagcc tgttaaccga agtcgaaacg  
     2041 ccaattcgta atgaatgggg ctgccgctgc aatgattcgt ccgatagctt actcacagaa  
     2101 gttgaaaccc ctacaaaaaa cgaatgggaa tgtcgctgca atgattcatc agattcctta  
     2161 ttaaccgaag tcgaaactct tactcgcaac ggctggggtt gtcgctgtag tgattctagt  
     2221 gatcctctcg tagtcgccgc atctatcatt ggtatcttac acttgatttt atggatttta  
     2281 gaccgcctct tttttaaatg tatctatcgc cgcttcaaat atggattaaa acgcggacct  
     2341 agcaccgaag gagtacctga aagtatgcgt gaagaatacc gccaagaaca acaaaacgct  
     2401 gtagacgttg atgatggtca ttttgtaaac attgaattag aataatggat ccactagtcc  
     2461 agtgtggtgg aattctgcag atatccagca cagtggcggc cgctcgagtc tagagggccc  
     2521 gtttaaaccc gctgatcagc ctcgactgtg ccttctagtt gccagccatc tgttgtttgc  
     2581 ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct ttcctaataa  
     2641 aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg gggtggggtg  
     2701 gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg ggatgcggtg  
     2761 ggctctatgg cttctgaggc ggaaagaacc aggacctcga gggggggccc ggtacccaat  
     2821 tcgccctata gtgagtcgta ttacgcgcgc tcactggccg tcgttttaca acgtgagttt  
     2881 tcgttccact gagcgtcaga ccccgtagaa aagatcaaag gatcttcttg agatcctttt  
     2941 tttctgcgcg taatctgctg cttgcaaaca aaaaaaccac cgctaccagc ggtggtttgt  
     3001 ttgccggatc aagagctacc aactcttttt ccgaaggtaa ctggcttcag cagagcgcag  
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     3061 ataccaaata ctgtccttct agtgtagccg tagttaggcc accacttcaa gaactctgta  
     3121 gcaccgccta catacctcgc tctgctaatc ctgttaccag tggctgctgc cagtggcgat  
     3181 aagtcgtgtc ttaccgggtt ggactcaaga cgatagttac cggataaggc gcagcggtcg  
     3241 ggctgaacgg ggggttcgtg cacacagccc agcttggagc gaacgaccta caccgaactg  
     3301 agatacctac agcgtgagct atgagaaagc gccacgcttc ccgaagggag aaaggcggac  
     3361 aggtatccgg taagcggcag ggtcggaaca ggagagcgca cgagggagct tccaggggga  
     3421 aacgcctggt atctttatag tcctgtcggg tttcgccacc tctgacttga gcgtcgattt  
     3481 ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg ccagcaacgc ggccttttta  
     3541 cggttcctgg ccttttgctg gccttttgct cacatgttct ttcctgcgtt atcccctgat  
     3601 tctgtggata accgtattac cgcctttgag tgagctgata ccgctcgccg cagccgaacg  
     3661 accgagcgca gcgagtcagt gagcgaggaa gcggaagagc gcccaatacg caaaccgcct  
     3721 ctccccgcgc gttggccgat tcattaatgc agggccggcc tcatgaatgg tgttaagcgg  
     3781 gcggttttga gatgtaaact cgcccgttta acataatgga tcttgcgcgc accgcccgaa  
     3841 caccactcgc cacaaaaaac cgccggaacg tccaaaagta cgggttttgc tgcccgcaaa  
     3901 cgggctgttc tggtgttgct agtttgttat cagaatcgca gatccggctt caggtttgcc  
     3961 ggctgaaagc gctatttctt ccagaattgc catgattttt tccccacggg aggcgtcact  
     4021 ggctcccgtg ttgtcggcag ctttgattcg ataagcagca tcgcctgttt caggctgtct  
4081agcttat cgatgataag cttcatgac  // 
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A.3 Preliminary tests on monomodal microwave heating of water and 
water-support slurry 
A.3.1 Method 
  A.3.1.1 Microwave heating profile of water at small volume 
  Distilled water (1 to 5 mL) in a 10 mL reaction vessel (CEM Corporation, 
Matthews, NC, USA) was heated under mixing in a CEM Discover S-Class microwave 
apparatus using a ‘fixed power’ method. A fixed amount of microwave power (10 to 40 W) 
was supplied for a fixed period of time (10 to 30 s). On-line reading of water temperature was 
taken immediately before and after heating using the CEM microwave’s built-in infrared 
sensor (see Fig. A.2). 
 
Fig. A.2 Setup for microwave heating of water in 10 mL reaction vessel  
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A.3.1.2 Microwave heating profile of water at large volume 
  Distilled water (10 to 50 mL) in a 100 mL round bottom flask was heated 
under mixing in a CEM Discover microwave apparatus using a ‘fixed power’ method. A 
fixed amount of microwave power (10 to 40 W) was supplied for a fixed period of time (10 to 
30 s). On-line reading of water temperature was taken immediately before and after heating 
using the CEM microwave’s built-in infrared sensor (see Fig. A.3). 
 
Fig. A.3 Setup for microwave heating of water in 100 mL round bottom flask. 
 
  A.3.1.3 Microwave heating profile of water-supports slurry 
  Two millilitres of Sepharose CL-6B in distilled water slurry (50-80% v/v 
supports) in a 10 mL reaction vessel was heated under mixing in a CEM Discover microwave 
apparatus using a ‘fixed power’ method. A fixed amount of microwave power (10 to 40 W) 
was supplied for a fixed period of time (10 to 30 s). On-line reading of water temperature was 
taken immediately before and after heating using the CEM microwave’s built-in infrared 
sensor (see Fig. A.4). 
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Fig. A.4  Setup for microwave heating of Sepharose CL-6B slurry in 10 mL reaction 
vessel.  
 
 A.3.2  Results and discussions 
  A.3.2.1 Microwave heating profiles in water 
  Temperature change (ΔT) profile against microwave power input (power x 
time/volume) in water is shown in Fig. A.5. Fixed power mode of microwave heating was 
applied to heat up 1-5 mL water in 10 mL reaction vessels. Data plots obtained by heating 3-5 
mL water appeared to collapses on the same line, indicated that absorbance of microwave 
energy by water at these volumes remains consistent. However, when the volume of water 
decrease to 2 mL, data plots shifted slightly downward while those for 1 mL shifted down 
significantly further. The difference in heating profile at 1-2 mL water compared to at 3-5 mL 
may caused by an insufficient height of sample in the vessel to be fully irradiated by 
microwave radiation in reaction chamber. It was suspected that some microwave radiation in 
the CEM Discover chamber hits the reaction vessel at a height range above the maximum 
liquid height for the 1 mL and 2 mL samples (11 mm and 19 mm height respectively) and a 
loss of some microwave radiation was likely to occur (see Fig. A.6). As a result, the amount 
Microwave 
source
Microwave 
source
15 ml test tube
IR temperature sensor
Slurry
10 mL reaction vessel 
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of radiation absorbed by the 1-2 mL samples is less than that for 3-5 mL samples, which have 
liquid heights of 27-43 mm.  
 
Fig. A.5  Effects of microwave energy on temperature change for microwave heating of 
1-5 ml water in 10 mL reaction vessels using ‘fixed power’ mode. Symbols;  : 1 mL,  : 2 
mL,  : 3 mL,  : 4 mL and  : 5 mL. 
 
 
 
Fig. A.6 Schematic diagram showing microwave radiation on the small volume sample 
(1-5 mL in 10 mL reaction vessel) in irradiation chamber. 
Microwave 
source
Microwave 
source
Microwave radiation here does not encounter
the sample and remains unabsorbed
Microwave radiation here encounters
the sample and is absorbed
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The similar heating profile was also observed when microwave heating was 
performed in a larger container (100 mL round bottom flasks) containing large volume of 
water (10-50 mL). Again, data plots obtained from heating of 30-50 mL water by microwave 
radiation overlapped each other to create a linear relationship. At lower volumes of 10 and 20 
mL, heating profiles resulted in 2 distinguished data plots showing shallower slopes when 
less volume of water was applied (Fig A.7). This similar heating behaviour confirmed the 
previous findings when small amount of water was applied. The heights of water in this test 
were also measured. It was convincing that the lower heating performances for 10 and 20 mL 
water were caused by, again, the insufficient heights of the sample (13 and 19 mm, 
respectively) to be interacted with microwave radiation supplied in the chamber. The similar 
heating profiles obtained from 30-50 mL water indicated that microwave radiation fully 
interacted with liquid at this range of liquid height (24-31 mm). Effectiveness of microwave 
heating at small and large volume of water seemed to be similar, giving a slope of 0.25 and 
0.2 for 3-5 mL water and 30-50 mL water, respectively.  
 
Fig. A.7  Effects of microwave energy on temperature change for microwave heating of 
10-50 ml water in 100 mL round bottom flask using ‘fixed power’ mode. Symbols;  : 10 
mL,  : 20 mL,  : 30 mL,  : 40 mL and  : 50 mL. 
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A.3.2.2 Microwave heating profiles in water-support slurry 
 Increasing support content in the slurry led to increased microwave energy required to 
achieve a determined temperature rise (Fig. A.8). At 80% (v/v) Sepharose CL-6B content, 
approx. 50% increase in microwave energy was required to achieve the same temperature rise 
when only water was used. For example, 50oC rise required 200 kJ /L for water and 300 
kJ/L for an 80% (v/v) Sepharose CL-6B slurry. However, such extra energy requirement is 
considered to be relatively small due to the structure of Sepharose CL-6B which consists of 
approx. 94% water. The extra energy required is believed to be corresponded to the skeletal 
polymer of this support, cross- linked agarose. 
 
Fig. A.8  Effects of microwave energy on temperature change for microwave heating of 
2 mL Sepharose CL-6B slurries in 10 mL reaction vessels with ‘fixed power’ mode. 
Symbols;  : 0% (v/v),  : 50% (v/v),  : 60% (v/v), and  : 80% (v/v). 
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A.4 Calibration curves 
A.4.1 Bromine: for bromine assays 
 
Fig. A.9 Bromine standard curve for bromine assays. 
 
 
A.4.2 NaCl: for ionic capacity measurements 
 
Fig. A.10 NaCl standard curve for ionic capacity measurements. 
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A.4.3 Calf thymus DNA: for DPA assays 
 
Fig. A.11 Calf thymus DNA standard curve for DPA assays. 
 
 
A.4.4 BSA: for BCA assays in microcentrifuge tubes 
 
Fig. A.12 BSA standard curve for BCA assays in microcentrifuge tubes. 
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 A.4.5 BSA: for BCA assays in microplates 
 
Fig. A.13 BSA standard curve for BCA assays in microplates. 
 
A.4.6 RNA: for orcinol assays 
 
Fig. A.14 RNA standard curve for orcinol assays. 
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